: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

Flying Publisher

COVID-19: Daily Top 10 Papers

Autoimmune Disorders

Free Subscription

Articles published in Mult Scler
Retrieve available abstracts of 876 articles:
HTML format

Single Articles

April 2021

TROJANO M, Ramio-Torrenta L, Grimaldi LM, Lubetzki C, et al
A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis.
Mult Scler. 2021 Apr 6:13524585211003020. doi: 10.1177/13524585211003020.
PubMed Abstract available

BESSING B, Honan CA, van der Mei I, Taylor BV, et al
Development and psychometric properties of the Multiple Sclerosis Knowledge Assessment Scale: Rasch analysis of a novel tool for evaluating MS knowledge.
Mult Scler. 2021;27:767-777.
PubMed Abstract available

March 2021

HOWLETT-PRIETO Q, Feng X, Kramer JF, Kramer KJ, et al
Anti-CD20 therapy corrects a CD8 regulatory T cell deficit in multiple sclerosis.
Mult Scler. 2021 Mar 30:13524585211003301. doi: 10.1177/13524585211003301.
PubMed Abstract available

THEODORSDOTTIR A, Debrabant B, Magyari M, Kant M, et al
Alemtuzumab treatment in Denmark: A national study based on the Danish Multiple Sclerosis Registry.
Mult Scler. 2021 Mar 29:13524585211003291. doi: 10.1177/13524585211003291.
PubMed Abstract available

CREE BA, Cohen JA, Reder AT, Tomic D, et al
Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis.
Mult Scler. 2021 Mar 26:13524585211000280. doi: 10.1177/13524585211000280.
PubMed Abstract available

PORTACCIO E, Fonderico M, Hemmer B, Derfuss T, et al
Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey.
Mult Scler. 2021 Mar 25:13524585211005339. doi: 10.1177/13524585211005339.
PubMed Abstract available

LEE LE, Vavasour IM, Dvorak A, Liu H, et al
Cervical cord myelin abnormality is associated with clinical disability in multiple sclerosis.
Mult Scler. 2021 Mar 22:13524585211001780. doi: 10.1177/13524585211001780.
PubMed Abstract available

HARROUD A, Mitchell RE, Richardson TG, Morris JA, et al
Childhood obesity and multiple sclerosis: A Mendelian randomization study.
Mult Scler. 2021 Mar 22:13524585211001781. doi: 10.1177/13524585211001781.
PubMed Abstract available

BRIGGS FB, Krill D, Hill E, Conway DS, et al
Age of hypertension onset in multiple sclerosis patients.
Mult Scler. 2021 Mar 18:13524585211003016. doi: 10.1177/13524585211003016.
PubMed Abstract available

MASSAROTTI C, Sbragia E, Boffa G, Vercelli C, et al
Menstrual cycle resumption and female fertility after autologous hematopoietic stem cell transplantation for multiple sclerosis.
Mult Scler. 2021 Mar 12:13524585211000616. doi: 10.1177/13524585211000616.
PubMed Abstract available

SCHOONHEIM MM, Douw L, Broeders TA, Eijlers AJ, et al
The cerebellum and its network: Disrupted static and dynamic functional connectivity patterns and cognitive impairment in multiple sclerosis.
Mult Scler. 2021 Mar 8:1352458521999274. doi: 10.1177/1352458521999274.
PubMed Abstract available

MACHLANSKA A, Helbig G, Chromik K, Zapala M, et al
Hemophagocytic lymphohistiocytosis associated with ocrelizumab treatment in a patient with multiple sclerosis.
Mult Scler. 2021 Mar 5:1352458521993070. doi: 10.1177/1352458521993070.
PubMed Abstract available

LORSCHEIDER J
When does a heap become a heap?
Mult Scler. 2021;27:329-330.
PubMed

February 2021

SZILASIOVA J, Mikula P, Rosenberger J, Fedicova M, et al
Plasma neurofilament light chain levels are predictors of disease activity in multiple sclerosis as measured by four-domain NEDA status, including brain volume loss.
Mult Scler. 2021 Feb 26:1352458521998039. doi: 10.1177/1352458521998039.
PubMed Abstract available

FOX RJ, Raska P, Barro C, Karafa M, et al
Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis.
Mult Scler. 2021 Feb 26:1352458520986956. doi: 10.1177/1352458520986956.
PubMed Abstract available

MHANNA E, Nouchi A, Louapre C, De Paz R, et al
Human papillomavirus lesions in 16 MS patients treated with fingolimod: Outcomes and vaccination.
Mult Scler. 2021 Feb 25:1352458521991433. doi: 10.1177/1352458521991433.
PubMed Abstract available

COPETTI M, Liu D
Machine and deep learning in multiple sclerosis research are just powerful statistics - Commentary.
Mult Scler. 2021 Feb 24:1352458521996699. doi: 10.1177/1352458521996699.
PubMed

HARROUD A, Manousaki D, Butler-Laporte G, Mitchell RE, et al
The relative contributions of obesity, vitamin D, leptin, and adiponectin to multiple sclerosis risk: A Mendelian randomization mediation analysis.
Mult Scler. 2021 Feb 19:1352458521995484. doi: 10.1177/1352458521995484.
PubMed Abstract available

BINZER S, Jiang X, Hillert J, Manouchehrinia A, et al
Depression and multiple sclerosis: A bidirectional Mendelian randomisation study.
Mult Scler. 2021 Feb 19:1352458521996601. doi: 10.1177/1352458521996601.
PubMed Abstract available

LEMA DOPICO A, Choi S, Hua J, Li X, et al
Multi-layer analysis of quantitative 7 T magnetic resonance imaging in the cortex of multiple sclerosis patients reveals pathology associated with disability.
Mult Scler. 2021 Feb 18:1352458521994556. doi: 10.1177/1352458521994556.
PubMed Abstract available

HARROUD A, Marrie RA, Fitzgerald KC, Salter A, et al
Mendelian randomization provides no evidence for a causal role in the bidirectional relationship between depression and multiple sclerosis.
Mult Scler. 2021 Feb 16:1352458521993075. doi: 10.1177/1352458521993075.
PubMed Abstract available

BESSING B, Hussain MA, Claflin SB, Chen J, et al
Changes in multiple sclerosis symptoms are associated with changes in work productivity of people living with multiple sclerosis.
Mult Scler. 2021 Feb 16:1352458521994557. doi: 10.1177/1352458521994557.
PubMed Abstract available

BELVISI D, Canevelli M, Baione V, Buscarinu MC, et al
Operationalization of a frailty index in patients with multiple sclerosis: A cross-sectional investigation.
Mult Scler. 2021 Feb 10:1352458520987541. doi: 10.1177/1352458520987541.
PubMed Abstract available

MIDAGLIA L, Sastre-Garriga J, Pappolla A, Quibus L, et al
The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of Catalonia.
Mult Scler. 2021 Feb 10:1352458520988148. doi: 10.1177/1352458520988148.
PubMed Abstract available

VELDKAMP R, Kalron A, Baert I, Hamalainen P, et al
Differential effects and discriminative validity of motor and cognitive tasks varying in difficulty on cognitive-motor interference in persons with multiple sclerosis.
Mult Scler. 2021 Feb 10:1352458520986960. doi: 10.1177/1352458520986960.
PubMed Abstract available

KRASNIUK S, Classen S, Morrow SA, Alvarez L, et al
Clinical predictors of driving simulator performance in drivers with multiple sclerosis.
Mult Scler. 2021 Feb 10:1352458521992507. doi: 10.1177/1352458521992507.
PubMed Abstract available

DAS J, Snowden JA, Burman J, Freedman MS, et al
Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with 'aggressive' multiple sclerosis.
Mult Scler. 2021 Feb 10:1352458520985238. doi: 10.1177/1352458520985238.
PubMed Abstract available

Incidence and clinical outcome of Coronavirus disease 2019 in a cohort of 11,560 Brazilian patients with multiple sclerosis.
Mult Scler. 2021 Feb 2:1352458520978354. doi: 10.1177/1352458520978354.
PubMed Abstract available

NYIRENDA MH, Fadda G, Healy LM, Mexhitaj I, et al
Pro-inflammatory adiponectin in pediatric-onset multiple sclerosis.
Mult Scler. 2021 Feb 1:1352458521989090. doi: 10.1177/1352458521989090.
PubMed Abstract available

YEH EA
Real-world outcomes in pediatric MS: Psychiatric comorbidities and school performance.
Mult Scler. 2021;27:165-166.
PubMed

TANASESCU R, Gran B
Uncovering the underhanded: B-cell depletion therapies and severe viral infections - Commentary on 'Fatal underhanded chronic enterovirus infection associated with anti-CD20 monotherapy for central nervous system demyelinating disease'.
Mult Scler. 2021;27:323-324.
PubMed

January 2021

MANOUCHEHRINIA A, Kingwell E, Zhu F, Tremlett H, et al
A multiple sclerosis disease progression measure based on cumulative disability.
Mult Scler. 2021 Jan 25:1352458520988632. doi: 10.1177/1352458520988632.
PubMed Abstract available

JALUSIC KO, Ellenberger D, Rommer P, Stahmann A, et al
Effect of applying inclusion and exclusion criteria of phase III clinical trials to multiple sclerosis patients in routine clinical care.
Mult Scler. 2021 Jan 20:1352458520985118. doi: 10.1177/1352458520985118.
PubMed Abstract available

BLACK LJ, Hetherton S, Forkan M, Gonzales EG, et al
An exploratory study of diet in childhood and young adulthood and adult-onset multiple sclerosis.
Mult Scler. 2021 Jan 19:1352458520986964. doi: 10.1177/1352458520986964.
PubMed Abstract available

ROOS I, Leray E, Frascoli F, Casey R, et al
Determinants of therapeutic lag in multiple sclerosis.
Mult Scler. 2021 Jan 11:1352458520981300. doi: 10.1177/1352458520981300.
PubMed Abstract available

FITZGERALD KC, Damian A, Conway D, Mowry EM, et al
Vascular comorbidity is associated with lower brain volumes and lower neuroperformance in a large multiple sclerosis cohort.
Mult Scler. 2021 Jan 8:1352458520984746. doi: 10.1177/1352458520984746.
PubMed Abstract available

GONZALEZ-ESCAMILLA G, Groppa S
7 Tesla MRI will soon be helpful to guide clinical practice in multiple sclerosis centres - No.
Mult Scler. 2021 Jan 6:1352458520969662. doi: 10.1177/1352458520969662.
PubMed

SATI P, Reich DS
7 Tesla MRI will soon be helpful to guide clinical practice in multiple sclerosis centers - Commentary.
Mult Scler. 2021 Jan 6:1352458520981738. doi: 10.1177/1352458520981738.
PubMed

LOUAPRE C, Beigneux Y
7 Tesla MRI will soon be helpful to guide clinical practice in multiple sclerosis centres - Yes.
Mult Scler. 2021 Jan 6:1352458520972270. doi: 10.1177/1352458520972270.
PubMed

ROLLOT F, Casey R, Leray E, Debouverie M, et al
Cumulative effects of therapies on disability in relapsing multiple sclerosis.
Mult Scler. 2021 Jan 6:1352458520980366. doi: 10.1177/1352458520980366.
PubMed Abstract available

MARRIE RA, Leung S, Cutter GR, Fox RJ, et al
Comparative responsiveness of the health utilities index and the RAND-12 for multiple sclerosis.
Mult Scler. 2021 Jan 5:1352458520981370. doi: 10.1177/1352458520981370.
PubMed Abstract available

AMATO MP, Portaccio E, De Meo E
Understanding the pathophysiology of cognitive changes in MS: A step forward.
Mult Scler. 2021;27:4-5.
PubMed

BISTROM M, Hultdin J, Sundstrom P
Response to 'Mendelian randomization analysis does not support a role for leptin in multiple sclerosis'.
Mult Scler. 2021;27:161-162.
PubMed

AL-ARAJI S, Ciccarelli O
A possible case of serum sickness after ocrelizumab infusion - Commentary.
Mult Scler. 2021;27:158-159.
PubMed Abstract available

December 2020

NIELSEN NM, Gortz S, Hjalgrim H, Rostgaard K, et al
Maternal diabetes and risk of multiple sclerosis in the offspring: A Danish nationwide register-based cohort study.
Mult Scler. 2020 Dec 17:1352458520977120. doi: 10.1177/1352458520977120.
PubMed Abstract available

GALLO A, Bisecco A
Psychological resilience explains functional variability across people with multiple sclerosis - Commentary.
Mult Scler. 2020 Dec 17:1352458520978213. doi: 10.1177/1352458520978213.
PubMed

LEAVITT VM, Kever A
Psychological resilience explains functional variability across people with multiple sclerosis - Yes.
Mult Scler. 2020 Dec 17:1352458520972263. doi: 10.1177/1352458520972263.
PubMed

PLOUGHMAN M
Psychological resilience explains functional variability across people with multiple sclerosis - No.
Mult Scler. 2020 Dec 17:1352458520973633. doi: 10.1177/1352458520973633.
PubMed

COMABELLA M, Deutschmann C, Midaglia L, Schierack P, et al
Chitinase 3-like 1 is not a target antigen in patients with multiple sclerosis.
Mult Scler. 2020 Dec 17:1352458520980141. doi: 10.1177/1352458520980141.
PubMed Abstract available

HYLAND MH, Robb JF
Teleconsultation will replace most face-to-face interactions in the multiple sclerosis clinic - Yes.
Mult Scler. 2020 Dec 16:1352458520973640. doi: 10.1177/1352458520973640.
PubMed

MOCCIA M
Teleconsultation will replace most face-to-face interactions in the multiple sclerosis clinic - No.
Mult Scler. 2020 Dec 16:1352458520968815. doi: 10.1177/1352458520968815.
PubMed

D'HAESELEER M
Teleconsultation will replace most face-to-face interactions in the multiple sclerosis clinic - Commentary.
Mult Scler. 2020 Dec 16:1352458520979303. doi: 10.1177/1352458520979303.
PubMed

CALABRESI PA, Arnold DL, Sangurdekar D, Singh CM, et al
Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring.
Mult Scler. 2020 Dec 14:1352458520972573. doi: 10.1177/1352458520972573.
PubMed Abstract available

FILIPPATOU AG, Moniruzzaman M, Sotirchos ES, Fitzgerald KC, et al
Serum ceramide levels are altered in multiple sclerosis.
Mult Scler. 2020 Dec 14:1352458520971816. doi: 10.1177/1352458520971816.
PubMed Abstract available

CHAN CK, Tian F, Pimentel Maldonado D, Mowry EM, et al
Depression in multiple sclerosis across the adult lifespan.
Mult Scler. 2020 Dec 14:1352458520979304. doi: 10.1177/1352458520979304.
PubMed Abstract available

TAPIA-MALTOS MA, Trevino-Frenk I, Garcia-Gonzalez HB, Rosetti M, et al
Identification of regulatory T cell molecules associated with severity of multiple sclerosis.
Mult Scler. 2020 Dec 10:1352458520977045. doi: 10.1177/1352458520977045.
PubMed Abstract available

NAUTA IM, Kulik SD, Breedt LC, Eijlers AJ, et al
Functional brain network organization measured with magnetoencephalography predicts cognitive decline in multiple sclerosis.
Mult Scler. 2020 Dec 9:1352458520977160. doi: 10.1177/1352458520977160.
PubMed Abstract available

JACOBS BM, Smets I, Giovannoni G, Noyce A, et al
Regarding: Nicotinic acetylcholine receptors alpha7 and alpha9 modify tobacco smoke risk for multiple sclerosis.
Mult Scler. 2020 Dec 8:1352458520969941. doi: 10.1177/1352458520969941.
PubMed

BRIGGS F
Response to Jacobs et al, Nicotinic acetylcholine receptors alpha7 and alpha9 modify tobacco smoke risk for multiple sclerosis.
Mult Scler. 2020 Dec 8:1352458520977027. doi: 10.1177/1352458520977027.
PubMed

KOUBIYR I, Deloire M, Brochet B, Besson P, et al
Structural constraints of functional connectivity drive cognitive impairment in the early stages of multiple sclerosis.
Mult Scler. 2020 Dec 7:1352458520971807. doi: 10.1177/1352458520971807.
PubMed Abstract available

VUKUSIC S, Ionescu I, Cornu C, Bossard N, et al
Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study.
Mult Scler. 2020 Dec 3:1352458520978218. doi: 10.1177/1352458520978218.
PubMed Abstract available

RAMANUJAM R, Zhu F, Fink K, Karrenbauer VD, et al
Accurate classification of secondary progression in multiple sclerosis using a decision tree.
Mult Scler. 2020 Dec 2:1352458520975323. doi: 10.1177/1352458520975323.
PubMed Abstract available

SHAH S
Real-world evidence: One tweet at a time.
Mult Scler. 2020;26:1965-1966.
PubMed

COETZEE T, Thompson AJ
Atlas of MS 2020: Informing global policy change.
Mult Scler. 2020;26:1807-1808.
PubMed

PILUTTI LA, Fakolade A
Rehabilitation should be prescribed acutely in motor relapses - Commentary.
Mult Scler. 2020;26:1825-1827.
PubMed

YONG KP, Kim HJ
Smelling the danger.
Mult Scler. 2020;26:1960-1961.
PubMed

November 2020

STEPHENS S, Berenbaum T, Finlayson M, Motl RW, et al
Youth with multiple sclerosis have low levels of fitness.
Mult Scler. 2020 Nov 27:1352458520974360. doi: 10.1177/1352458520974360.
PubMed Abstract available

ROMEO AR, Rowles WM, Schleimer ES, Barba P, et al
An electronic, unsupervised patient-reported Expanded Disability Status Scale for multiple sclerosis.
Mult Scler. 2020 Nov 25:1352458520968814. doi: 10.1177/1352458520968814.
PubMed Abstract available

LANGESKOV-CHRISTENSEN M, Hvid LG, Jensen HB, Nielsen HH, et al
Efficacy of high-intensity aerobic exercise on cognitive performance in people with multiple sclerosis: A randomized controlled trial.
Mult Scler. 2020 Nov 24:1352458520973619. doi: 10.1177/1352458520973619.
PubMed Abstract available

KLISTORNER S, Barnett MH, Yiannikas C, Barton J, et al
Expansion of chronic lesions is linked to disease progression in relapsing-remitting multiple sclerosis patients.
Mult Scler. 2020 Nov 20:1352458520974357. doi: 10.1177/1352458520974357.
PubMed Abstract available

IAFFALDANO P, Lucisano G, Patti F, Brescia Morra V, et al
Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors.
Mult Scler. 2020 Nov 19:1352458520974366. doi: 10.1177/1352458520974366.
PubMed Abstract available

LARONI A, Schiavetti I, Sormani MP, Uccelli A, et al
COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments.
Mult Scler. 2020 Nov 18:1352458520971817. doi: 10.1177/1352458520971817.
PubMed Abstract available

CREE BA, Magnusson B, Rouyrre N, Fox RJ, et al
Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis.
Mult Scler. 2020 Nov 18:1352458520971819. doi: 10.1177/1352458520971819.
PubMed Abstract available

GLUKHOVSKY L, Kurz D, Brandstadter R, Leavitt VM, et al
Depression and cognitive function in early multiple sclerosis: Multitasking is more sensitive than traditional assessments.
Mult Scler. 2020 Nov 16:1352458520958359. doi: 10.1177/1352458520958359.
PubMed Abstract available

PREZIOSA P, Pagani E, Moiola L, Rodegher M, et al
Occurrence and microstructural features of slowly expanding lesions on fingolimod or natalizumab treatment in multiple sclerosis.
Mult Scler. 2020 Nov 13:1352458520969105. doi: 10.1177/1352458520969105.
PubMed Abstract available

HEITMANN H, Andlauer TFM, Korn T, Muhlau M, et al
Fatigue, depression, and pain in multiple sclerosis: How neuroinflammation translates into dysfunctional reward processing and anhedonic symptoms.
Mult Scler. 2020 Nov 12:1352458520972279. doi: 10.1177/1352458520972279.
PubMed Abstract available

SACCO R, Braga A, Disanto G, Digesu GA, et al
Effectiveness of percutaneous posterior tibial nerve stimulation for the management of bowel dysfunction in multiple sclerosis patients.
Mult Scler. 2020 Nov 12:1352458520972267. doi: 10.1177/1352458520972267.
PubMed Abstract available

KARIM ME, Pellegrini F, Platt RW, Simoneau G, et al
The use and quality of reporting of propensity score methods in multiple sclerosis literature: A review.
Mult Scler. 2020 Nov 12:1352458520972557. doi: 10.1177/1352458520972557.
PubMed Abstract available

AVILA M, Okai A, Thakolwiboon S, O'Bryan C, et al
The effect of tonsillectomy on John Cunningham virus serological status in multiple sclerosis patients: A retrospective case-control study.
Mult Scler. 2020 Nov 12:1352458520971822. doi: 10.1177/1352458520971822.
PubMed Abstract available

WALTON C, King R, Rechtman L, Kaye W, et al
Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition.
Mult Scler. 2020 Nov 11:1352458520970841. doi: 10.1177/1352458520970841.
PubMed Abstract available

HEDSTROM AK, Olsson T, Alfredsson L
Cotinine as a measure of smoking in observational studies of multiple sclerosis.
Mult Scler. 2020 Nov 10:1352458520968803. doi: 10.1177/1352458520968803.
PubMed Abstract available

LAM KH, Meijer KA, Loonstra FC, Coerver E, et al
Real-world keystroke dynamics are a potentially valid biomarker for clinical disability in multiple sclerosis.
Mult Scler. 2020 Nov 5:1352458520968797. doi: 10.1177/1352458520968797.
PubMed Abstract available

BUYUKTURKOGLU K, Zeng D, Bharadwaj S, Tozlu C, et al
Classifying multiple sclerosis patients on the basis of SDMT performance using machine learning.
Mult Scler. 2020 Nov 4:1352458520958362. doi: 10.1177/1352458520958362.
PubMed Abstract available

October 2020

LOZINSKI BM, Yong VW
Exercise and the brain in multiple sclerosis.
Mult Scler. 2020 Oct 30:1352458520969099. doi: 10.1177/1352458520969099.
PubMed Abstract available

AFZAL HMR, Luo S, Ramadan S, Lechner-Scott J, et al
The emerging role of artificial intelligence in multiple sclerosis imaging.
Mult Scler. 2020 Oct 28:1352458520966298. doi: 10.1177/1352458520966298.
PubMed Abstract available

PROSPERINI L, Haggiag S, Tortorella C, Galgani S, et al
Age-related adverse events of disease-modifying treatments for multiple sclerosis: A meta-regression.
Mult Scler. 2020 Oct 26:1352458520964778. doi: 10.1177/1352458520964778.
PubMed Abstract available

STRIK M, Chard DT, Dekker I, Meijer KA, et al
Increased functional sensorimotor network efficiency relates to disability in multiple sclerosis.
Mult Scler. 2020 Oct 26:1352458520966292. doi: 10.1177/1352458520966292.
PubMed Abstract available

KOSCH R, Schiffmann I, Daumer M, Lederer C, et al
Long-term prognostic counselling in people with multiple sclerosis using an online analytical processing tool.
Mult Scler. 2020 Oct 26:1352458520964774. doi: 10.1177/1352458520964774.
PubMed Abstract available

TECCHIO F, Bertoli M, Gianni E, L'Abbate T, et al
Parietal dysfunctional connectivity in depression in multiple sclerosis.
Mult Scler. 2020 Oct 21:1352458520964412. doi: 10.1177/1352458520964412.
PubMed

JAEGER S, Paul F, Finke C
Functional connectivity alterations of striato-cortical circuits in multiple sclerosis.
Mult Scler. 2020 Oct 21:1352458520966303. doi: 10.1177/1352458520966303.
PubMed

BERMEL RA, Fedler JK, Kaiser P, Novalis C, et al
Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis.
Mult Scler. 2020 Oct 15:1352458520964409. doi: 10.1177/1352458520964409.
PubMed Abstract available

SIDORE C, Orru V, Cocco E, Steri M, et al
PRF1 mutation alters immune system activation, inflammation, and risk of autoimmunity.
Mult Scler. 2020 Oct 14:1352458520963937. doi: 10.1177/1352458520963937.
PubMed Abstract available

MARRIE RA, Walld R, Bolton JM, Sareen J, et al
Effect of mood and anxiety disorders on health care utilization in multiple sclerosis.
Mult Scler. 2020 Oct 13:1352458520963880. doi: 10.1177/1352458520963880.
PubMed Abstract available

CASTELLI L, Quartuccio ME, Ruggieri S, De Giglio L, et al
'Posture second' strategy predicts disability progression in multiple sclerosis.
Mult Scler. 2020 Oct 13:1352458520963926. doi: 10.1177/1352458520963926.
PubMed Abstract available

VEREB D, Toth E, Bozsik B, Kiraly A, et al
Altered brain network function during attention-modulated visual processing in multiple sclerosis.
Mult Scler. 2020 Oct 5:1352458520958360. doi: 10.1177/1352458520958360.
PubMed Abstract available

LANGER-GOULD A, Black LJ, Waubant E, Smith JB, et al
Seafood, fatty acid biosynthesis genes, and multiple sclerosis susceptibility.
Mult Scler. 2020;26:1476-1485.
PubMed Abstract available

CHEN J, Taylor B, Winzenberg T, Palmer AJ, et al
Comorbidities are prevalent and detrimental for employment outcomes in people of working age with multiple sclerosis.
Mult Scler. 2020;26:1550-1559.
PubMed Abstract available

HULST HE, Penner IK
Cognition and its relation to brain health in patients with MS.
Mult Scler. 2020;26:1611-1613.
PubMed

HOBART J, Giovannoni G
Cognition and its relation to brain health in patients with MS: Response to letter.
Mult Scler. 2020;26:1613-1614.
PubMed

AZEVEDO CJ, Zamvil SS
New cases of vasculitis after alemtuzumab.
Mult Scler. 2020;26:1606-1608.
PubMed

September 2020

PISA M, Chieffo R, Congiu M, Dalla Costa G, et al
Intracortical motor conduction is associated with hand dexterity in progressive multiple sclerosis.
Mult Scler. 2020 Sep 25:1352458520960374. doi: 10.1177/1352458520960374.
PubMed Abstract available

FERRE L, Mogavero A, Clarelli F, Moiola L, et al
Early evidence of disease activity during fingolimod predicts medium-term inefficacy in relapsing-remitting multiple sclerosis.
Mult Scler. 2020 Sep 25:1352458520961690. doi: 10.1177/1352458520961690.
PubMed Abstract available

BOESEN MS, Blinkenberg M, Thygesen LC, Eriksson F, et al
School performance, psychiatric comorbidity, and healthcare utilization in pediatric multiple sclerosis: A nationwide population-based observational study.
Mult Scler. 2020 Sep 25:1352458520959673. doi: 10.1177/1352458520959673.
PubMed Abstract available

CALVI A, Haider L, Prados F, Tur C, et al
In vivo imaging of chronic active lesions in multiple sclerosis.
Mult Scler. 2020 Sep 23:1352458520958589. doi: 10.1177/1352458520958589.
PubMed Abstract available

RIVA A, Barcella V, Benatti SV, Capobianco M, et al
Vaccinations in patients with multiple sclerosis: A Delphi consensus statement.
Mult Scler. 2020 Sep 17:1352458520952310. doi: 10.1177/1352458520952310.
PubMed Abstract available

MOIOLA L, Barcella V, Benatti S, Capobianco M, et al
The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement.
Mult Scler. 2020 Sep 17:1352458520952311. doi: 10.1177/1352458520952311.
PubMed Abstract available

FEYS P, Swinnen E
Powered exoskeletons for walking in multiple sclerosis.
Mult Scler. 2020 Sep 15:1352458520958351. doi: 10.1177/1352458520958351.
PubMed

WEE SK, Ho CY, Tan SL, Ong CH, et al
Enhancing quality of life in progressive multiple sclerosis with powered robotic exoskeleton.
Mult Scler. 2020 Sep 15:1352458520943080. doi: 10.1177/1352458520943080.
PubMed Abstract available

CORDANI C, Hidalgo de la Cruz M, Meani A, Valsasina P, et al
MRI correlates of clinical disability and hand-motor performance in multiple sclerosis phenotypes.
Mult Scler. 2020 Sep 14:1352458520958356. doi: 10.1177/1352458520958356.
PubMed Abstract available

ZHANG Y, Taylor BV, Simpson S Jr, Blizzard L, et al
Feelings of depression, pain and walking difficulties have the largest impact on the quality of life of people with multiple sclerosis, irrespective of clinical phenotype.
Mult Scler. 2020 Sep 14:1352458520958369. doi: 10.1177/1352458520958369.
PubMed Abstract available

BRIGGS FB
Nicotinic acetylcholine receptors alpha7 and alpha9 modifies tobacco smoke risk for multiple sclerosis.
Mult Scler. 2020 Sep 14:1352458520958361. doi: 10.1177/1352458520958361.
PubMed Abstract available

KUNCHOK A, Flanagan EP, Krecke KN, Chen JJ, et al
MOG-IgG1 and co-existence of neuronal autoantibodies.
Mult Scler. 2020 Sep 10:1352458520951046. doi: 10.1177/1352458520951046.
PubMed Abstract available

MARTINO M, Magioncalda P, El Mendili MM, Droby A, et al
Depression is associated with disconnection of neurotransmitter-related nuclei in multiple sclerosis.
Mult Scler. 2020 Sep 10:1352458520948214. doi: 10.1177/1352458520948214.
PubMed Abstract available

CHEN J, Taylor B, Blizzard L, Simpson-Yap S, et al
Risk factors for leaving employment due to multiple sclerosis and changes in risk over the past decades: Using competing risk survival analysis.
Mult Scler. 2020 Sep 3:1352458520954167. doi: 10.1177/1352458520954167.
PubMed Abstract available

YILMAZER C, Lamers I, Solaro C, Feys P, et al
Clinical perspective on pain in multiple sclerosis.
Mult Scler. 2020 Sep 3:1352458520952015. doi: 10.1177/1352458520952015.
PubMed Abstract available

HAWTON A, Goodwin E, Boddy K, Freeman J, et al
Measuring the cost-effectiveness of treatments for people with multiple sclerosis: Beyond quality-adjusted life-years.
Mult Scler. 2020 Sep 3:1352458520954172. doi: 10.1177/1352458520954172.
PubMed Abstract available

JOISTEN N, Proschinger S, Rademacher A, Schenk A, et al
High-intensity interval training reduces neutrophil-to-lymphocyte ratio in persons with multiple sclerosis during inpatient rehabilitation.
Mult Scler. 2020 Sep 3:1352458520951382. doi: 10.1177/1352458520951382.
PubMed Abstract available

CICCARELLI O, Cohen JA, Thompson A
Response of the multiple sclerosis community to COVID-19.
Mult Scler. 2020;26:1134-1136.
PubMed

YAM C, Jokubaitis V, Hellwig K, Dobson R, et al
MS, pregnancy and COVID-19.
Mult Scler. 2020;26:1137-1146.
PubMed Abstract available

MECA-LALLANA V
COVID-19 will change MS care forever - Yes.
Mult Scler. 2020;26:1147-1148.
PubMed

PREZIOSA P, Rocca MA, Filippi M
COVID-19 will change MS care forever - No.
Mult Scler. 2020;26:1149-1151.
PubMed

August 2020

MIDAGLIA L, Otero S, Baro F, Montalban X, et al
Menopause and multiple sclerosis: Influence on prognosis and role of disease-modifying drugs and hormonal replacement therapy.
Mult Scler. 2020 Aug 28:1352458520952022. doi: 10.1177/1352458520952022.
PubMed Abstract available

DISANTO G, Ripellino P, Riccitelli GC, Sacco R, et al
De-escalating rituximab dose results in stability of clinical, radiological, and serum neurofilament levels in multiple sclerosis.
Mult Scler. 2020 Aug 25:1352458520952036. doi: 10.1177/1352458520952036.
PubMed Abstract available

BOFFA G, Sbragia E, Raiola AM, Varaldo R, et al
Autologous hematopoietic stem cell transplantation following alemtuzumab therapy in aggressive multiple sclerosis: A report of three cases.
Mult Scler. 2020 Aug 25:1352458520914818. doi: 10.1177/1352458520914818.
PubMed Abstract available

SMITH AD, Prokopiusova T, Jones R, Burge T, et al
Functional electrical stimulation for foot drop in people with multiple sclerosis: The relevance and importance of addressing quality of movement.
Mult Scler. 2020 Aug 24:1352458520923958. doi: 10.1177/1352458520923958.
PubMed Abstract available

SADIGH G, Lava N, Switchenko J, Duszak R Jr, et al
Patient-reported financial toxicity in multiple sclerosis: Predictors and association with care non-adherence.
Mult Scler. 2020 Aug 18:1352458520913977. doi: 10.1177/1352458520913977.
PubMed Abstract available

JORDAN AL, Yang J, Fisher CJ, Racke MK, et al
Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients.
Mult Scler. 2020 Aug 18:1352458520949158. doi: 10.1177/1352458520949158.
PubMed Abstract available

SEYMAN E, Jones A, Guenette M, Vosoughi R, et al
Clinical and MRI characteristics of multiple sclerosis in patients of Middle Eastern and North African ancestry residing in Ontario, Canada.
Mult Scler. 2020 Aug 11:1352458520948212. doi: 10.1177/1352458520948212.
PubMed Abstract available

MOSS BP, Mahajan KR, Bermel RA, Hellisz K, et al
Multiple sclerosis management during the COVID-19 pandemic.
Mult Scler. 2020 Aug 10:1352458520948231. doi: 10.1177/1352458520948231.
PubMed Abstract available

BROWNLEE WJ
COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual?
Mult Scler. 2020 Aug 7:1352458520948211. doi: 10.1177/1352458520948211.
PubMed

WURM H, Attfield K, Iversen AK, Gold R, et al
Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient.
Mult Scler. 2020 Aug 7:1352458520943791. doi: 10.1177/1352458520943791.
PubMed Abstract available

DERSCH R, Wehrum T, Fahndrich S, Engelhardt M, et al
COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment.
Mult Scler. 2020 Aug 7:1352458520943783. doi: 10.1177/1352458520943783.
PubMed Abstract available

JAWORSKI MG 3RD, Fuchs TA, Dwyer MG, Wojcik C, et al
Conscientiousness and deterioration in employment status in multiple sclerosis over 3 years.
Mult Scler. 2020 Aug 6:1352458520946019. doi: 10.1177/1352458520946019.
PubMed Abstract available

GERALDES R, Jurynczyk M, Dos Passos GR, Pichler A, et al
The role of pontine lesion location in differentiating multiple sclerosis from vascular risk factor-related small vessel disease.
Mult Scler. 2020 Aug 6:1352458520943777. doi: 10.1177/1352458520943777.
PubMed Abstract available

GUISSET F, Lolli V, Bugli C, Perrotta G, et al
The central vein sign in multiple sclerosis patients with vascular comorbidities.
Mult Scler. 2020 Aug 4:1352458520943785. doi: 10.1177/1352458520943785.
PubMed Abstract available

ALEXANDER S, Peryer G, Gray E, Barkhof F, et al
Wearable technologies to measure clinical outcomes in multiple sclerosis: A scoping review.
Mult Scler. 2020 Aug 4:1352458520946005. doi: 10.1177/1352458520946005.
PubMed Abstract available

LIPP I, Foster C, Stickland R, Sgarlata E, et al
Predictors of training-related improvement in visuomotor performance in patients with multiple sclerosis: A behavioural and MRI study.
Mult Scler. 2020 Aug 4:1352458520943788. doi: 10.1177/1352458520943788.
PubMed Abstract available

ABBOUD H
Iatrogenic demyelinating disorders: New insights, new culprits.
Mult Scler. 2020;26:1129-1130.
PubMed

July 2020

RINGH MV, Hagemann-Jensen M, Needhamsen M, Kullberg S, et al
Methylome and transcriptome signature of bronchoalveolar cells from multiple sclerosis patients in relation to smoking.
Mult Scler. 2020 Jul 30:1352458520943768. doi: 10.1177/1352458520943768.
PubMed Abstract available

CORRIGENDUM to "Effectiveness of the transcutaneous tibial nerve stimulation and pelvic floor muscle training with biofeedback in women with multiple sclerosis for the management of overactive bladder".
Mult Scler. 2020 Jul 24:1352458520945512. doi: 10.1177/1352458520945512.
PubMed

SIMPSON-YAP S, Oddy WH, Taylor B, Lucas RM, et al
High Prudent diet factor score predicts lower relapse hazard in early multiple sclerosis.
Mult Scler. 2020 Jul 23:1352458520943087. doi: 10.1177/1352458520943087.
PubMed Abstract available

INOJOSA H, Ziemssen T
How to reduce the delay of diagnosing secondary progression in multiple sclerosis.
Mult Scler. 2020 Jul 22:1352458520943799. doi: 10.1177/1352458520943799.
PubMed

CONWAY DS, Thompson NR, Meng X, Johnson K, et al
Patient reported outcomes and performance metrics at diagnosis of secondary progressive multiple sclerosis.
Mult Scler. 2020 Jul 16:1352458520936214. doi: 10.1177/1352458520936214.
PubMed Abstract available

HUBBARD AL, Golla H, Lausberg H
What's in a name? That which we call Multiple Sclerosis Fatigue.
Mult Scler. 2020 Jul 16:1352458520941481. doi: 10.1177/1352458520941481.
PubMed Abstract available

PEETERS LM, Parciak T, Walton C, Geys L, et al
COVID-19 in people with multiple sclerosis: A global data sharing initiative.
Mult Scler. 2020 Jul 14:1352458520941485. doi: 10.1177/1352458520941485.
PubMed Abstract available

HIDALGO DE LA CRUZ M, Valsasina P, Gobbi C, Gallo A, et al
Longitudinal cortical thinning progression differs across multiple sclerosis phenotypes and is clinically relevant: A multicentre study.
Mult Scler. 2020 Jul 14:1352458520940548. doi: 10.1177/1352458520940548.
PubMed Abstract available

BARCELLOS LF, Horton M, Shao X, Bellesis KH, et al
A validation study for remote testing of cognitive function in multiple sclerosis.
Mult Scler. 2020 Jul 14:1352458520937385. doi: 10.1177/1352458520937385.
PubMed Abstract available

LOONSTRA FC, Hoitsma E, van Kempen ZL, Killestein J, et al
COVID-19 in multiple sclerosis: The Dutch experience.
Mult Scler. 2020 Jul 14:1352458520942198. doi: 10.1177/1352458520942198.
PubMed Abstract available

STORELLI L, Pagani E, Preziosa P, Filippi M, et al
Measurement of white matter fiber-bundle cross-section in multiple sclerosis using diffusion-weighted imaging.
Mult Scler. 2020 Jul 14:1352458520938999. doi: 10.1177/1352458520938999.
PubMed Abstract available

ABBATEMARCO JR, Griffin A, Jones NG, Hartman J, et al
Long-term outcomes of intrathecal baclofen in ambulatory multiple sclerosis patients: A single-center experience.
Mult Scler. 2020 Jul 14:1352458520936912. doi: 10.1177/1352458520936912.
PubMed Abstract available

WU P, Li R, Zhang W, Lu H, et al
Mendelian randomization analysis does not support a role for leptin in multiple sclerosis.
Mult Scler. 2020 Jul 14:1352458520938990. doi: 10.1177/1352458520938990.
PubMed

PINTER D, Khalil M, Pirpamer L, Damulina A, et al
Long-term course and morphological MRI correlates of cognitive function in multiple sclerosis.
Mult Scler. 2020 Jul 14:1352458520941474. doi: 10.1177/1352458520941474.
PubMed Abstract available

CROTEAU D, Tobenkin A, Brinker A, Kortepeter CM, et al
Tumefactive multiple sclerosis in association with fingolimod initiation and discontinuation.
Mult Scler. 2020 Jul 14:1352458520938354. doi: 10.1177/1352458520938354.
PubMed Abstract available

GERALDES R
Two-armed active comparator trials are unethical in pediatric multiple sclerosis - No.
Mult Scler. 2020 Jul 10:1352458520931784. doi: 10.1177/1352458520931784.
PubMed

WAUBANT E
Two-armed active comparator trials are unethical in paediatric multiple sclerosis - Commentary.
Mult Scler. 2020 Jul 10:1352458520936243. doi: 10.1177/1352458520936243.
PubMed

KRUPP LB, Charvet LE
Two-armed active comparator trials are unethical in pediatric multiple sclerosis - Yes.
Mult Scler. 2020 Jul 10:1352458520931796. doi: 10.1177/1352458520931796.
PubMed

CHITNIS T, Banwell B, Krupp L, Arnold DL, et al
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study.
Mult Scler. 2020 Jul 7:1352458520936934. doi: 10.1177/1352458520936934.
PubMed Abstract available

FITZGERALD KC, Morris B, Soroosh A, Balshi A, et al
Pilot randomized active-placebo-controlled trial of low-dose ketamine for the treatment of multiple sclerosis-related fatigue.
Mult Scler. 2020 Jul 7:1352458520936226. doi: 10.1177/1352458520936226.
PubMed Abstract available

HACOHEN Y, Banwell B, Ciccarelli O
What does first-line therapy mean for paediatric multiple sclerosis in the current era?
Mult Scler. 2020 Jul 7:1352458520937644. doi: 10.1177/1352458520937644.
PubMed Abstract available

KUNCHOK A, Flanagan EP, Snyder M, Saadeh R, et al
Coexisting systemic and organ-specific autoimmunity in MOG-IgG1-associated disorders versus AQP4-IgG+ NMOSD.
Mult Scler. 2020 Jul 7:1352458520933884. doi: 10.1177/1352458520933884.
PubMed Abstract available

BSTEH G, Berek K, Hegen H, Altmann P, et al
Macular ganglion cell-inner plexiform layer thinning as a biomarker of disability progression in relapsing multiple sclerosis.
Mult Scler. 2020 Jul 2:1352458520935724. doi: 10.1177/1352458520935724.
PubMed Abstract available

THRUE C, Riemenschneider M, Hvid LG, Stenager E, et al
Time matters: Early-phase multiple sclerosis is accompanied by considerable impairments across multiple domains.
Mult Scler. 2020 Jul 2:1352458520936231. doi: 10.1177/1352458520936231.
PubMed Abstract available

ARRAMBIDE G
MOG-antibody-associated disease-getting the whole picture.
Mult Scler. 2020;26:1000-1001.
PubMed

June 2020

FEINSTEIN A, Meza C, Stefan C, Staines WR, et al
Discontinuing cannabis improves depression in people with multiple sclerosis: A short report.
Mult Scler. 2020 Jun 26:1352458520934070. doi: 10.1177/1352458520934070.
PubMed Abstract available

SIGNORI A, Boffa G, Bovis F, Mariottini A, et al
Prevalence of disability improvement as a potential outcome for multiple sclerosis trials.
Mult Scler. 2020 Jun 26:1352458520936236. doi: 10.1177/1352458520936236.
PubMed Abstract available

Household paired design reduces variance and increases power in multi-city gut microbiome study in multiple sclerosis.
Mult Scler. 2020 Jun 26:1352458520924594. doi: 10.1177/1352458520924594.
PubMed Abstract available

MEHNDIRATTA A, Treaba CA, Barletta V, Herranz E, et al
Characterization of thalamic lesions and their correlates in multiple sclerosis by ultra-high-field MRI.
Mult Scler. 2020 Jun 25:1352458520932804. doi: 10.1177/1352458520932804.
PubMed Abstract available

BOVE R, Rowles W, Zhao C, Anderson A, et al
A novel in-home digital treatment to improve processing speed in people with multiple sclerosis: A pilot study.
Mult Scler. 2020 Jun 25:1352458520930371. doi: 10.1177/1352458520930371.
PubMed Abstract available

WIENDL H, Spelman T, Butzkueven H, Kappos L, et al
Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program.
Mult Scler. 2020 Jun 24:1352458520926869. doi: 10.1177/1352458520926869.
PubMed Abstract available

GLUKHOVSKY L, Brandstadter R, Leavitt VM, Krieger S, et al
Hippocampal volume is more related to patient-reported memory than objective memory performance in early multiple sclerosis.
Mult Scler. 2020 Jun 22:1352458520922830. doi: 10.1177/1352458520922830.
PubMed Abstract available

SASTRE-GARRIGA J, Tintore M, Montalban X
Keeping standards of multiple sclerosis care through the COVID-19 pandemic.
Mult Scler. 2020 Jun 19:1352458520931785. doi: 10.1177/1352458520931785.
PubMed

LEVIN SN, Ezuma C, Levine L, Vargas WS, et al
Switching from natalizumab to ocrelizumab in patients with multiple sclerosis.
Mult Scler. 2020 Jun 19:1352458520927631. doi: 10.1177/1352458520927631.
PubMed

GHEZZI A, Banwell B, Bar-Or A, Chitnis T, et al
Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations.
Mult Scler. 2020 Jun 19:1352458520932798. doi: 10.1177/1352458520932798.
PubMed Abstract available

BHARGAVA P, Nogueras-Ortiz C, Kim S, Delgado-Peraza F, et al
Synaptic and complement markers in extracellular vesicles in multiple sclerosis.
Mult Scler. 2020 Jun 17:1352458520924590. doi: 10.1177/1352458520924590.
PubMed Abstract available

RICIGLIANO VA, Tonietto M, Palladino R, Poirion E, et al
Thalamic energy dysfunction is associated with thalamo-cortical tract damage in multiple sclerosis: A diffusion spectroscopy study.
Mult Scler. 2020 Jun 17:1352458520921362. doi: 10.1177/1352458520921362.
PubMed Abstract available

YAVARPOUR-BALI H, Ghasemi-Kasman M
The role of inflammasomes in multiple sclerosis.
Mult Scler. 2020 Jun 16:1352458520932776. doi: 10.1177/1352458520932776.
PubMed Abstract available

GHEZZI A, Amato MP, Edan G, Hartung HP, et al
The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges.
Mult Scler. 2020 Jun 16:1352458520930620. doi: 10.1177/1352458520930620.
PubMed Abstract available

LE M, Malpas C, Sharmin S, Horakova D, et al
Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis.
Mult Scler. 2020 Jun 15:1352458520926955. doi: 10.1177/1352458520926955.
PubMed Abstract available

IACOBAEUS E, Arrambide G, Pia Amato M, Derfuss T, et al
Aggressive multiple sclerosis (1): Towards a definition of the phenotype.
Mult Scler. 2020 Jun 12:1352458520925369. doi: 10.1177/1352458520925369.
PubMed Abstract available

ARRAMBIDE G, Iacobaeus E, Amato MP, Derfuss T, et al
Aggressive multiple sclerosis (2): Treatment.
Mult Scler. 2020 Jun 12:1352458520924595. doi: 10.1177/1352458520924595.
PubMed Abstract available

LIZAK N, Hodgkinson S, Butler E, Lechner-Scott J, et al
Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy.
Mult Scler. 2020 Jun 12:1352458520921087. doi: 10.1177/1352458520921087.
PubMed Abstract available

POLAT DUNYA C, Tulek Z, Kurtuncu M, Panicker JN, et al
Effectiveness of the transcutaneous tibial nerve stimulation and pelvic floor muscle training with biofeedback in women with multiple sclerosis for the management of overactive bladder.
Mult Scler. 2020 Jun 9:1352458520926666. doi: 10.1177/1352458520926666.
PubMed Abstract available

SOLARI A, Oliver D
Palliative care in multiple sclerosis: European guideline.
Mult Scler. 2020 Jun 9:1352458520926467. doi: 10.1177/1352458520926467.
PubMed

XU Y, Hiyoshi A, Brand JS, Smith KA, et al
Higher body mass index at ages 16 to 20 years is associated with increased risk of a multiple sclerosis diagnosis in subsequent adulthood among men.
Mult Scler. 2020 Jun 8:1352458520928061. doi: 10.1177/1352458520928061.
PubMed Abstract available

BROWN J, Quattrochi B, Everett C, Hong BY, et al
Gut commensals, dysbiosis, and immune response imbalance in the pathogenesis of multiple sclerosis.
Mult Scler. 2020 Jun 8:1352458520928301. doi: 10.1177/1352458520928301.
PubMed Abstract available

CELIUS EG
Breastfeeding and treatment of multiple sclerosis.
Mult Scler. 2020 Jun 8:1352458520931786. doi: 10.1177/1352458520931786.
PubMed

PIHL-JENSEN G, Wanscher B, Frederiksen JL
Predictive value of optical coherence tomography, multifocal visual evoked potentials, and full-field visual evoked potentials of the fellow, non-symptomatic eye for subsequent multiple sclerosis development in patients with acute optic neuritis.
Mult Scler. 2020 Jun 8:1352458520917924. doi: 10.1177/1352458520917924.
PubMed Abstract available

ROJAS JI, Patrucco L, Alonso R, Garcea O, et al
Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis: Multicenter study in Argentina.
Mult Scler. 2020 Jun 2:1352458520924586. doi: 10.1177/1352458520924586.
PubMed Abstract available

OH J, Chen M, Cybulsky K, Suthiphosuwan S, et al
Five-year longitudinal changes in quantitative spinal cord MRI in multiple sclerosis.
Mult Scler. 2020 Jun 1:1352458520923970. doi: 10.1177/1352458520923970.
PubMed Abstract available

COSTELLO F, Petzold A
Weighting evidence in MS: Obesity and neurodegeneration.
Mult Scler. 2020;26:748-750.
PubMed

BOYKO A
Radiologically isolated syndrome with oligoclonal bands in CSF (RIS + OCB) can be classified as high MS risk group.
Mult Scler. 2020;26:869-870.
PubMed

DE STEFANO N
Response to Dr Boyko's letter: 'Radiologically isolated syndrome with oligoclonal bands in CSF (RIS + OCB) can be classified as highly MS-risk group'.
Mult Scler. 2020;26:871.
PubMed

VAN DER WALT A
Addressing the treatment gap in MS-associated tremor: A new door opens.
Mult Scler. 2020;26:858.
PubMed

May 2020

VARGAS WS, Noble KG, Banwell B, De Jager P, et al
The educational impact of childhood-onset multiple sclerosis: Why assessing academic achievement is imperative.
Mult Scler. 2020 May 28:1352458520923946. doi: 10.1177/1352458520923946.
PubMed Abstract available

VON WYL V, Benkert P, Moser A, Lorscheider J, et al
Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate.
Mult Scler. 2020 May 28:1352458520918489. doi: 10.1177/1352458520918489.
PubMed Abstract available

CARANDINI T, Pietroboni AM, Sacchi L, De Riz MA, et al
Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression.
Mult Scler. 2020 May 28:1352458520926459. doi: 10.1177/1352458520926459.
PubMed

PASQUA G, Tommasin S, Bharti K, Ruggieri S, et al
Resting-state functional connectivity of anterior and posterior cerebellar lobes is altered in multiple sclerosis.
Mult Scler. 2020 May 28:1352458520922770. doi: 10.1177/1352458520922770.
PubMed Abstract available

AYRIGNAC X, Larochelle C, Keezer M, Roger E, et al
Frailty in ageing persons with multiple sclerosis.
Mult Scler. 2020 May 27:1352458520923945. doi: 10.1177/1352458520923945.
PubMed Abstract available

CORONADO I, Gabr RE, Narayana PA
Deep learning segmentation of gadolinium-enhancing lesions in multiple sclerosis.
Mult Scler. 2020 May 22:1352458520921364. doi: 10.1177/1352458520921364.
PubMed Abstract available

WANG FM, Davis MF, Briggs FB
Predicting self-reported depression after the onset of multiple sclerosis using genetic and non-genetic factors.
Mult Scler. 2020 May 18:1352458520921073. doi: 10.1177/1352458520921073.
PubMed Abstract available

BRUIJSTENS AL, Blok KM, Smolders J, Wokke BH, et al
Pediatric MS patients with a primary progressive-like disease may still have relevant inflammatory activity and may benefit from regular MS treatment.
Mult Scler. 2020 May 14:1352458520921367. doi: 10.1177/1352458520921367.
PubMed

VALBURG C, Sonti A, Stern JN, Najjar S, et al
Dietary factors in experimental autoimmune encephalomyelitis and multiple sclerosis: A comprehensive review.
Mult Scler. 2020 May 14:1352458520923955. doi: 10.1177/1352458520923955.
PubMed Abstract available

KILJAN S, Preziosa P, Jonkman LE, van de Berg WD, et al
Cortical axonal loss is associated with both gray matter demyelination and white matter tract pathology in progressive multiple sclerosis: Evidence from a combined MRI-histopathology study.
Mult Scler. 2020 May 11:1352458520918978. doi: 10.1177/1352458520918978.
PubMed Abstract available

GHARAKHANLOU R, Wesselmann L, Rademacher A, Lampit A, et al
Exercise training and cognitive performance in persons with multiple sclerosis: A systematic review and multilevel meta-analysis of clinical trials.
Mult Scler. 2020 May 11:1352458520917935. doi: 10.1177/1352458520917935.
PubMed Abstract available

LUNEMANN JD, Diaz-Diaz J, Stankoff B, Young C, et al
Highlights from the 2019 European Congress on Treatment and Research in Multiple Sclerosis (ECTRIMS 2019).
Mult Scler. 2020 May 4:1352458520918377. doi: 10.1177/1352458520918377.
PubMed Abstract available

BOSE G, Thebault S, Rush CA, Atkins HL, et al
Autologous hematopoietic stem cell transplantation for multiple sclerosis: A current perspective.
Mult Scler. 2020 May 4:1352458520917936. doi: 10.1177/1352458520917936.
PubMed Abstract available

LAMBE J, Saidha S, Bermel RA
Optical coherence tomography and multiple sclerosis: Update on clinical application and role in clinical trials.
Mult Scler. 2020;26:624-639.
PubMed Abstract available

HARTUNG HP, Mares J, Barnett MH
Alemtuzumab: Rare serious adverse events of a high-efficacy drug.
Mult Scler. 2020;26:737-740.
PubMed

KRIEGER SC, Sumowski JF
Toward biologically meaningful categories of MS-related fatigue.
Mult Scler. 2020;26:620-621.
PubMed

PROSCHMANN U, Sehr T, Akgun K, Ziemssen T, et al
Letter to the editor regarding "Therapeutic drug monitoring of natalizumab".
Mult Scler. 2020;26:741-742.
PubMed

April 2020

FOX E, Lovett-Racke AE, Gormley M, Liu Y, et al
A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis.
Mult Scler. 2020 Apr 30:1352458520918375. doi: 10.1177/1352458520918375.
PubMed Abstract available

KALB R, Brown TR, Coote S, Costello K, et al
Exercise and lifestyle physical activity recommendations for people with multiple sclerosis throughout the disease course.
Mult Scler. 2020 Apr 23:1352458520915629. doi: 10.1177/1352458520915629.
PubMed Abstract available

AHRABIAN D, Neill L, Bell R, Leary SM, et al
Acute cardiotoxicity associated with alemtuzumab infusion for multiple sclerosis.
Mult Scler. 2020 Apr 16:1352458519855725. doi: 10.1177/1352458519855725.
PubMed Abstract available

FILIPPATOU AG, Lambe J, Sotirchos ES, Fitzgerald KC, et al
Association of body mass index with longitudinal rates of retinal atrophy in multiple sclerosis.
Mult Scler. 2020 Apr 16:1352458519900942. doi: 10.1177/1352458519900942.
PubMed Abstract available

UHER T, McComb M, Galkin S, Srpova B, et al
Neurofilament levels are associated with blood-brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis.
Mult Scler. 2020 Apr 7:1352458520912379. doi: 10.1177/1352458520912379.
PubMed Abstract available

YUSUF F, Wijnands JM, Kingwell E, Zhu F, et al
Fatigue, sleep disorders, anaemia and pain in the multiple sclerosis prodrome.
Mult Scler. 2020 Apr 6:1352458520908163. doi: 10.1177/1352458520908163.
PubMed Abstract available

BELBASIS L, Bellou V, Evangelou E, Tzoulaki I, et al
Environmental factors and risk of multiple sclerosis: Findings from meta-analyses and Mendelian randomization studies.
Mult Scler. 2020;26:397-404.
PubMed Abstract available

SOLOMON AJ
Progress towards a diagnostic biomarker for MS: Central vein sign.
Mult Scler. 2020;26:394-396.
PubMed

LEVY M
Expanding the spectrum of MOG antibody disease.
Mult Scler. 2020;26:515-516.
PubMed

March 2020

HEALY BC, Barker L, Bakshi R, Benedict RHB, et al
Trajectories of Symbol Digit Modalities Test performance in individuals with multiple sclerosis.
Mult Scler. 2020 Mar 31:1352458520913439. doi: 10.1177/1352458520913439.
PubMed Abstract available

TREMLETT H, Marrie RA
The multiple sclerosis prodrome: Emerging evidence, challenges, and opportunities.
Mult Scler. 2020 Mar 31:1352458520914844. doi: 10.1177/1352458520914844.
PubMed Abstract available

MOTL RW, Sandroff BM, Benedict RH, Hubbard EM, et al
Do subcortical gray matter volumes and aerobic capacity account for cognitive-motor coupling in multiple sclerosis?
Mult Scler. 2020 Mar 31:1352458520914822. doi: 10.1177/1352458520914822.
PubMed Abstract available

DEMORTIERE S, Rico A, Maarouf A, Boutiere C, et al
Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis.
Mult Scler. 2020 Mar 23:1352458520912637. doi: 10.1177/1352458520912637.
PubMed Abstract available

JACOBS BM, Giovannoni G, Cuzick J, Dobson R, et al
Systematic review and meta-analysis of the association between Epstein-Barr virus, multiple sclerosis and other risk factors.
Mult Scler. 2020 Mar 23:1352458520907901. doi: 10.1177/1352458520907901.
PubMed Abstract available

DADAR M, Narayanan S, Arnold DL, Collins DL, et al
Conversion of diffusely abnormal white matter to focal lesions is linked to progression in secondary progressive multiple sclerosis.
Mult Scler. 2020 Mar 23:1352458520912172. doi: 10.1177/1352458520912172.
PubMed Abstract available

OTURAI DB, Bach Sondergaard H, Koch-Henriksen N, Andersen C, et al
Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis.
Mult Scler. 2020 Mar 23:1352458520912500. doi: 10.1177/1352458520912500.
PubMed Abstract available

PEREZ T, Rico A, Boutiere C, Maarouf A, et al
Comparison of rituximab originator (MabThera((R))) to biosimilar (Truxima((R))) in patients with multiple sclerosis.
Mult Scler. 2020 Mar 17:1352458520912170. doi: 10.1177/1352458520912170.
PubMed Abstract available

SOLOMON AJ, Pettigrew R, Naismith RT, Chahin S, et al
Challenges in multiple sclerosis diagnosis: Misunderstanding and misapplication of the McDonald criteria.
Mult Scler. 2020 Mar 12:1352458520910496. doi: 10.1177/1352458520910496.
PubMed Abstract available

SMITH KA, Burkill S, Hiyoshi A, Olsson T, et al
Comorbid disease burden among MS patients 1968-2012: A Swedish register-based cohort study.
Mult Scler. 2020 Mar 12:1352458520910497. doi: 10.1177/1352458520910497.
PubMed Abstract available

BERTOLI M, Tecchio F
Fatigue in multiple sclerosis: Does the functional or structural damage prevail?
Mult Scler. 2020 Mar 12:1352458520912175. doi: 10.1177/1352458520912175.
PubMed Abstract available

DALGAS U, Hvid LG, Kwakkel G, Motl RW, et al
Moving exercise research in multiple sclerosis forward (the MoXFo initiative): Developing consensus statements for research.
Mult Scler. 2020 Mar 12:1352458520910360. doi: 10.1177/1352458520910360.
PubMed Abstract available

NG HS, Kingwell E, Zhu F, Zhang T, et al
Adherence to laboratory monitoring among people taking oral drugs for multiple sclerosis: A Canadian population-based study.
Mult Scler. 2020 Mar 6:1352458520910500. doi: 10.1177/1352458520910500.
PubMed Abstract available

ABDEL-MANNAN O, Cortese R, Wassmer E, Hemingway C, et al
Primary progressive multiple sclerosis presenting under the age of 18 years: Fact or fiction?
Mult Scler. 2020 Mar 3:1352458520910361. doi: 10.1177/1352458520910361.
PubMed Abstract available

FUJIHARA K
MOG-antibody-associated disease is different from MS and NMOSD and should be classified as a distinct disease entity - Commentary.
Mult Scler. 2020;26:276-278.
PubMed

LEITE MI, Sato DK
MOG-antibody-associated disease is different from MS and NMOSD and should be considered as a distinct disease entity - Yes.
Mult Scler. 2020;26:272-274.
PubMed

COBO-CALVO A, Marignier R
MOG-antibody-associated disease is different from MS and NMO and should be considered as a distinct disease entity - No.
Mult Scler. 2020;26:274-276.
PubMed

DURAND-DUBIEF F, Marignier R, Berthezene Y, Cottin J, et al
Spontaneous multiple cervical artery dissections after alemtuzumab.
Mult Scler. 2020;26:381-383.
PubMed Abstract available

CHIARAVALLOTI ND, Moore NB, DeLuca J
The efficacy of the modified Story Memory Technique in progressive MS.
Mult Scler. 2020;26:354-362.
PubMed Abstract available

ROSSOR T, Benetou C, Wright S, Duignan S, et al
Early predictors of epilepsy and subsequent relapse in children with acute disseminated encephalomyelitis.
Mult Scler. 2020;26:333-342.
PubMed Abstract available

February 2020

SECHI E, Krecke KN, Pittock SJ, Dubey D, et al
Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies.
Mult Scler. 2020 Feb 27:1352458520907900. doi: 10.1177/1352458520907900.
PubMed Abstract available

POVOLO CA, Reid JN, Shariff SZ, Welk B, et al
Concussion in adolescence and the risk of multiple sclerosis: A retrospective cohort study.
Mult Scler. 2020 Feb 24:1352458520908037. doi: 10.1177/1352458520908037.
PubMed Abstract available

FONDERICO M, Biagioli T, Lanzilao L, Bellinvia A, et al
Prognostic role of intrathecal IgM synthesis in multiple sclerosis: Results from a clinical series.
Mult Scler. 2020 Feb 24:1352458520907913. doi: 10.1177/1352458520907913.
PubMed Abstract available

HORISBERGER A, Pantazou V, Cuendet G, Ribi C, et al
ANCA-associated life-threatening systemic vasculitis after alemtuzumab treatment for multiple sclerosis.
Mult Scler. 2020 Feb 21:1352458519895449. doi: 10.1177/1352458519895449.
PubMed Abstract available

BIGAUT K, Lambert C, Kremer L, Lebrun C, et al
Atypical myelitis in patients with multiple sclerosis: Characterization and comparison with typical multiple sclerosis and neuromyelitis optica spectrum disorders.
Mult Scler. 2020 Feb 20:1352458520906995. doi: 10.1177/1352458520906995.
PubMed Abstract available

MAHLANZA TD, Manieri MC, Klawiter EC, Solomon AJ, et al
Prospective growth and developmental outcomes in infants born to mothers with multiple sclerosis.
Mult Scler. 2020 Feb 17:1352458520904545. doi: 10.1177/1352458520904545.
PubMed Abstract available

MCKEON A, Zekeridou A
Autoimmune encephalitis management: MS centers and beyond.
Mult Scler. 2020 Feb 13:1352458520905485. doi: 10.1177/1352458520905485.
PubMed Abstract available

SERRA A, Petzold A
Can stability of visual fixation be a measure for disability in multiple sclerosis?
Mult Scler. 2020 Feb 7:1352458520903296. doi: 10.1177/1352458520903296.
PubMed

SHEEHY CK, Bensinger ES, Romeo A, Rani L, et al
Fixational microsaccades: A quantitative and objective measure of disability in multiple sclerosis.
Mult Scler. 2020 Feb 7:1352458519894712. doi: 10.1177/1352458519894712.
PubMed Abstract available

BSTEH G, Berger T
Commentary on "Lymphocytic colitis in the setting of teriflunomide use for relapsing multiple sclerosis".
Mult Scler. 2020 Feb 7:1352458520904546. doi: 10.1177/1352458520904546.
PubMed

SON M, McEwan L, Ubaidat M, Bovell K, et al
Lymphocytic colitis in the setting of teriflunomide use for relapsing multiple sclerosis.
Mult Scler. 2020 Feb 7:1352458519900961. doi: 10.1177/1352458519900961.
PubMed Abstract available

BISTROM M, Hultdin J, Andersen O, Alonso-Magdalena L, et al
Leptin levels are associated with multiple sclerosis risk.
Mult Scler. 2020 Feb 7:1352458520905033. doi: 10.1177/1352458520905033.
PubMed Abstract available

BOUVET L, Chassard D
Is neuraxial anesthesia not associated with increased risk of post-partum relapses in multiple sclerosis? More precise assessment is required.
Mult Scler. 2020 Feb 5:1352458519898344. doi: 10.1177/1352458519898344.
PubMed

MARIOTTINI A, Filippini S, Innocenti C, Forci B, et al
Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis.
Mult Scler. 2020 Feb 3:1352458520902392. doi: 10.1177/1352458520902392.
PubMed Abstract available

ABSINTA M, Ontaneda D
Controversial association between leptomeningeal enhancement and demyelinated cortical lesions in multiple sclerosis.
Mult Scler. 2020;26:135-136.
PubMed

THOMPSON AJ, Cohen JA, Kim HJ, Geurts J, et al
MSJ 2020 - Editorial comment.
Mult Scler. 2020;26:134.
PubMed

LUBLIN F
Real-world studies provide reliable comparisons of disease modifying therapies in MS - Commentary.
Mult Scler. 2020;26:163-164.
PubMed

SORMANI MP
Real-world studies provide reliable comparisons of disease modifying therapies in MS - No.
Mult Scler. 2020;26:161-162.
PubMed

KALINCIK T
Real-world studies provide reliable comparisons of disease modifying therapies in MS - Yes.
Mult Scler. 2020;26:159-161.
PubMed

January 2020

CHARABATI M, Donkers SJ, Kirkland MC, Osborne LC, et al
A critical analysis of helminth immunotherapy in multiple sclerosis.
Mult Scler. 2020 Jan 23:1352458519899040. doi: 10.1177/1352458519899040.
PubMed Abstract available

PALOTAI M, Cavallari M, Healy BC, Guttmann CR, et al
A novel classification of fatigue in multiple sclerosis based on longitudinal assessments.
Mult Scler. 2020 Jan 23:1352458519898112. doi: 10.1177/1352458519898112.
PubMed Abstract available

BENEDICT RH, Pol J, Yasin F, Hojnacki D, et al
Recovery of cognitive function after relapse in multiple sclerosis.
Mult Scler. 2020 Jan 23:1352458519898108. doi: 10.1177/1352458519898108.
PubMed Abstract available

CHITNIS T, Prat A
A roadmap to precision medicine for multiple sclerosis.
Mult Scler. 2020 Jan 22:1352458519881558. doi: 10.1177/1352458519881558.
PubMed Abstract available

BOSE G, Freedman MS
Precision medicine in the multiple sclerosis clinic: Selecting the right patient for the right treatment.
Mult Scler. 2020 Jan 22:1352458519887324. doi: 10.1177/1352458519887324.
PubMed Abstract available

MYCKO MP, Baranzini SE
microRNA and exosome profiling in multiple sclerosis.
Mult Scler. 2020 Jan 22:1352458519879303. doi: 10.1177/1352458519879303.
PubMed Abstract available

VOSKUHL RR
The effect of sex on multiple sclerosis risk and disease progression.
Mult Scler. 2020 Jan 22:1352458519892491. doi: 10.1177/1352458519892491.
PubMed Abstract available

PATSOPOULOS NA, De Jager PL
Genetic and gene expression signatures in multiple sclerosis.
Mult Scler. 2020 Jan 22:1352458519898332. doi: 10.1177/1352458519898332.
PubMed Abstract available

BHARGAVA P, Anthony D
Metabolomics in multiple sclerosis disease course and progression.
Mult Scler. 2020 Jan 22:1352458519876020. doi: 10.1177/1352458519876020.
PubMed Abstract available

KISTER I, Kantarci OH
Multiple Sclerosis Severity Score: Concept and applications.
Mult Scler. 2020 Jan 22:1352458519880125. doi: 10.1177/1352458519880125.
PubMed Abstract available

CARNERO CONTENTTI E, Giachello S, Correale J
Barriers to access and utilization of multiple sclerosis care services in a large cohort of Latin American patients.
Mult Scler. 2020 Jan 21:1352458519898590. doi: 10.1177/1352458519898590.
PubMed Abstract available

SRPOVA B, Uher T, Hrnciarova T, Barro C, et al
Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis.
Mult Scler. 2020 Jan 21:1352458519901272. doi: 10.1177/1352458519901272.
PubMed Abstract available

CORTESE R, Tur C, Prados F, Schneider T, et al
Ongoing microstructural changes in the cervical cord underpin disability progression in early primary progressive multiple sclerosis.
Mult Scler. 2020 Jan 21:1352458519900971. doi: 10.1177/1352458519900971.
PubMed Abstract available

MCDONELL J, Costello K, Laurson-Doube J, Rijke N, et al
World Health Organization Essential Medicines List: Multiple sclerosis disease-modifying therapies application.
Mult Scler. 2020 Jan 16:1352458519898340. doi: 10.1177/1352458519898340.
PubMed Abstract available

SALTER A, Fox RJ, Tyry T, Cutter G, et al
New applications for independent activities of daily living in measuring disability in multiple sclerosis.
Mult Scler. 2020 Jan 14:1352458519898591. doi: 10.1177/1352458519898591.
PubMed Abstract available

WARNKE C, Hartung HP
Big data in MS-What can we learn from large international observational studies such as MSBase?
Mult Scler. 2020;26:4-5.
PubMed

REDDEL SW
Clinical commentary on 'Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis'.
Mult Scler. 2020;26:126-127.
PubMed

VUKUSIC S, Casey R, Rollot F, Brochet B, et al
Observatoire Francais de la Sclerose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France.
Mult Scler. 2020;26:118-122.
PubMed Abstract available

MELI R, Roccatagliata L, Capello E, Bruschi N, et al
Ecological impact of isolated cognitive relapses in MS.
Mult Scler. 2020;26:114-117.
PubMed Abstract available

AOYAMA S, Mori M, Uzawa A, Uchida T, et al
Serum anti-John Cunningham virus antibody seroprevalence and index among Japanese patients with neuromyelitis optica spectrum disorders.
Mult Scler. 2020;26:128-129.
PubMed

December 2019

CROUSE DL, Foroughi I, Gupta N
Neighbourhood environments and the risk of hospital admission for cardiometabolic and mental health comorbidities in multiple sclerosis: A population cohort analysis using linked administrative data.
Mult Scler. 2019 Dec 20:1352458519895985. doi: 10.1177/1352458519895985.
PubMed Abstract available

COULOUME L, Barbin L, Leray E, Wiertlewski S, et al
High-dose biotin in progressive multiple sclerosis: A prospective study of 178 patients in routine clinical practice.
Mult Scler. 2019 Dec 17:1352458519894713. doi: 10.1177/1352458519894713.
PubMed Abstract available

KALKERS NF, Galan I, Kerbrat A, Tacchino A, et al
Differential item functioning of the Arm function in Multiple Sclerosis Questionnaire (AMSQ) by language, a study in six countries.
Mult Scler. 2019 Dec 17:1352458519895450. doi: 10.1177/1352458519895450.
PubMed Abstract available

KVISTAD SAS, Lehmann AK, Trovik LH, Kristoffersen EK, et al
Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway.
Mult Scler. 2019 Dec 13:1352458519893926. doi: 10.1177/1352458519893926.
PubMed Abstract available

HOLTON KF, Kirkland AE
Moving past antioxidant supplementation for the dietary treatment of multiple sclerosis.
Mult Scler. 2019 Dec 11:1352458519893925. doi: 10.1177/1352458519893925.
PubMed Abstract available

RAHNAMA'I MS
Neuromodulation for functional bladder disorders in patients with multiple sclerosis.
Mult Scler. 2019 Dec 9:1352458519894714. doi: 10.1177/1352458519894714.
PubMed Abstract available

BISECCO A, Capuano R, Caiazzo G, d'Ambrosio A, et al
Regional changes in thalamic shape and volume are related to cognitive performance in multiple sclerosis.
Mult Scler. 2019 Dec 3:1352458519892552. doi: 10.1177/1352458519892552.
PubMed Abstract available

HARDY TA
Regulatory B cells: The key to post-alemtuzumab rebound phenomena in multiple sclerosis?
Mult Scler. 2019;25:1945-1946.
PubMed

November 2019

GONZALEZ CAMPO C, Salamone PC, Rodriguez-Arriagada N, Richter F, et al
Fatigue in multiple sclerosis is associated with multimodal interoceptive abnormalities.
Mult Scler. 2019 Nov 28:1352458519888881. doi: 10.1177/1352458519888881.
PubMed Abstract available

COHEN JA, Trojano M, Mowry EM, Uitdehaag BM, et al
Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment.
Mult Scler. 2019 Nov 28:1352458519892555. doi: 10.1177/1352458519892555.
PubMed Abstract available

WALLACH AI, Waltz M, Casper TC, Aaen G, et al
Cognitive processing speed in pediatric-onset multiple sclerosis: Baseline characteristics of impairment and prediction of decline.
Mult Scler. 2019 Nov 28:1352458519891984. doi: 10.1177/1352458519891984.
PubMed Abstract available

LI CMF, Hung PS, Chu PP, Tohyama S, et al
Trigeminal neuralgia associated with multiple sclerosis: A multimodal assessment of brainstem plaques and response to Gamma Knife radiosurgery.
Mult Scler. 2019 Nov 26:1352458519886070. doi: 10.1177/1352458519886070.
PubMed Abstract available

COMI G, Alroughani R, Boster AL, Bass AD, et al
Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
Mult Scler. 2019 Nov 25:1352458519888610. doi: 10.1177/1352458519888610.
PubMed Abstract available

KIM JE, Park SH, Han K, Kim HJ, et al
Prevalence and incidence of neuromyelitis optica spectrum disorder and multiple sclerosis in Korea.
Mult Scler. 2019 Nov 21:1352458519888609. doi: 10.1177/1352458519888609.
PubMed Abstract available

BRANDSTADTER R, Fabian M, Leavitt VM, Krieger S, et al
Word-finding difficulty is a prevalent disease-related deficit in early multiple sclerosis.
Mult Scler. 2019 Nov 19:1352458519881760. doi: 10.1177/1352458519881760.
PubMed Abstract available

BAETGE SJ, Filser M, Renner A, Ullrich S, et al
On the validity of single tests, two-test combinations and the full Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) in detecting patients with cognitive impairment.
Mult Scler. 2019 Nov 19:1352458519887897. doi: 10.1177/1352458519887897.
PubMed Abstract available

ZURAWSKI J, Tauhid S, Chu R, Khalid F, et al
7T MRI cerebral leptomeningeal enhancement is common in relapsing-remitting multiple sclerosis and is associated with cortical and thalamic lesions.
Mult Scler. 2019 Nov 12:1352458519885106. doi: 10.1177/1352458519885106.
PubMed Abstract available

BOESEN F, Norgaard M, Skjerbaek AG, Rasmussen PV, et al
Can inpatient multidisciplinary rehabilitation improve health-related quality of life in MS patients on the long term - The Danish MS Hospitals Rehabilitation Study.
Mult Scler. 2019 Nov 5:1352458519884244. doi: 10.1177/1352458519884244.
PubMed Abstract available

PELLEGRINI F, Copetti M, Sormani MP, Bovis F, et al
Predicting disability progression in multiple sclerosis: Insights from advanced statistical modeling.
Mult Scler. 2019 Nov 5:1352458519887343. doi: 10.1177/1352458519887343.
PubMed Abstract available

CORDANI C, Valsasina P, Preziosa P, Meani A, et al
Action observation training promotes motor improvement and modulates functional network dynamic connectivity in multiple sclerosis.
Mult Scler. 2019 Nov 5:1352458519887332. doi: 10.1177/1352458519887332.
PubMed Abstract available

COLLORONE S, Cawley N, Grussu F, Prados F, et al
Reduced neurite density in the brain and cervical spinal cord in relapsing-remitting multiple sclerosis: A NODDI study.
Mult Scler. 2019 Nov 4:1352458519885107. doi: 10.1177/1352458519885107.
PubMed Abstract available

MILO R, Korczyn AD, Manouchehri N, Stuve O, et al
The temporal and causal relationship between inflammation and neurodegeneration in multiple sclerosis.
Mult Scler. 2019 Nov 4:1352458519886943. doi: 10.1177/1352458519886943.
PubMed Abstract available

NAISMITH RT, Wolinsky JS, Wundes A, LaGanke C, et al
Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
Mult Scler. 2019 Nov 4:1352458519881761. doi: 10.1177/1352458519881761.
PubMed Abstract available

KUHLE J, Plavina T, Barro C, Disanto G, et al
Neurofilament light levels are associated with long-term outcomes in multiple sclerosis.
Mult Scler. 2019 Nov 4:1352458519885613. doi: 10.1177/1352458519885613.
PubMed Abstract available

VAN WIJMEERSCH B, Singer BA, Boster A, Broadley S, et al
Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
Mult Scler. 2019 Nov 1:1352458519881759. doi: 10.1177/1352458519881759.
PubMed Abstract available

MOSTERT JP, De Keyser J
Response to Grech et al.: FLOUX-PMS study sample considerations.
Mult Scler. 2019;25:1820-1821.
PubMed

GRECH LB, Butler E, Stuckey S, Hester R, et al
Letter to the editor: FLOUX-PMS study sample considerations.
Mult Scler. 2019;25:1819-1820.
PubMed

October 2019

RYAN JM, Fortune J, Stennett A, Kilbride C, et al
Safety, feasibility, acceptability and effects of a behaviour-change intervention to change physical activity behaviour among people with multiple sclerosis: Results from the iStep-MS randomised controlled trial.
Mult Scler. 2019 Oct 31:1352458519886231. doi: 10.1177/1352458519886231.
PubMed Abstract available

LEAVITT VM, Riley CS, De Jager PL, Bloom S, et al
eSupport: Feasibility trial of telehealth support group participation to reduce loneliness in multiple sclerosis.
Mult Scler. 2019 Oct 31:1352458519884241. doi: 10.1177/1352458519884241.
PubMed Abstract available

ZHOU Y, Claflin SB, Stankovich J, van der Mei I, et al
Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype.
Mult Scler. 2019 Oct 31:1352458519881994. doi: 10.1177/1352458519881994.
PubMed Abstract available

CLARKE MA, Samaraweera AP, Falah Y, Pitiot A, et al
Single Test to ARrive at Multiple Sclerosis (STAR-MS) diagnosis: A prospective pilot study assessing the accuracy of the central vein sign in predicting multiple sclerosis in cases of diagnostic uncertainty.
Mult Scler. 2019 Oct 31:1352458519882282. doi: 10.1177/1352458519882282.
PubMed Abstract available

BSTEH G, Berek K, Hegen H, Teuchner B, et al
Serum neurofilament levels correlate with retinal nerve fiber layer thinning in multiple sclerosis.
Mult Scler. 2019 Oct 31:1352458519882279. doi: 10.1177/1352458519882279.
PubMed Abstract available

WOJCIK CM, Beier M, Costello K, DeLuca J, et al
Computerized neuropsychological assessment devices in multiple sclerosis: A systematic review.
Mult Scler. 2019 Oct 22:1352458519879094. doi: 10.1177/1352458519879094.
PubMed Abstract available

CHITNIS T
Serum NFL levels should be used to monitor multiple sclerosis evolution - Commentary.
Mult Scler. 2019 Oct 18:1352458519880471. doi: 10.1177/1352458519880471.
PubMed

MYHR KM, Torkildsen O
Serum NFL levels should be used to monitor multiple sclerosis evolution - No.
Mult Scler. 2019 Oct 18:1352458519872891. doi: 10.1177/1352458519872891.
PubMed

LEPPERT D, Kuhle J
Serum NfL levels should be used to monitor multiple sclerosis evolution - Yes.
Mult Scler. 2019 Oct 18:1352458519872921. doi: 10.1177/1352458519872921.
PubMed

JOHANSSON S, Ytterberg C, Gottberg K, Holmqvist LW, et al
Participation in social/lifestyle activities in people with multiple sclerosis: Changes across 10 years and predictors of sustained participation.
Mult Scler. 2019 Oct 17:1352458519881991. doi: 10.1177/1352458519881991.
PubMed Abstract available

BILODEAU PA, Kumar V, Rodriguez AE, Li CT, et al
MOG-IgG myelitis coexisting with systemic lupus erythematosus in the post-partum setting.
Mult Scler. 2019 Oct 17:1352458519872895. doi: 10.1177/1352458519872895.
PubMed Abstract available

MANEZ-MIRO JU, Martinez-Fernandez R, Del Alamo M, Pineda-Pardo JA, et al
Focused ultrasound thalamotomy for multiple sclerosis-associated tremor.
Mult Scler. 2019 Oct 16:1352458519861597. doi: 10.1177/1352458519861597.
PubMed Abstract available

JAKIMOVSKI D, Zivadinov R, Ramanthan M, Hagemeier J, et al
Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study.
Mult Scler. 2019 Oct 15:1352458519881428. doi: 10.1177/1352458519881428.
PubMed Abstract available

DAMASCENO A, Pimentel-Silva LR, Damasceno BP, Cendes F, et al
Cognitive trajectories in relapsing-remitting multiple sclerosis: A longitudinal 6-year study.
Mult Scler. 2019 Oct 11:1352458519878685. doi: 10.1177/1352458519878685.
PubMed Abstract available

BIANCHI A, Ciccarelli O
Daclizumab-induced encephalitis in multiple sclerosis.
Mult Scler. 2019;25:1557-1559.
PubMed

IGHANI M, Jonas S, Izbudak I, Choi S, et al
No association between cortical lesions and leptomeningeal enhancement on 7-Tesla MRI in multiple sclerosis.
Mult Scler. 2019 Oct 1:1352458519876037. doi: 10.1177/1352458519876037.
PubMed Abstract available

GRYTTEN N, Myhr KM, Celius EG, Benjaminsen E, et al
Risk of cancer among multiple sclerosis patients, siblings, and population controls: A prospective cohort study.
Mult Scler. 2019 Oct 1:1352458519877244. doi: 10.1177/1352458519877244.
PubMed Abstract available

ZECCA C, Bovis F, Novi G, Capobianco M, et al
Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience.
Mult Scler. 2019 Oct 1:1352458519872889. doi: 10.1177/1352458519872889.
PubMed Abstract available

MACARON G, Ontaneda D
Clinical commentary on "Warts and all: Fingolimod and unusual HPV associated lesions".
Mult Scler. 2019;25:1550-1552.
PubMed

BERGER JR
PML with dimethyl fumarate-No role for natalizumab?
Mult Scler. 2019;25:1686-1687.
PubMed

September 2019

PALOTAI M, Guttmann CR
Brain anatomical correlates of fatigue in multiple sclerosis.
Mult Scler. 2019 Sep 19:1352458519876032. doi: 10.1177/1352458519876032.
PubMed Abstract available

MAGGI P, Absinta M, Sati P, Perrotta G, et al
The "central vein sign" in patients with diagnostic "red flags" for multiple sclerosis: A prospective multicenter 3T study.
Mult Scler. 2019 Sep 19:1352458519876031. doi: 10.1177/1352458519876031.
PubMed Abstract available

MARRIE RA, Tremlett H, Kingwell E, Schaffer SA, et al
Disparities in management and outcomes of myocardial infarction in multiple sclerosis: A matched cohort study.
Mult Scler. 2019 Sep 13:1352458519876038. doi: 10.1177/1352458519876038.
PubMed Abstract available

VAN GEEL F, Veldkamp R, Severijns D, Dalgas U, et al
Day-to-day reliability, agreement and discriminative validity of measuring walking-related performance fatigability in persons with multiple sclerosis.
Mult Scler. 2019 Sep 9:1352458519872465. doi: 10.1177/1352458519872465.
PubMed Abstract available

BRANDSTADTER R, Katz Sand I, Sumowski JF
Beyond rehabilitation: A prevention model of reserve and brain maintenance in multiple sclerosis.
Mult Scler. 2019;25:1372-1378.
PubMed Abstract available

WEBER E, Goverover Y, DeLuca J
Beyond cognitive dysfunction: Relevance of ecological validity of neuropsychological tests in multiple sclerosis.
Mult Scler. 2019;25:1412-1419.
PubMed Abstract available

August 2019

PALOTAI M, Cavallari M, Koubiyr I, Morales Pinzon A, et al
Microstructural fronto-striatal and temporo-insular alterations are associated with fatigue in patients with multiple sclerosis independent of white matter lesion load and depression.
Mult Scler. 2019 Aug 16:1352458519869185. doi: 10.1177/1352458519869185.
PubMed Abstract available

FAMBIATOS A, Jokubaitis V, Horakova D, Kubala Havrdova E, et al
Risk of secondary progressive multiple sclerosis: A longitudinal study.
Mult Scler. 2019 Aug 9:1352458519868990. doi: 10.1177/1352458519868990.
PubMed Abstract available

PISA M, Ratti F, Vabanesi M, Radaelli M, et al
Subclinical neurodegeneration in multiple sclerosis and neuromyelitis optica spectrum disorder revealed by optical coherence tomography.
Mult Scler. 2019 Aug 8:1352458519861603. doi: 10.1177/1352458519861603.
PubMed Abstract available

SIVAKOLUNDU DK, West KL, Maruthy GB, Zuppichini M, et al
Reduced arterial compliance along the cerebrovascular tree predicts cognitive slowing in multiple sclerosis: Evidence for a neurovascular uncoupling hypothesis.
Mult Scler. 2019 Aug 2:1352458519866605. doi: 10.1177/1352458519866605.
PubMed Abstract available

KILLESTEIN J, van Oosten B
Emerging safety issues in alemtuzumab-treated MS patients.
Mult Scler. 2019;25:1206-1208.
PubMed

HERRANZ E, Louapre C, Treaba CA, Govindarajan ST, et al
Profiles of cortical inflammation in multiple sclerosis by (11)C-PBR28 MR-PET and 7 Tesla imaging.
Mult Scler. 2019 Aug 1:1352458519867320. doi: 10.1177/1352458519867320.
PubMed Abstract available

MCGINLEY MP, Cola PA, Fox RJ, Cohen JA, et al
Perspectives of individuals with multiple sclerosis on discontinuation of disease-modifying therapies.
Mult Scler. 2019 Aug 1:1352458519867314. doi: 10.1177/1352458519867314.
PubMed Abstract available

BOVE R, Rankin K, Lin C, Zhao C, et al
Effect of assisted reproductive technology on multiple sclerosis relapses: Case series and meta-analysis.
Mult Scler. 2019 Aug 1:1352458519865118. doi: 10.1177/1352458519865118.
PubMed Abstract available

BEECHAM AH, Amezcua L, Chinea A, Manrique CP, et al
The genetic diversity of multiple sclerosis risk among Hispanic and African American populations living in the United States.
Mult Scler. 2019 Aug 1:1352458519863764. doi: 10.1177/1352458519863764.
PubMed Abstract available

July 2019

SOTIRCHOS ES, Filippatou A, Fitzgerald KC, Salama S, et al
Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning.
Mult Scler. 2019 Jul 31:1352458519864928. doi: 10.1177/1352458519864928.
PubMed Abstract available

SCHWEHR NA, Kuntz KM, Butler M, Enns EA, et al
Age-related decreases in relapses among adults with relapsing-onset multiple sclerosis.
Mult Scler. 2019 Jul 29:1352458519866613. doi: 10.1177/1352458519866613.
PubMed Abstract available

CAMPBELL JA, Simpson S Jr, Ahmad H, Taylor BV, et al
Change in multiple sclerosis prevalence over time in Australia 2010-2017 utilising disease-modifying therapy prescription data.
Mult Scler. 2019 Jul 26:1352458519861270. doi: 10.1177/1352458519861270.
PubMed Abstract available

LARSSON D, Akerfeldt T, Carlson K, Burman J, et al
Intrathecal immunoglobulins and neurofilament light after autologous haematopoietic stem cell transplantation for multiple sclerosis.
Mult Scler. 2019 Jul 26:1352458519863983. doi: 10.1177/1352458519863983.
PubMed Abstract available

PRAVATA E, Valsasina P, Gobbi C, Zecca C, et al
Influence of CNS T2-focal lesions on cervical cord atrophy and disability in multiple sclerosis.
Mult Scler. 2019 Jul 26:1352458519865989. doi: 10.1177/1352458519865989.
PubMed Abstract available

CALLESEN J, Cattaneo D, Brincks J, Kjeldgaard Jorgensen ML, et al
How do resistance training and balance and motor control training affect gait performance and fatigue impact in people with multiple sclerosis? A randomized controlled multi-center study.
Mult Scler. 2019 Jul 24:1352458519865740. doi: 10.1177/1352458519865740.
PubMed Abstract available

BRIGGS FB, Hill E
Estimating the prevalence of multiple sclerosis using 56.6 million electronic health records from the United States.
Mult Scler. 2019 Jul 24:1352458519864681. doi: 10.1177/1352458519864681.
PubMed Abstract available

HACOHEN Y, Brownlee W, Mankad K, Chong WK', et al
Improved performance of the 2017 McDonald criteria for diagnosis of multiple sclerosis in children in a real-life cohort.
Mult Scler. 2019 Jul 18:1352458519863781. doi: 10.1177/1352458519863781.
PubMed Abstract available

CAMARA-LEMARROY CR, Silva C, Greenfield J, Liu WQ, et al
Biomarkers of intestinal barrier function in multiple sclerosis are associated with disease activity.
Mult Scler. 2019 Jul 18:1352458519863133. doi: 10.1177/1352458519863133.
PubMed Abstract available

WARNKE C, Hartung HP
Challenging a concept: Pulsed treatment regimen-No risk of PML?
Mult Scler. 2019;25:1076-1078.
PubMed

GEREVINI S, Capra R, Bertoli D, Sottini A, et al
Immune profiling of a patient with alemtuzumab-associated progressive multifocal leukoencephalopathy.
Mult Scler. 2019;25:1196-1201.
PubMed Abstract available

PREZIOSA P, Rocca MA, Filippi M
PET is necessary to make the next step forward in understanding MS pathophysiology - No.
Mult Scler. 2019;25:1088-1090.
PubMed

BODINI B, Stankoff B
PET is necessary to make the next step forward in understanding MS pathophysiology - Yes.
Mult Scler. 2019;25:1086-1087.
PubMed

KUMAR N, Abboud H
Iatrogenic CNS demyelination in the era of modern biologics.
Mult Scler. 2019;25:1079-1085.
PubMed Abstract available

COMBES B, Kerbrat A, Ferre JC, Callot V, et al
Focal and diffuse cervical spinal cord damage in patients with early relapsing-remitting MS: A multicentre magnetisation transfer ratio study.
Mult Scler. 2019;25:1113-1123.
PubMed Abstract available

BICHUETTI DB, Perin MMM, Souza NA, Oliveira EML, et al
Treating neuromyelitis optica with azathioprine: 20-year clinical practice.
Mult Scler. 2019;25:1150-1161.
PubMed Abstract available

KANG Y, Gauthier SA
PET is necessary to make the next step forward in understanding MS pathophysiology - Commentary.
Mult Scler. 2019;25:1090-1091.
PubMed

June 2019

DE LOTT LB, Zerafa S, Shedden K, Dunietz GL, et al
Multiple sclerosis relapse risk in the postoperative period: Effects of invasive surgery and anesthesia.
Mult Scler. 2019 Jun 25:1352458519860304. doi: 10.1177/1352458519860304.
PubMed Abstract available

INEICHEN BV, Moridi T, Granberg T, Piehl F, et al
Rituximab treatment for multiple sclerosis.
Mult Scler. 2019 Jun 25:1352458519858604. doi: 10.1177/1352458519858604.
PubMed Abstract available

GHEZZI L, Cantoni C, Cignarella F, Bollman B, et al
T cells producing GM-CSF and IL-13 are enriched in the cerebrospinal fluid of relapsing MS patients.
Mult Scler. 2019 Jun 25:1352458519852092. doi: 10.1177/1352458519852092.
PubMed Abstract available

LEAVITT VM, Brandstadter R, Fabian M, Katz Sand I, et al
Dissociable cognitive patterns related to depression and anxiety in multiple sclerosis.
Mult Scler. 2019 Jun 24:1352458519860319. doi: 10.1177/1352458519860319.
PubMed Abstract available

PERONI S, Sorosina M, Malhotra S, Clarelli F, et al
A pharmacogenetic study implicates NINJ2 in the response to Interferon-beta in multiple sclerosis.
Mult Scler. 2019 Jun 21:1352458519851428. doi: 10.1177/1352458519851428.
PubMed Abstract available

MARCK CH, das Nair R, Grech LB, Borland R, et al
Modifiable risk factors for poor health outcomes in multiple sclerosis: The urgent need for research to maximise smoking cessation success.
Mult Scler. 2019 Jun 20:1352458519858730. doi: 10.1177/1352458519858730.
PubMed Abstract available

FUCHS TA, Benedict RH, Wilding G, Wojcik C, et al
Trait Conscientiousness predicts rate of brain atrophy in multiple sclerosis.
Mult Scler. 2019 Jun 20:1352458519858605. doi: 10.1177/1352458519858605.
PubMed Abstract available

CHATAWAY J, Weir CJ, Fox RJ
The FLUOX-PMS trial: Underestimating the challenge in progressive multiple sclerosis trials.
Mult Scler. 2019 Jun 20:1352458519856985. doi: 10.1177/1352458519856985.
PubMed

CAMBRON M, Mostert J, D'Hooghe M, Nagels G, et al
Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial.
Mult Scler. 2019 Jun 20:1352458519843051. doi: 10.1177/1352458519843051.
PubMed Abstract available

SPRENGER T, Kappos L, Radue EW, Gaetano L, et al
Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide.
Mult Scler. 2019 Jun 14:1352458519855722. doi: 10.1177/1352458519855722.
PubMed Abstract available

GABR RE, Coronado I, Robinson M, Sujit SJ, et al
Brain and lesion segmentation in multiple sclerosis using fully convolutional neural networks: A large-scale study.
Mult Scler. 2019 Jun 13:1352458519856843. doi: 10.1177/1352458519856843.
PubMed Abstract available

KLINEOVA S, Brandstadter R, Fabian MT, Sand IK, et al
Psychological resilience is linked to motor strength and gait endurance in early multiple sclerosis.
Mult Scler. 2019 Jun 7:1352458519852725. doi: 10.1177/1352458519852725.
PubMed Abstract available

BROWN JWL, Prados Carrasco F, Eshaghi A, Sudre CH, et al
Periventricular magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumab.
Mult Scler. 2019 Jun 6:1352458519852093. doi: 10.1177/1352458519852093.
PubMed Abstract available

MARRIE RA, Dufault B, Tyry T, Cutter GR, et al
Developing a crosswalk between the RAND-12 and the health utilities index for multiple sclerosis.
Mult Scler. 2019 Jun 4:1352458519852722. doi: 10.1177/1352458519852722.
PubMed Abstract available

STAMPANONI BASSI M, Iezzi E, Buttari F, Gilio L, et al
Obesity worsens central inflammation and disability in multiple sclerosis.
Mult Scler. 2019 Jun 4:1352458519853473. doi: 10.1177/1352458519853473.
PubMed Abstract available

MESCHERIAKOVA JY, Verkerk J, Amin N, Uitterlinden AG, et al
Response to Vilarino-Guell et al.
Mult Scler. 2019;25:1013-1015.
PubMed

SCALFARI A
MS progression is predominantly driven by age-related mechanisms - YES.
Mult Scler. 2019;25:902-904.
PubMed

MCGINLEY M, Ontaneda D
MS progression is predominantly driven by age-related mechanisms - NO.
Mult Scler. 2019;25:904-906.
PubMed

ROCCA MA, Savoldi F, Valsasina P, Radaelli M, et al
Cross-modal plasticity among sensory networks in neuromyelitis optica spectrum disorders.
Mult Scler. 2019;25:968-979.
PubMed Abstract available

ZEYDAN B, Kantarci OH
MS progression is predominantly driven by age-related mechanisms - Commentary.
Mult Scler. 2019;25:906-908.
PubMed

May 2019

SCARPAZZA C, Signori A, Cosottini M, Sormani MP, et al
Should frequent MRI monitoring be performed in natalizumab-treated MS patients? A contribution to a recent debate.
Mult Scler. 2019 May 30:1352458519854162. doi: 10.1177/1352458519854162.
PubMed Abstract available

AKGUN K, Ziemssen T
Response to Hyun J.W. et al. "Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis".
Mult Scler. 2019 May 30:1352458519854263. doi: 10.1177/1352458519854263.
PubMed

PELLEGRINI F, Copetti M, Bovis F, Cheng D, et al
A proof-of-concept application of a novel scoring approach for personalized medicine in multiple sclerosis.
Mult Scler. 2019 May 30:1352458519849513. doi: 10.1177/1352458519849513.
PubMed Abstract available

ARROYO R, Bury DP, Guo JD, Margolin DH, et al
Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis.
Mult Scler. 2019 May 30:1352458519849796. doi: 10.1177/1352458519849796.
PubMed Abstract available

MOBERG JY, Laursen B, Thygesen LC, Magyari M, et al
Reproductive history of the Danish multiple sclerosis population: A register-based study.
Mult Scler. 2019 May 30:1352458519851245. doi: 10.1177/1352458519851245.
PubMed Abstract available

CAPONE F, Collorone S, Cortese R, Di Lazzaro V, et al
Fatigue in multiple sclerosis: The role of thalamus.
Mult Scler. 2019 May 29:1352458519851247. doi: 10.1177/1352458519851247.
PubMed Abstract available

MCCOMBE PA
Women who contributed to past research in multiple sclerosis.
Mult Scler. 2019 May 28:1352458519846101. doi: 10.1177/1352458519846101.
PubMed Abstract available

MARRIE RA
Recognizing the diversity gap in multiple sclerosis.
Mult Scler. 2019 May 28:1352458519850070. doi: 10.1177/1352458519850070.
PubMed

AHRWEILLER K, Rousseau C, Le Page E, Bajeux E, et al
Decreasing impact of late relapses on disability worsening in secondary progressive multiple sclerosis.
Mult Scler. 2019 May 16:1352458519848090. doi: 10.1177/1352458519848090.
PubMed Abstract available

MURPHY OC, Kwakyi O, Iftikhar M, Zafar S, et al
Alterations in the retinal vasculature occur in multiple sclerosis and exhibit novel correlations with disability and visual function measures.
Mult Scler. 2019 May 16:1352458519845116. doi: 10.1177/1352458519845116.
PubMed Abstract available

PUGLIATTI M
Changes in the sex ratio are a good indicator of changes in multiple sclerosis incidence - Commentary.
Mult Scler. 2019 May 15:1352458519845114. doi: 10.1177/1352458519845114.
PubMed

KOPP TI, Blinkenberg M, Chalmer TA, Petersen T, et al
Predictors of treatment outcome in patients with paediatric onset multiple sclerosis.
Mult Scler. 2019 May 13:1352458519846100. doi: 10.1177/1352458519846100.
PubMed Abstract available

CONTE A, Gianni C, Belvisi D, Cortese A, et al
Deep grey matter involvement and altered sensory gating in multiple sclerosis.
Mult Scler. 2019 May 13:1352458519845287. doi: 10.1177/1352458519845287.
PubMed Abstract available

FITZGERALD KC, Salter A, Tyry T, Fox RJ, et al
Measures of general and abdominal obesity and disability severity in a large population of people with multiple sclerosis.
Mult Scler. 2019 May 13:1352458519845836. doi: 10.1177/1352458519845836.
PubMed Abstract available

MOSS BP, Cohen JA
The emergence of follow-on disease-modifying therapies for multiple sclerosis.
Mult Scler. 2019 May 10:1352458519845106. doi: 10.1177/1352458519845106.
PubMed Abstract available

TUR C, Grussu F, Prados F, Charalambous T, et al
A multi-shell multi-tissue diffusion study of brain connectivity in early multiple sclerosis.
Mult Scler. 2019 May 10:1352458519845105. doi: 10.1177/1352458519845105.
PubMed Abstract available

FALET JR, Deshmukh S, Al-Jassim A, Sigler G, et al
The neurologist's role in disabling multiple sclerosis: A qualitative study of patient and care provider perspectives.
Mult Scler. 2019 May 10:1352458519845107. doi: 10.1177/1352458519845107.
PubMed Abstract available

FAZEKAS F
Instead of tweaking the diagnostic criteria for MS in those with CIS, we should develop diagnostic criteria that distinguish MS from other conditions - Commentary.
Mult Scler. 2019;25:770-771.
PubMed

SOLOMON AJ
Instead of tweaking the diagnostic criteria for MS in those with CIS, we should develop diagnostic criteria that distinguish MS from other conditions - Yes.
Mult Scler. 2019;25:766-768.
PubMed

BROWNLEE WJ
Instead of tweaking the diagnostic criteria for MS in those with CIS, we should develop diagnostic criteria that distinguish MS from other conditions - No.
Mult Scler. 2019;25:768-770.
PubMed

TRIPLETT J, Vijayan S, Prince R, Kermode A, et al
Dimethyl fumarate-associated transient bone marrow oedema syndrome.
Mult Scler. 2019;25:876-879.
PubMed Abstract available

ROSATO R, Testa S, Bertolotto A, Scavelli F, et al
eMSQOL-29: Prospective validation of the abbreviated, electronic version of MSQOL-54.
Mult Scler. 2019;25:856-866.
PubMed Abstract available

GOODIN DS, Reder AT, Traboulsee AL, Li DK, et al
Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b.
Mult Scler. 2019;25:837-847.
PubMed Abstract available

DUROZARD P, Maarouf A, Boutiere C, Ruet A, et al
Efficacy of rituximab in refractory RRMS.
Mult Scler. 2019;25:828-836.
PubMed Abstract available

April 2019

PHELPS R, Winston JA, Wynn D, Habek M, et al
Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis.
Mult Scler. 2019 Apr 15:1352458519841829. doi: 10.1177/1352458519841829.
PubMed Abstract available

BARLETTA VT, Herranz E, Treaba CA, Ouellette R, et al
Evidence of diffuse cerebellar neuroinflammation in multiple sclerosis by (11)C-PBR28 MR-PET.
Mult Scler. 2019 Apr 11:1352458519843048. doi: 10.1177/1352458519843048.
PubMed Abstract available

VUKUSIC S, Coyle PK, Jurgensen S, Truffinet P, et al
Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience.
Mult Scler. 2019 Apr 10:1352458519843055. doi: 10.1177/1352458519843055.
PubMed Abstract available

BROWN JWL, Chowdhury A, Kanber B, Prados Carrasco F, et al
Magnetisation transfer ratio abnormalities in primary and secondary progressive multiple sclerosis.
Mult Scler. 2019 Apr 8:1352458519841810. doi: 10.1177/1352458519841810.
PubMed Abstract available

BANWELL B
Are children with multiple sclerosis really "old" adults.
Mult Scler. 2019 Apr 4:1352458519841505. doi: 10.1177/1352458519841505.
PubMed

BARTELS F, Nobis K, Cooper G, Wendel E, et al
Childhood multiple sclerosis is associated with reduced brain volumes at first clinical presentation and brain growth failure.
Mult Scler. 2019 Apr 4:1352458519829698. doi: 10.1177/1352458519829698.
PubMed Abstract available

LAVIE C, Rollot F, Durand-Dubief F, Marignier R, et al
Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS.
Mult Scler. 2019;25:591-600.
PubMed Abstract available

BUCK D, Andlauer TF, Igl W, Wicklein EM, et al
Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.
Mult Scler. 2019;25:565-573.
PubMed Abstract available

HYUN JW, Huh SY, Shin HJ, Woodhall M, et al
Evaluation of brain lesion distribution criteria at disease onset in differentiating MS from NMOSD and MOG-IgG-associated encephalomyelitis.
Mult Scler. 2019;25:585-590.
PubMed Abstract available

ZELEK WM, Watkins LM, Howell OW, Evans R, et al
Measurement of soluble CD59 in CSF in demyelinating disease: Evidence for an intrathecal source of soluble CD59.
Mult Scler. 2019;25:523-531.
PubMed Abstract available

MANOUSAKI D, Richards JB
Vitamin D deficiency is an etiological factor for MS - Yes.
Mult Scler. 2019;25:637-639.
PubMed

LANGER-GOULD A, Lucas RM
Vitamin D deficiency is an etiological factor for MS - No.
Mult Scler. 2019;25:639-641.
PubMed

WILLIAMS T, Chataway J
Immune-mediated encephalitis with daclizumab: The final nail.
Mult Scler. 2019;25:753-754.
PubMed Abstract available

THOUVENOT E, Hinsinger G, Demattei C, Uygunoglu U, et al
Cerebrospinal fluid chitinase-3-like protein 1 level is not an independent predictive factor for the risk of clinical conversion in radiologically isolated syndrome.
Mult Scler. 2019;25:669-677.
PubMed Abstract available

March 2019

HYUN JW, Kim Y, Kim G, Kim SH, et al
Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis.
Mult Scler. 2019 Mar 26:1352458519840757. doi: 10.1177/1352458519840757.
PubMed Abstract available

BOONSTRA FM, Noffs G, Perera T, Jokubaitis VG, et al
Functional neuroplasticity in response to cerebello-thalamic injury underpins the clinical presentation of tremor in multiple sclerosis.
Mult Scler. 2019 Mar 25:1352458519837706. doi: 10.1177/1352458519837706.
PubMed Abstract available

BAGNATO F, Franco G, Ye F, Fan R, et al
Selective inversion recovery quantitative magnetization transfer imaging: Toward a 3 T clinical application in multiple sclerosis.
Mult Scler. 2019 Mar 25:1352458519833018. doi: 10.1177/1352458519833018.
PubMed Abstract available

D'AMBROSIO A, Valsasina P, Gallo A, De Stefano N, et al
Reduced dynamics of functional connectivity and cognitive impairment in multiple sclerosis.
Mult Scler. 2019 Mar 19:1352458519837707. doi: 10.1177/1352458519837707.
PubMed Abstract available

RUSSO CV, Sacca F, Paternoster M, Buonomo AR, et al
Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis.
Mult Scler. 2019 Mar 18:1352458518813110. doi: 10.1177/1352458518813110.
PubMed

MEYER CE, Gao JL, Cheng JY, Oberoi MR, et al
Axonal damage in spinal cord is associated with gray matter atrophy in sensorimotor cortex in experimental autoimmune encephalomyelitis.
Mult Scler. 2019 Mar 7:1352458519830614. doi: 10.1177/1352458519830614.
PubMed Abstract available

STRAUDI S, Manfredini F, Lamberti N, Martinuzzi C, et al
Robot-assisted gait training is not superior to intensive overground walking in multiple sclerosis with severe disability (the RAGTIME study): A randomized controlled trial.
Mult Scler. 2019 Mar 4:1352458519833901. doi: 10.1177/1352458519833901.
PubMed Abstract available

BARANZINI SE
Insights into microbiome research 6: The role of consortia in studying the role of microbes in health and disease.
Mult Scler. 2019;25:336-337.
PubMed Abstract available

CAMARA-LEMARROY CR, Burton JM
Area postrema syndrome: A short history of a pearl in demyelinating diseases.
Mult Scler. 2019;25:325-329.
PubMed Abstract available

WATTJES MP, Killestein J
Imaging of meningeal inflammation should become part of the routine MRI protocol - No.
Mult Scler. 2019;25:331-333.
PubMed

ABSINTA M, Reich DS
Imaging of meningeal inflammation should become part of the routine MRI protocol - Yes.
Mult Scler. 2019;25:330-331.
PubMed

DEISENHAMMER F, Jank M, Lauren A, Sjodin A, et al
Prediction of natalizumab anti-drug antibodies persistency.
Mult Scler. 2019;25:392-398.
PubMed Abstract available

ROCCA MA, Riccitelli GC, Meani A, Pagani E, et al
Cognitive reserve, cognition, and regional brain damage in MS: A 2 -year longitudinal study.
Mult Scler. 2019;25:372-381.
PubMed Abstract available

AL-LOUZI O, Sotirchos ES, Vidal-Jordana A, Beh SC, et al
Characteristics of morphologic macular abnormalities in neuroimmunology practice.
Mult Scler. 2019;25:361-371.
PubMed Abstract available

February 2019

PALMER AJ, van der Mei I, Taylor BV, Clarke PM, et al
Modelling the impact of multiple sclerosis on life expectancy, quality-adjusted life years and total lifetime costs: Evidence from Australia.
Mult Scler. 2019 Feb 26:1352458519831213. doi: 10.1177/1352458519831213.
PubMed Abstract available

URRU SA, Antonelli A, Sechi GM
Prevalence of multiple sclerosis in Sardinia: A systematic cross-sectional multi-source survey.
Mult Scler. 2019 Feb 22:1352458519828600. doi: 10.1177/1352458519828600.
PubMed Abstract available

PORTACCIO E, Amato MP
Breastfeeding and post-partum relapses in multiple sclerosis patients.
Mult Scler. 2019 Feb 22:1352458519830588. doi: 10.1177/1352458519830588.
PubMed Abstract available

CUKER A, Bass AD, Nadj C, Agius MA, et al
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.
Mult Scler. 2019 Feb 20:1352458518816612. doi: 10.1177/1352458518816612.
PubMed Abstract available

JAKIMOVSKI D, Ramanathan M, Weinstock-Guttman B, Bergsland N, et al
Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: A case-controlled magnetization transfer ratio study.
Mult Scler. 2019 Feb 13:1352458519828667. doi: 10.1177/1352458519828667.
PubMed Abstract available

SOTIRCHOS ES, Gonzalez-Caldito N, Dewey BE, Fitzgerald KC, et al
Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis.
Mult Scler. 2019 Feb 11:1352458519826364. doi: 10.1177/1352458519826364.
PubMed Abstract available

CICERO CE, Patti F, Lo Fermo S, Giuliano L, et al
Lack of association between Toxocara canis and multiple sclerosis: A population-based case-control study.
Mult Scler. 2019 Feb 11:1352458518825394. doi: 10.1177/1352458518825394.
PubMed

LEFEUVRE JA, Guy JR, Luciano NJ, Ha SK, et al
The spectrum of spinal cord lesions in a primate model of multiple sclerosis.
Mult Scler. 2019 Feb 7:1352458518822408. doi: 10.1177/1352458518822408.
PubMed Abstract available

NICOLETTI CG, Monteleone F, Marfia GA, Usiello A, et al
Oral D-Aspartate enhances synaptic plasticity reserve in progressive multiple sclerosis.
Mult Scler. 2019 Feb 7:1352458519828294. doi: 10.1177/1352458519828294.
PubMed Abstract available

RAIMO S, Spitaleri D, Trojano L, Santangelo G, et al
Apathy as a herald of cognitive changes in multiple sclerosis: A 2-year follow-up study.
Mult Scler. 2019 Feb 7:1352458519828296. doi: 10.1177/1352458519828296.
PubMed Abstract available

PLANCHE V, Su JH, Mournet S, Saranathan M, et al
White-matter-nulled MPRAGE at 7T reveals thalamic lesions and atrophy of specific thalamic nuclei in multiple sclerosis.
Mult Scler. 2019 Feb 7:1352458519828297. doi: 10.1177/1352458519828297.
PubMed Abstract available

CHARD DT
Commentary on Al Hussona et al. 'New-onset seizures as a sole clinical presentation of multiple sclerosis'.
Mult Scler. 2019;25:298-299.
PubMed Abstract available

BARANZINI SE
Insights into microbiome research 5: Mapping is first but function must come next.
Mult Scler. 2019;25:193-195.
PubMed Abstract available

HELLWIG K
We need to conduct clinical trials of disease-modifying therapy in pregnancy to optimize care of women with MS - No.
Mult Scler. 2019;25:189-190.
PubMed

ALVAREZ E, Mowry EM
We need to conduct clinical trials of disease-modifying therapy in pregnancy to optimize care of women with MS - Yes.
Mult Scler. 2019;25:187-188.
PubMed

BOVE R
We need to conduct clinical trials of disease-modifying therapy in pregnancy to optimize care of women with MS - Commentary.
Mult Scler. 2019;25:190-192.
PubMed

HEDSTROM AK
Smoking and its interaction with genetics in MS etiology.
Mult Scler. 2019;25:180-186.
PubMed Abstract available

BSTEH G, Hegen H, Ladstatter F, Berek K, et al
Change of olfactory function as a marker of inflammatory activity and disability progression in MS.
Mult Scler. 2019;25:267-274.
PubMed Abstract available

BOVIS F, De Stefano N, Steinerman JR, Knappertz V, et al
Validating the use of brain volume cutoffs to identify clinically relevant atrophy in RRMS.
Mult Scler. 2019;25:217-223.
PubMed Abstract available

January 2019

SECHI E, Flanagan EP
Area postrema syndrome in autoimmune GFAP astrocytopathy.
Mult Scler. 2019 Jan 21:1352458519826489. doi: 10.1177/1352458519826489.
PubMed

STORK L, Bruck W, von Gottberg P, Pulkowski U, et al
Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis.
Mult Scler. 2019 Jan 18:1352458518819098. doi: 10.1177/1352458518819098.
PubMed Abstract available

CORDANI C, Meani A, Esposito F, Valsasina P, et al
Imaging correlates of hand motor performance in multiple sclerosis: A multiparametric structural and functional MRI study.
Mult Scler. 2019 Jan 18:1352458518822145. doi: 10.1177/1352458518822145.
PubMed Abstract available

VALENCIA-SANCHEZ C, Goodman BP, Carter JL, Wingerchuk DM, et al
The spectrum of acute cardiopulmonary events associated with multiple sclerosis exacerbations.
Mult Scler. 2019 Jan 18:1352458518823482. doi: 10.1177/1352458518823482.
PubMed Abstract available

VAN MUNSTER CE, Kaya L, Obura M, Kalkers NF, et al
Minimal clinically important difference of improvement on the Arm Function in Multiple Sclerosis Questionnaire (AMSQ).
Mult Scler. 2019 Jan 18:1352458518823489. doi: 10.1177/1352458518823489.
PubMed Abstract available

BARIN L, Kamm CP, Salmen A, Dressel H, et al
How do patients enter the healthcare system after the first onset of multiple sclerosis symptoms? The influence of setting and physician specialty on speed of diagnosis.
Mult Scler. 2019 Jan 18:1352458518823955. doi: 10.1177/1352458518823955.
PubMed Abstract available

MARRODAN M, Alessandro L, Farez MF, Correale J, et al
The role of infections in multiple sclerosis.
Mult Scler. 2019 Jan 14:1352458518823940. doi: 10.1177/1352458518823940.
PubMed Abstract available

PAGANI E, Rocca MA, De Meo E, Horsfield MA, et al
Structural connectivity in multiple sclerosis and modeling of disconnection.
Mult Scler. 2019 Jan 9:1352458518820759. doi: 10.1177/1352458518820759.
PubMed Abstract available

JAKIMOVSKI D, Benedict RH, Marr K, Gandhi S, et al
Lower total cerebral arterial flow contributes to cognitive performance in multiple sclerosis patients.
Mult Scler. 2019 Jan 9:1352458518819608. doi: 10.1177/1352458518819608.
PubMed Abstract available

FUCHS TA, Wojcik C, Wilding GE, Pol J, et al
Trait Conscientiousness predicts rate of longitudinal SDMT decline in multiple sclerosis.
Mult Scler. 2019 Jan 7:1352458518820272. doi: 10.1177/1352458518820272.
PubMed Abstract available

BARANZINI SE
Insights into microbiome research 4: The computational analysis.
Mult Scler. 2019;25:21-22.
PubMed Abstract available

THOMPSON AJ, Antel J, Carroll WB, Geurts J, et al
MSJ 2019 - Editorial comment.
Mult Scler. 2019;25:4-5.
PubMed

SA M, Thornton R, Chong WK, Kaliakatsos M, et al
Paediatric MOG antibody-associated ADEM with complex movement disorder: A case report.
Mult Scler. 2019;25:125-128.
PubMed Abstract available

BREZA M, Smyrni N, Koutsis G, Anagnostou E, et al
Ocular flutter as presenting manifestation of pediatric MOG antibody-associated demyelination: A case report.
Mult Scler. 2019;25:122-125.
PubMed Abstract available

PITT D, Ponath G
Astrocytes play a crucial role in the formation and evolution of MS lesions - Yes.
Mult Scler. 2019;25:15-17.
PubMed

KERLERO DE ROSBO N
Astrocytes play a crucial role in the formation and evolution of MS lesions - No.
Mult Scler. 2019;25:17-19.
PubMed

VIJAYASINGHAM L, Viswanathan S
A call for more research and global collaboration in South-East Asia to address challenges of DMT access and MS management in the region.
Mult Scler. 2019;25:130-131.
PubMed

PATEL VP, Feinstein A
The link between depression and performance on the Symbol Digit Modalities Test: Mechanisms and clinical significance.
Mult Scler. 2019;25:118-121.
PubMed Abstract available

MAZZOLA MA, Raheja R, Regev K, Beynon V, et al
Monomethyl fumarate treatment impairs maturation of human myeloid dendritic cells and their ability to activate T cells.
Mult Scler. 2019;25:63-71.
PubMed Abstract available

MARIGNIER R
Unusual presentations of MOG antibody-associated central nervous system demyelination: Expanding the spectrum.
Mult Scler. 2019;25:128-129.
PubMed

QUINTANA FJ
Astrocytes play a crucial role in the formation and evolution of MS lesions - Commentary.
Mult Scler. 2019;25:19-20.
PubMed

December 2018

HOGEL H, Rissanen E, Barro C, Matilainen M, et al
Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity.
Mult Scler. 2018 Dec 20:1352458518819380. doi: 10.1177/1352458518819380.
PubMed Abstract available

SATCHIDANAND N, Drake A, Smerbeck A, Hojnacki D, et al
Dalfampridine benefits ambulation but not cognition in multiple sclerosis.
Mult Scler. 2018 Dec 19:1352458518815795. doi: 10.1177/1352458518815795.
PubMed Abstract available

ELLIOTT C, Wolinsky JS, Hauser SL, Kappos L, et al
Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions.
Mult Scler. 2018 Dec 19:1352458518814117. doi: 10.1177/1352458518814117.
PubMed Abstract available

MATTHEWS L
Clinical commentary on 'Relapsing remitting multiple sclerosis in progressive external ophthalmoplegia: A report of two cases'.
Mult Scler. 2018 Dec 17:1352458518816621. doi: 10.1177/1352458518816621.
PubMed

PATEL KR, Karaa A, Mateen FJ
Relapsing remitting multiple sclerosis in progressive external ophthalmoplegia: A report of two cases.
Mult Scler. 2018 Dec 17:1352458518800794. doi: 10.1177/1352458518800794.
PubMed Abstract available

POURCHER V, Todesco E, Dubois C, Pallier C, et al
False hepatitis B and C viral serologies in patients with multiple sclerosis receiving high-dose biotin.
Mult Scler. 2018 Dec 11:1352458518818294. doi: 10.1177/1352458518818294.
PubMed

BSTEH G, Algrang L, Hegen H, Auer M, et al
Pregnancy and multiple sclerosis in the DMT era: A cohort study in Western Austria.
Mult Scler. 2018 Dec 3:1352458518816614. doi: 10.1177/1352458518816614.
PubMed Abstract available

VAUGHN CB, Kavak KS, Dwyer MG, Bushra A, et al
Fatigue at enrollment predicts EDSS worsening in the New York State Multiple Sclerosis Consortium.
Mult Scler. 2018 Dec 3:1352458518816619. doi: 10.1177/1352458518816619.
PubMed Abstract available

November 2018

CHIEN C, Scheel M, Schmitz-Hubsch T, Borisow N, et al
Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity.
Mult Scler. 2018 Nov 26:1352458518815596. doi: 10.1177/1352458518815596.
PubMed Abstract available

BSTEH G, Berek K, Hegen H, Teuchner B, et al
Smelling multiple sclerosis: Different qualities of olfactory function reflect either inflammatory activity or neurodegeneration.
Mult Scler. 2018 Nov 22:1352458518814113. doi: 10.1177/1352458518814113.
PubMed Abstract available

WOJCIK CM, Rao SM, Schembri AJ, Drake AS, et al
Necessity of technicians for computerized neuropsychological assessment devices in multiple sclerosis.
Mult Scler. 2018 Nov 22:1352458518813287. doi: 10.1177/1352458518813287.
PubMed Abstract available

WALLECZEK NK, Frommlet F, Bsteh G, Eggers C, et al
Month-of-birth-effect in multiple sclerosis in Austria.
Mult Scler. 2018 Nov 22:1352458518810924. doi: 10.1177/1352458518810924.
PubMed Abstract available

SEGAL BM
Enhancing natural killer cells is beneficial in multiple sclerosis - Commentary.
Mult Scler. 2018 Nov 13:1352458518809296. doi: 10.1177/1352458518809296.
PubMed

LIU Q, Shi FD
Enhancing natural killer cells is beneficial in multiple sclerosis - No.
Mult Scler. 2018 Nov 13:1352458518799591. doi: 10.1177/1352458518799591.
PubMed

LARONI A
Enhancing natural killer cells is beneficial in multiple sclerosis - Yes.
Mult Scler. 2018 Nov 13:1352458518800776. doi: 10.1177/1352458518800776.
PubMed

RAATS J, Lamers I, Baert I, Willekens B, et al
Cognitive-motor interference in persons with multiple sclerosis during five upper limb motor tasks with different complexity.
Mult Scler. 2018 Nov 12:1352458518808194. doi: 10.1177/1352458518808194.
PubMed Abstract available

FOX EJ, Markowitz C, Applebee A, Montalban X, et al
Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial.
Mult Scler. 2018 Nov 12:1352458518808189. doi: 10.1177/1352458518808189.
PubMed Abstract available

LUIJTEN MA, Eekhout I, D'Hooghe M, Uitdehaag BM, et al
Development of the Arm Function in Multiple Sclerosis Questionnaire-Short Form (AMSQ-SF): A static 10-item version.
Mult Scler. 2018 Nov 9:1352458518808197. doi: 10.1177/1352458518808197.
PubMed Abstract available

LAMERS I, Feys P
Patient reported outcome measures of upper limb function in multiple sclerosis: A critical overview.
Mult Scler. 2018 Nov 9:1352458518809294. doi: 10.1177/1352458518809294.
PubMed

HYUN JW, Kim Y, Kim G, Kim SH, et al
Severe B cell-mediated disease activation despite two cycles of alemtuzumab in a patient with multiple sclerosis.
Mult Scler. 2018 Nov 7:1352458518810261. doi: 10.1177/1352458518810261.
PubMed Abstract available

ACHIRON A, Sarova-Pinhas I, Magalashvili D, Stern Y, et al
Residual disability after severe relapse in people with multiple sclerosis treated with disease-modifying therapy.
Mult Scler. 2018 Nov 1:1352458518809903. doi: 10.1177/1352458518809903.
PubMed Abstract available

HOBART J, Bowen A, Pepper G, Crofts H, et al
International consensus on quality standards for brain health-focused care in multiple sclerosis.
Mult Scler. 2018 Nov 1:1352458518809326. doi: 10.1177/1352458518809326.
PubMed Abstract available

HEALY BC, Zurawski J, Gonzalez CT, Chitnis T, et al
Assessment of computer adaptive testing version of the Neuro-QOL for people with multiple sclerosis.
Mult Scler. 2018 Nov 1:1352458518810159. doi: 10.1177/1352458518810159.
PubMed Abstract available

PEETERS LM, van Munster CE, Van Wijmeersch B, Bruyndonckx R, et al
Multidisciplinary data infrastructures in multiple sclerosis: Why they are needed and can be done!
Mult Scler. 2018 Nov 1:1352458518807076. doi: 10.1177/1352458518807076.
PubMed Abstract available

October 2018

FARRELL R
Clinical commentary on "De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine".
Mult Scler. 2018 Oct 30:1352458518810661. doi: 10.1177/1352458518810661.
PubMed

PANICUCCI E, Cohen M, Bourg V, Rocher F, et al
De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine.
Mult Scler. 2018 Oct 30:1352458518790379. doi: 10.1177/1352458518790379.
PubMed Abstract available

DOBSON R
Clinical commentary on 'Life-threatening vitamin D intoxication due to intake of ultra-high doses in multiple sclerosis: a note of caution'.
Mult Scler. 2018 Oct 25:1352458518807053. doi: 10.1177/1352458518807053.
PubMed

FEIGE J, Salmhofer H, Hecker C, Kunz AB, et al
Life-threatening vitamin D intoxication due to intake of ultra-high doses in multiple sclerosis: A note of caution.
Mult Scler. 2018 Oct 25:1352458518807059. doi: 10.1177/1352458518807059.
PubMed Abstract available

AHMAD H, van der Mei I, Taylor BV, Lucas RM, et al
Estimation of annual probabilities of changing disability levels in Australians with relapsing-remitting multiple sclerosis.
Mult Scler. 2018 Oct 23:1352458518806103. doi: 10.1177/1352458518806103.
PubMed Abstract available

SOELBERG SORENSEN P, Giovannoni G, Montalban X, Thalheim C, et al
The Multiple Sclerosis Care Unit.
Mult Scler. 2018 Oct 23:1352458518807082. doi: 10.1177/1352458518807082.
PubMed Abstract available

ROTSTEIN DL, Cortese M, Fung TT, Chitnis T, et al
Diet quality and risk of multiple sclerosis in two cohorts of US women.
Mult Scler. 2018 Oct 23:1352458518807061. doi: 10.1177/1352458518807061.
PubMed Abstract available

STROBER L, DeLuca J, Benedict RH, Jacobs A, et al
Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis.
Mult Scler. 2018 Oct 18:1352458518808204. doi: 10.1177/1352458518808204.
PubMed Abstract available

BURROWS DJ, McGown A, Jain SA, De Felice M, et al
Animal models of multiple sclerosis: From rodents to zebrafish.
Mult Scler. 2018 Oct 15:1352458518805246. doi: 10.1177/1352458518805246.
PubMed Abstract available

DUBUISSON N, Marta M, Gnanapavan S, Turner B, et al
Inclusion criteria used in trials of people with progressive multiple sclerosis.
Mult Scler. 2018 Oct 15:1352458518803769. doi: 10.1177/1352458518803769.
PubMed

GRAF J, Ringelstein M, Lepka K, Schaller J, et al
Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment.
Mult Scler. 2018 Oct 11:1352458518771276. doi: 10.1177/1352458518771276.
PubMed Abstract available

WILLIS MD, Hope-Gill B, Flood-Page P, Joseph F, et al
Sarcoidosis following alemtuzumab treatment for multiple sclerosis.
Mult Scler. 2018 Oct 11:1352458518790391. doi: 10.1177/1352458518790391.
PubMed Abstract available

PFEUFFER S
Sarcoidosis following alemtuzumab treatment: Autoimmunity mediated by T cells and interferon-gamma.
Mult Scler. 2018 Oct 11:1352458518804124. doi: 10.1177/1352458518804124.
PubMed

CONWAY BL, Zeydan B, Uygunoglu U, Novotna M, et al
Age is a critical determinant in recovery from multiple sclerosis relapses.
Mult Scler. 2018 Oct 10:1352458518800815. doi: 10.1177/1352458518800815.
PubMed Abstract available

KALB R, Beier M, Benedict RH, Charvet L, et al
Recommendations for cognitive screening and management in multiple sclerosis care.
Mult Scler. 2018 Oct 10:1352458518803785. doi: 10.1177/1352458518803785.
PubMed Abstract available

VILARINO-GUELL C, Encarnacion M, Bernales CQ, Sadovnick AD, et al
Analysis of Canadian multiple sclerosis patients does not support a role for FKBP6 in disease.
Mult Scler. 2018 Oct 9:1352458518803789. doi: 10.1177/1352458518803789.
PubMed

KREMER D, Akkermann R, Kury P, Dutta R, et al
Current advancements in promoting remyelination in multiple sclerosis.
Mult Scler. 2018 Oct 1:1352458518800827. doi: 10.1177/1352458518800827.
PubMed Abstract available

TATEO F, Grassivaro F, Ermani M, Puthenparampil M, et al
PM2.5 levels strongly associate with multiple sclerosis prevalence in the Province of Padua, Veneto Region, North-East Italy.
Mult Scler. 2018 Oct 1:1352458518803273. doi: 10.1177/1352458518803273.
PubMed Abstract available

September 2018

BOSE G, Atkins HL, Bowman M, Freedman MS, et al
Autologous hematopoietic stem cell transplantation improves fatigue in multiple sclerosis.
Mult Scler. 2018 Sep 25:1352458518802544. doi: 10.1177/1352458518802544.
PubMed Abstract available

MIN M, Spelman T, Lugaresi A, Boz C, et al
Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis.
Mult Scler. 2018 Sep 20:1352458518798147. doi: 10.1177/1352458518798147.
PubMed Abstract available

LAVORGNA L, Brigo F, Moccia M, Leocani L, et al
e-Health and multiple sclerosis: An update.
Mult Scler. 2018 Sep 19:1352458518799629. doi: 10.1177/1352458518799629.
PubMed Abstract available

ANTONAZZO IC, Poluzzi E, Forcesi E, Riise T, et al
Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System.
Mult Scler. 2018 Sep 19:1352458518799598. doi: 10.1177/1352458518799598.
PubMed Abstract available

ROMMER PS, Eichstadt K, Ellenberger D, Flachenecker P, et al
Symptomatology and symptomatic treatment in multiple sclerosis: Results from a nationwide MS registry.
Mult Scler. 2018 Sep 19:1352458518799580. doi: 10.1177/1352458518799580.
PubMed Abstract available

O'GRADY KP, Dula AN, Lyttle BD, Thompson LM, et al
Glutamate-sensitive imaging and evaluation of cognitive impairment in multiple sclerosis.
Mult Scler. 2018 Sep 19:1352458518799583. doi: 10.1177/1352458518799583.
PubMed Abstract available

BENJAMIN LA
A tale of two demyelinating diseases and Zika virus.
Mult Scler. 2018 Sep 18:1352458518799584. doi: 10.1177/1352458518799584.
PubMed

August 2018

VAN ROSSUM JA, Killestein J, Villar LM, Riskind PN, et al
gMS-Classifier1 does not predict disability progression in multiple sclerosis.
Mult Scler. 2018 Aug 31:1352458518798048. doi: 10.1177/1352458518798048.
PubMed

VAN MUNSTER CE, D'Souza M, Steinheimer S, Kamm CP, et al
Tasks of activities of daily living (ADL) are more valuable than the classical neurological examination to assess upper extremity function and mobility in multiple sclerosis.
Mult Scler. 2018 Aug 31:1352458518796690. doi: 10.1177/1352458518796690.
PubMed Abstract available

O'MAHONY J, Marrie RA, Laporte A, Bar-Or A, et al
Pediatric-onset multiple sclerosis is associated with reduced parental health-related quality of life and family functioning.
Mult Scler. 2018 Aug 30:1352458518796676. doi: 10.1177/1352458518796676.
PubMed Abstract available

BOVE R, Bevan C, Crabtree E, Zhao C, et al
Toward a low-cost, in-home, telemedicine-enabled assessment of disability in multiple sclerosis.
Mult Scler. 2018 Aug 24:1352458518793527. doi: 10.1177/1352458518793527.
PubMed Abstract available

NICHOLAS RS, Han E, Raffel J, Chataway J, et al
Over three decades study populations in progressive multiple sclerosis have become older and more disabled, but have lower on-trial progression rates: A systematic review and meta-analysis of 43 randomised placebo-controlled trials.
Mult Scler. 2018 Aug 24:1352458518794063. doi: 10.1177/1352458518794063.
PubMed Abstract available

SKJERBAEK AG, Boesen F, Petersen T, Rasmussen PV, et al
Can we trust self-reported walking distance when determining EDSS scores in patients with multiple sclerosis? The Danish MS hospitals rehabilitation study.
Mult Scler. 2018 Aug 20:1352458518795416. doi: 10.1177/1352458518795416.
PubMed Abstract available

ANDERSEN C, Sondergaard HB, Bang Oturai D, Laursen JH, et al
Alcohol consumption in adolescence is associated with a lower risk of multiple sclerosis in a Danish cohort.
Mult Scler. 2018 Aug 20:1352458518795418. doi: 10.1177/1352458518795418.
PubMed Abstract available

GAUZZI MC
Vitamin D-binding protein and multiple sclerosis: Evidence, controversies, and needs.
Mult Scler. 2018 Aug 16:1352458518792433. doi: 10.1177/1352458518792433.
PubMed Abstract available

SELLEBJERG F, Royen L, Soelberg Sorensen P, Oturai AB, et al
Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis.
Mult Scler. 2018 Aug 16:1352458518794308. doi: 10.1177/1352458518794308.
PubMed Abstract available

VISWANATHAN S, Wah LM
A nationwide epidemiological study on the prevalence of multiple sclerosis and neuromyelitis optica spectrum disorder with important multi-ethnic differences in Malaysia.
Mult Scler. 2018 Aug 16:1352458518792430. doi: 10.1177/1352458518792430.
PubMed Abstract available

SEEBACHER B, Kuisma R, Glynn A, Berger T, et al
Effects and mechanisms of differently cued and non-cued motor imagery in people with multiple sclerosis: A randomised controlled trial.
Mult Scler. 2018 Aug 14:1352458518795332. doi: 10.1177/1352458518795332.
PubMed Abstract available

PIETROBONI AM, Caprioli M, Carandini T, Scarioni M, et al
CSF beta-amyloid predicts prognosis in patients with multiple sclerosis.
Mult Scler. 2018 Aug 7:1352458518791709. doi: 10.1177/1352458518791709.
PubMed Abstract available

ROCCA MA, Meani A, Fumagalli S, Pagani E, et al
Functional and structural plasticity following action observation training in multiple sclerosis.
Mult Scler. 2018 Aug 7:1352458518792771. doi: 10.1177/1352458518792771.
PubMed Abstract available

KUSPINAR A, Mayo NE
Validation of the preference-based multiple sclerosis index.
Mult Scler. 2018 Aug 2:1352458518792423. doi: 10.1177/1352458518792423.
PubMed Abstract available

TOMASSINI V, Fanelli F, Prosperini L, Cerqua R, et al
Predicting the profile of increasing disability in multiple sclerosis.
Mult Scler. 2018 Aug 2:1352458518790397. doi: 10.1177/1352458518790397.
PubMed Abstract available

PETERSEN ER, Sondergaard HB, Laursen JH, Olsson AG, et al
Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis.
Mult Scler. 2018 Aug 2:1352458518791753. doi: 10.1177/1352458518791753.
PubMed Abstract available

DI STADIO A, Ralli M
Inner ear involvement in multiple sclerosis: An underestimated condition?
Mult Scler. 2018;24:1264-1265.
PubMed

BHAN A, Jacobsen C, Myhr KM, Dalen I, et al
Neurofilaments and 10-year follow-up in multiple sclerosis.
Mult Scler. 2018 Aug 1:1352458518782005. doi: 10.1177/1352458518782005.
PubMed Abstract available

July 2018

YANG R, Dunn JF
Multiple sclerosis disease progression: Contributions from a hypoxia-inflammation cycle.
Mult Scler. 2018 Jul 27:1352458518791683. doi: 10.1177/1352458518791683.
PubMed Abstract available

SACCA F, Lanzillo R, Signori A, Maniscalco GT, et al
Determinants of therapy switch in multiple sclerosis treatment-naive patients: A real-life study.
Mult Scler. 2018 Jul 25:1352458518790390. doi: 10.1177/1352458518790390.
PubMed Abstract available

HYUN JW, Kim W, Huh SY, Park MS, et al
Application of the 2017 McDonald diagnostic criteria for multiple sclerosis in Korean patients with clinically isolated syndrome.
Mult Scler. 2018 Jul 25:1352458518790702. doi: 10.1177/1352458518790702.
PubMed Abstract available

HOLM HANSEN R, Hojsgaard Chow H, Sellebjerg F, Rode von Essen M, et al
Dimethyl fumarate therapy suppresses B cell responses and follicular helper T cells in relapsing-remitting multiple sclerosis.
Mult Scler. 2018 Jul 25:1352458518790417. doi: 10.1177/1352458518790417.
PubMed Abstract available

COHEN JA, Comi G, Arnold DL, Bar-Or A, et al
Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
Mult Scler. 2018 Jul 25:1352458518789884. doi: 10.1177/1352458518789884.
PubMed Abstract available

LIN F, Zivadinov R, Hagemeier J, Weinstock-Guttman B, et al
Altered nuclei-specific thalamic functional connectivity patterns in multiple sclerosis and their associations with fatigue and cognition.
Mult Scler. 2018 Jul 1:1352458518788218. doi: 10.1177/1352458518788218.
PubMed Abstract available

SENDERS A, Hanes D, Bourdette D, Carson K, et al
Impact of mindfulness-based stress reduction for people with multiple sclerosis at 8 weeks and 12 months: A randomized clinical trial.
Mult Scler. 2018 Jul 1:1352458518786650. doi: 10.1177/1352458518786650.
PubMed Abstract available

FISSOLO N, Cervera-Carles L, Villar Guimerans LM, Lleo A, et al
Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosis.
Mult Scler. 2018 Jul 1:1352458518786055. doi: 10.1177/1352458518786055.
PubMed Abstract available

OSHIMA Y, Tanimoto T, Yuji K, Tojo A, et al
Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
Mult Scler. 2018 Jul 1:1352458518786075. doi: 10.1177/1352458518786075.
PubMed Abstract available

WIJNANDS JM, Zhu F, Kingwell E, Zhao Y, et al
Five years before multiple sclerosis onset: Phenotyping the prodrome.
Mult Scler. 2018 Jul 1:1352458518783662. doi: 10.1177/1352458518783662.
PubMed Abstract available

WONG YYM, van der Vuurst de Vries RM, van Pelt ED, Ketelslegers IA, et al
T-cell activation marker sCD27 is associated with clinically definite multiple sclerosis in childhood-acquired demyelinating syndromes.
Mult Scler. 2018 Jul 1:1352458518786655. doi: 10.1177/1352458518786655.
PubMed Abstract available

KEARNEY H
Clinical monitoring of multiple sclerosis should routinely include spinal cord imaging - No.
Mult Scler. 2018 Jul 1:1352458518770279. doi: 10.1177/1352458518770279.
PubMed

SASTRE-GARRIGA J
Clinical monitoring of multiple sclerosis should routinely include spinal cord imaging - Commentary.
Mult Scler. 2018 Jul 1:1352458518783362. doi: 10.1177/1352458518783362.
PubMed

CORTESE R, Ciccarelli O
Clinical monitoring of multiple sclerosis should routinely include spinal cord imaging - Yes.
Mult Scler. 2018 Jul 1:1352458518778010. doi: 10.1177/1352458518778010.
PubMed

June 2018

MESCHERIAKOVA JY, Verkerk AJ, Amin N, Uitterlinden AG, et al
Linkage analysis and whole exome sequencing identify a novel candidate gene in a Dutch multiple sclerosis family.
Mult Scler. 2018 Jun 1:1352458518777202. doi: 10.1177/1352458518777202.
PubMed Abstract available

PUTHENPARAMPIL M, Zito A, Pantano G, Federle L, et al
Peripheral imbalanced TFH/TFR ratio correlates with intrathecal IgG synthesis in multiple sclerosis at clinical onset.
Mult Scler. 2018 Jun 1:1352458518779951. doi: 10.1177/1352458518779951.
PubMed Abstract available

AL HUSSONA M, Kearney H, Fisher A, Lynch J, et al
New onset seizures as a sole clinical presentation of multiple sclerosis.
Mult Scler. 2018 Jun 1:1352458518781994. doi: 10.1177/1352458518781994.
PubMed Abstract available

REDDEL SW, Barnett MH, Riminton S, Dugal T, et al
Successful implementation of an automated electronic support system for patient safety monitoring: The alemtuzumab in multiple sclerosis safety systems (AMS3) study.
Mult Scler. 2018 Jun 1:1352458518783673. doi: 10.1177/1352458518783673.
PubMed Abstract available

CHEN J, Taylor B, Palmer AJ, Kirk-Brown A, et al
Estimating MS-related work productivity loss and factors associated with work productivity loss in a representative Australian sample of people with multiple sclerosis.
Mult Scler. 2018 Jun 1:1352458518781971. doi: 10.1177/1352458518781971.
PubMed Abstract available

MANOUCHEHRINIA A, Zhu F, Piani-Meier D, Lange M, et al
Predicting risk of secondary progression in multiple sclerosis: A nomogram.
Mult Scler. 2018 Jun 1:1352458518783667. doi: 10.1177/1352458518783667.
PubMed Abstract available

GALLAGHER LG, Ilango S, Wundes A, Stobbe GA, et al
Lifetime exposure to ultraviolet radiation and the risk of multiple sclerosis in the US radiologic technologists cohort study.
Mult Scler. 2018 Jun 1:1352458518783343. doi: 10.1177/1352458518783343.
PubMed Abstract available

MAGALHAES S, Banwell B, Bar-Or A, Fortier I, et al
A framework for measurement and harmonization of pediatric multiple sclerosis etiologic research studies: The Pediatric MS Tool-Kit.
Mult Scler. 2018 Jun 1:1352458518783345. doi: 10.1177/1352458518783345.
PubMed Abstract available

ALVES-LEON SV, Lima MDR, Nunes PCG, Chimelli LMC, et al
Zika virus found in brain tissue of a multiple sclerosis patient undergoing an acute disseminated encephalomyelitis-like episode.
Mult Scler. 2018 Jun 1:1352458518781992. doi: 10.1177/1352458518781992.
PubMed Abstract available

May 2018

FROEHLICH A, Schmidt S, Landsberg J, Bieber T, et al
Spontaneous regression of tumor-stage cutaneous T-cell lymphoma in a multiple sclerosis patient after discontinuing fingolimod.
Mult Scler. 2018 May 1:1352458518774444. doi: 10.1177/1352458518774444.
PubMed

NAUTA IM, Balk LJ, Sonder JM, Hulst HE, et al
The clinical value of the patient-reported multiple sclerosis neuropsychological screening questionnaire.
Mult Scler. 2018 May 1:1352458518777295. doi: 10.1177/1352458518777295.
PubMed Abstract available

ROMME CHRISTENSEN J, Komori M, von Essen MR, Ratzer R, et al
CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage.
Mult Scler. 2018 May 1:1352458518774880. doi: 10.1177/1352458518774880.
PubMed Abstract available

MILLS EA, Mao-Draayer Y
Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients.
Mult Scler. 2018 May 1:1352458518775550. doi: 10.1177/1352458518775550.
PubMed Abstract available

VAN DER VUURST DE VRIES RM, Wong YYM, Mescheriakova JY, van Pelt ED, et al
High neurofilament levels are associated with clinically definite multiple sclerosis in children and adults with clinically isolated syndrome.
Mult Scler. 2018 May 1:1352458518775303. doi: 10.1177/1352458518775303.
PubMed Abstract available

SCHEE JP, Viswanathan S
Pure spinal multiple sclerosis: A possible novel entity within the multiple sclerosis disease spectrum.
Mult Scler. 2018 May 1:1352458518775912. doi: 10.1177/1352458518775912.
PubMed Abstract available

BOESEN MS, Koch-Henriksen N, Thygesen LC, Eriksson F, et al
Infections seem to be more frequent before onset of pediatric multiple sclerosis: A Danish nationwide nested case-control study.
Mult Scler. 2018 May 1:1352458518771871. doi: 10.1177/1352458518771871.
PubMed Abstract available

BAKER G, Nair KPS, Baster K, Rosato R, et al
Reliability and acceptability of the Multiple Sclerosis Quality of Life-29 questionnaire in an English-speaking cohort.
Mult Scler. 2018 May 1:1352458518776583. doi: 10.1177/1352458518776583.
PubMed Abstract available

BEESLEY R, Anderson V, Harding KE, Joseph F, et al
Impact of the 2017 revisions to McDonald criteria on the diagnosis of multiple sclerosis.
Mult Scler. 2018 May 1:1352458518778007. doi: 10.1177/1352458518778007.
PubMed

HUGOS CL, Cameron MH, Chen Z, Chen Y, et al
A multicenter randomized controlled trial of two group education programs for fatigue in multiple sclerosis: Long-term (12-month) follow-up at one site.
Mult Scler. 2018 May 1:1352458518775920. doi: 10.1177/1352458518775920.
PubMed Abstract available

TSAGKAS C, Magon S, Gaetano L, Pezold S, et al
Preferential spinal cord volume loss in primary progressive multiple sclerosis.
Mult Scler. 2018 May 1:1352458518775006. doi: 10.1177/1352458518775006.
PubMed Abstract available

MARANZANO J, Till C, Assemlal HE, Fonov V, et al
Detection and clinical correlation of leukocortical lesions in pediatric-onset multiple sclerosis on multi-contrast MRI.
Mult Scler. 2018 May 1:1352458518779952. doi: 10.1177/1352458518779952.
PubMed Abstract available

BJORNEVIK K, Myhr KM, Beiske A, Bjerve KS, et al
alpha-Linolenic acid is associated with MRI activity in a prospective cohort of multiple sclerosis patients.
Mult Scler. 2018 May 1:1352458518779925. doi: 10.1177/1352458518779925.
PubMed Abstract available

April 2018

ALMEIDA KJ, Barreto-Soares RV, Campos-Sousa RN, Campos-Sousa MG, et al
Pulmonary paracoccidioidomycosis associated with the use of natalizumab in multiple sclerosis.
Mult Scler. 2018 Apr 1:1352458518763091. doi: 10.1177/1352458518763091.
PubMed Abstract available

MCNICHOLAS N, Lockhart A, Yap SM, O'Connell K, et al
New versus old: Implications of evolving diagnostic criteria for relapsing-remitting multiple sclerosis.
Mult Scler. 2018 Apr 1:1352458518770088. doi: 10.1177/1352458518770088.
PubMed Abstract available

KREMER D, Kury P, Hartung HP
ECTRIMS/ACTRIMS 2017: Closing in on neurorepair in progressive multiple sclerosis.
Mult Scler. 2018 Apr 1:1352458518768770. doi: 10.1177/1352458518768770.
PubMed Abstract available

KOBELT G, Langdon D, Jonsson L
The effect of self-assessed fatigue and subjective cognitive impairment on work capacity: The case of multiple sclerosis.
Mult Scler. 2018 Apr 1:1352458518769837. doi: 10.1177/1352458518769837.
PubMed Abstract available

VAVASOUR IM, Tam R, Li DK, Laule C, et al
A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab.
Mult Scler. 2018 Apr 1:1352458518770085. doi: 10.1177/1352458518770085.
PubMed Abstract available

MARRIE RA, Montalban X
Disease-modifying therapy in multiple sclerosis: Two guidelines (almost) passing in the night.
Mult Scler. 2018;24:558-562.
PubMed

LORSCHEIDER J, Benkert P, Lienert C, Hanni P, et al
Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
Mult Scler. 2018 Apr 1:1352458518768433. doi: 10.1177/1352458518768433.
PubMed Abstract available

SAUL A, Taylor B, Simpson S Jr, Ponsonby AL, et al
Polymorphism in the serotonin transporter gene polymorphisms ( 5-HTTLPR) modifies the association between significant life events and depression in people with multiple sclerosis.
Mult Scler. 2018 Apr 1:1352458518770021. doi: 10.1177/1352458518770021.
PubMed Abstract available

LLUFRIU S, Rocca MA, Pagani E, Riccitelli GC, et al
Hippocampal-related memory network in multiple sclerosis: A structural connectivity analysis.
Mult Scler. 2018 Apr 1:1352458518771838. doi: 10.1177/1352458518771838.
PubMed Abstract available

CREARY LE, Mallempati KC, Gangavarapu S, Caillier SJ, et al
Deconstruction of HLA-DRB1*04:01:01 and HLA-DRB1*15:01:01 class II haplotypes using next-generation sequencing in European-Americans with multiple sclerosis.
Mult Scler. 2018 Apr 1:1352458518770019. doi: 10.1177/1352458518770019.
PubMed Abstract available

MCCLURG D, Bugge C, Elders A, Irshad T, et al
Factors affecting continuation of clean intermittent catheterisation in people with multiple sclerosis: Results of the COSMOS mixed-methods study.
Mult Scler. 2018 Apr 1:1352458518768722. doi: 10.1177/1352458518768722.
PubMed Abstract available

WAGLEY S, Bokori-Brown M, Morcrette H, Malaspina A, et al
Evidence of Clostridium perfringens epsilon toxin associated with multiple sclerosis.
Mult Scler. 2018 Apr 1:1352458518767327. doi: 10.1177/1352458518767327.
PubMed Abstract available

GIOVANNONI G, Soelberg Sorensen P, Cook S, Rammohan KW, et al
Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.
Mult Scler. 2018 Apr 1:1352458518771875. doi: 10.1177/1352458518771875.
PubMed Abstract available

GIORDANA MT, Cavalla P, Uccelli A, Laroni A, et al
Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation.
Mult Scler. 2018 Apr 1:1352458518763095. doi: 10.1177/1352458518763095.
PubMed Abstract available

GIACOMINI PS
Rebound disease in multiple sclerosis.
Mult Scler. 2018 Apr 1:1352458518772913. doi: 10.1177/1352458518772913.
PubMed

HARMEL P, Schlunk F, Harms L
Fulminant rebound of relapsing-remitting multiple sclerosis after discontinuation of dimethyl fumarate: A case report.
Mult Scler. 2018 Apr 1:1352458517741191. doi: 10.1177/1352458517741191.
PubMed Abstract available

March 2018

KOENIG KA, Rao SM, Lowe MJ, Lin J, et al
The role of the thalamus and hippocampus in episodic memory performance in patients with multiple sclerosis.
Mult Scler. 2018 Mar 1:1352458518760716. doi: 10.1177/1352458518760716.
PubMed Abstract available

GOBEL K, Ruck T, Meuth SG
Cytokine signaling in multiple sclerosis: Lost in translation.
Mult Scler. 2018 Mar 1:1352458518763094. doi: 10.1177/1352458518763094.
PubMed Abstract available

LEE JY, De Jager PL
What is the epigenome and is it involved in multiple sclerosis?
Mult Scler. 2018;24:268-269.
PubMed

SILLER N, Kuhle J, Muthuraman M, Barro C, et al
Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.
Mult Scler. 2018 Mar 1:1352458518765666. doi: 10.1177/1352458518765666.
PubMed Abstract available

SOWA P, Harbo HF, White NS, Celius EG, et al
Restriction spectrum imaging of white matter and its relation to neurological disability in multiple sclerosis.
Mult Scler. 2018 Mar 1:1352458518765671. doi: 10.1177/1352458518765671.
PubMed Abstract available

CORTI L, Ayrignac X, Carra Dalliere C, Charif M, et al
Late activity rebound in non-active multiple sclerosis: A rare event.
Mult Scler. 2018 Mar 1:1352458518765670. doi: 10.1177/1352458518765670.
PubMed

CASTELLI L, Prosperini L, Pozzilli C
Balance worsening associated with nabiximols in multiple sclerosis.
Mult Scler. 2018 Mar 1:1352458518765649. doi: 10.1177/1352458518765649.
PubMed Abstract available

GRAETZ C, Groger A, Luessi F, Salmen A, et al
Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis.
Mult Scler. 2018 Mar 1:1352458518763541. doi: 10.1177/1352458518763541.
PubMed Abstract available

HUA LH, Fan TH, Conway D, Thompson N, et al
Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60.
Mult Scler. 2018 Mar 1:1352458518765656. doi: 10.1177/1352458518765656.
PubMed Abstract available

LANZILLO R, Moccia M, Criscuolo C, Cennamo G, et al
Optical coherence tomography angiography detects retinal vascular alterations in different phases of multiple sclerosis.
Mult Scler. 2018 Mar 1:1352458518768060. doi: 10.1177/1352458518768060.
PubMed

VAN GEEST Q, Boeschoten RE, Keijzer MJ, Steenwijk MD, et al
Fronto-limbic disconnection in patients with multiple sclerosis and depression.
Mult Scler. 2018 Mar 1:1352458518767051. doi: 10.1177/1352458518767051.
PubMed Abstract available

TOLEDANO M, Weinshenker BG, Kaufmann TJ, Parisi JE, et al
Demographics and clinical characteristics of episodic hypothermia in multiple sclerosis.
Mult Scler. 2018 Mar 1:1352458518767045. doi: 10.1177/1352458518767045.
PubMed Abstract available

LEIBOVITCH EC, Lin CM, Billioux BJ, Graves J, et al
Prevalence of salivary human herpesviruses in pediatric multiple sclerosis cases and controls.
Mult Scler. 2018 Mar 1:1352458518765654. doi: 10.1177/1352458518765654.
PubMed Abstract available

KIRA JI
Reply to letter to the editor: Dimethyl fumarate for patients with neuromyelitis optica spectrum disorder by Pitarokoili and Gold.
Mult Scler. 2018;24:366-367.
PubMed

YAMOUT BI, Zeineddine MM
Letter to the editor.
Mult Scler. 2018;24:363.
PubMed

PITAROKOILI K, Gold R
Dimethyl fumarate for patients with neuromyelitis optica spectrum disorder.
Mult Scler. 2018;24:364-365.
PubMed

February 2018

JAEGER S, Paul F, Scheel M, Brandt A, et al
Multiple sclerosis-related fatigue: Altered resting-state functional connectivity of the ventral striatum and dorsolateral prefrontal cortex.
Mult Scler. 2018 Feb 1:1352458518758911. doi: 10.1177/1352458518758911.
PubMed Abstract available

DE STEFANO N, Giorgio A, Tintore M, Pia Amato M, et al
Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations.
Mult Scler. 2018;24:214-221.
PubMed

ROOSTAEI T, Sadaghiani S, Mashhadi R, Falahatian M, et al
Convergent effects of a functional C3 variant on brain atrophy, demyelination, and cognitive impairment in multiple sclerosis.
Mult Scler. 2018 Feb 1:1352458518760715. doi: 10.1177/1352458518760715.
PubMed Abstract available

CAVALERA C, Rovaris M, Mendozzi L, Pugnetti L, et al
Online meditation training for people with multiple sclerosis: A randomized controlled trial.
Mult Scler. 2018 Feb 1:1352458518761187. doi: 10.1177/1352458518761187.
PubMed Abstract available

CAMARA-LEMARROY CR, Castillo J, Sastre-Garriga J, Tintore M, et al
Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis: A case report.
Mult Scler. 2018 Feb 1:1352458518761185. doi: 10.1177/1352458518761185.
PubMed Abstract available

PIEHL F, Hillert J
Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Yes.
Mult Scler. 2018 Feb 1:1352458518757930. doi: 10.1177/1352458518757930.
PubMed

CREE BA
Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Commentary.
Mult Scler. 2018 Feb 1:1352458518760717. doi: 10.1177/1352458518760717.
PubMed

WALLIN MT
Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - No.
Mult Scler. 2018 Feb 1:1352458518757931. doi: 10.1177/1352458518757931.
PubMed

BARKHOF F
The optic nerve should be included as one of the typical CNS regions for establishing dissemination in space when diagnosing MS - Commentary.
Mult Scler. 2018;24:125-126.
PubMed

PORTER B
Commentary on "Localized pigmentation disorder after subcutaneous pegylated interferon beta 1a injection" by Coghe et al.
Mult Scler. 2018;24:233-235.
PubMed

January 2018

HILVEN K, Vandebergh M, Smets I, Mallants K, et al
Genetic basis for relapse rate in multiple sclerosis: Association with LRP2 genetic variation.
Mult Scler. 2018 Jan 1:1352458517749894. doi: 10.1177/1352458517749894.
PubMed Abstract available

FEUCHT N, Maier M, Lepennetier G, Pettenkofer M, et al
Optical coherence tomography angiography indicates associations of the retinal vascular network and disease activity in multiple sclerosis.
Mult Scler. 2018 Jan 1:1352458517750009. doi: 10.1177/1352458517750009.
PubMed Abstract available

DI STADIO A, Ralli M
Inner ear involvement in multiple sclerosis: An underestimated condition?
Mult Scler. 2018 Jan 1:1352458518750010. doi: 10.1177/1352458518750010.
PubMed

DAMOTTE V, Lizee A, Tremblay M, Agrawal A, et al
Harnessing electronic medical records to advance research on multiple sclerosis.
Mult Scler. 2018 Jan 1:1352458517747407. doi: 10.1177/1352458517747407.
PubMed Abstract available

DE STEFANO N, Giorgio A
Response to 'Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis?' by Schiffmann et al.
Mult Scler. 2018 Jan 1:1352458517748476. doi: 10.1177/1352458517748476.
PubMed

SCHIFFMANN I, Scheiderbauer J, Riemann-Lorenz K, Heesen C, et al
Does cladribine have an impact on brain atrophy in people with relapsing remitting multiple sclerosis?
Mult Scler. 2018 Jan 1:1352458517749895. doi: 10.1177/1352458517749895.
PubMed

SEGAL BM, Cohen JA, Antel J
Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2017: Environmental factors, genetics, and epigenetics in MS susceptibility and clinical course.
Mult Scler. 2018;24:4-5.
PubMed Abstract available

TREMLETT H, Waubant E
Gut microbiome and pediatric multiple sclerosis.
Mult Scler. 2018;24:64-68.
PubMed Abstract available

CASTRO K, Casaccia P
Epigenetic modifications in brain and immune cells of multiple sclerosis patients.
Mult Scler. 2018;24:69-74.
PubMed Abstract available

TANKOU SK, Regev K, Healy BC, Cox LM, et al
Investigation of probiotics in multiple sclerosis.
Mult Scler. 2018;24:58-63.
PubMed Abstract available

VOSKUHL RR, Sawalha AH, Itoh Y
Sex chromosome contributions to sex differences in multiple sclerosis susceptibility and progression.
Mult Scler. 2018;24:22-31.
PubMed Abstract available

HAASE S, Haghikia A, Gold R, Linker RA, et al
Dietary fatty acids and susceptibility to multiple sclerosis.
Mult Scler. 2018;24:12-16.
PubMed Abstract available

HARROUD A, Richards JB
Mendelian randomization in multiple sclerosis: A causal role for vitamin D and obesity?
Mult Scler. 2018;24:80-85.
PubMed Abstract available

DOLEI A
The aliens inside us: HERV-W endogenous retroviruses and multiple sclerosis.
Mult Scler. 2018;24:42-47.
PubMed Abstract available

CANTO E, Oksenberg JR
Multiple sclerosis genetics.
Mult Scler. 2018;24:75-79.
PubMed Abstract available

WAUBANT E
Effect of puberty on multiple sclerosis risk and course.
Mult Scler. 2018;24:32-35.
PubMed Abstract available

HODEL J, Bapst B, Outteryck O, Verclytte S, et al
Magnetic resonance imaging changes following natalizumab discontinuation in multiple sclerosis patients with progressive multifocal leukoencephalopathy.
Mult Scler. 2018 Jan 1:1352458517750765. doi: 10.1177/1352458517750765.
PubMed Abstract available

BOVE R, Healy BC, Musallam A, Soltany P, et al
Fatty acid binding protein-4 is associated with disability in multiple sclerosis patients.
Mult Scler. 2018 Jan 1:1352458517750768. doi: 10.1177/1352458517750768.
PubMed Abstract available

RIMKUS CM, Schoonheim MM, Steenwijk MD, Vrenken H, et al
Gray matter networks and cognitive impairment in multiple sclerosis.
Mult Scler. 2018 Jan 1:1352458517751650. doi: 10.1177/1352458517751650.
PubMed Abstract available

COHEN JA, Hunter SF, Brown TR, Gudesblatt M, et al
Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial.
Mult Scler. 2018 Jan 1:1352458518754716. doi: 10.1177/1352458518754716.
PubMed Abstract available

BARONCINI D, Zaffaroni M, Moiola L, Lorefice L, et al
Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study.
Mult Scler. 2018 Jan 1:1352458518754364. doi: 10.1177/1352458518754364.
PubMed Abstract available

FORD HL, Wicks CR, Stroud A, Tennant A, et al
Psychological determinants of job retention in multiple sclerosis.
Mult Scler. 2018 Jan 1:1352458518754362. doi: 10.1177/1352458518754362.
PubMed Abstract available

ROY S, Drake A, Fuchs T, Dwyer MG, et al
Longitudinal personality change associated with cognitive decline in multiple sclerosis.
Mult Scler. 2018 Jan 1:1352458517753720. doi: 10.1177/1352458517753720.
PubMed Abstract available

HAUPTS MR, Spill-Askeridis P, Humpert M, Seidel D, et al
Acute exacerbations after decades of non-active chronic multiple sclerosis.
Mult Scler. 2018 Jan 1:1352458518754365. doi: 10.1177/1352458518754365.
PubMed

DI IOIA M, Farina D, di Tommaso V, Travaglini D, et al
Simultaneous early-onset severe autoimmune hemolytic anemia and albuminuria during alemtuzumab treatment for multiple sclerosis.
Mult Scler. 2018 Jan 1:1352458517743093. doi: 10.1177/1352458517743093.
PubMed Abstract available

MEUNIER B, Rico A, Seguier J, Boutiere C, et al
Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.
Mult Scler. 2018 Jan 1:1352458517729766. doi: 10.1177/1352458517729766.
PubMed Abstract available

MONTALBAN X, Gold R, Thompson AJ, Otero-Romero S, et al
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.
Mult Scler. 2018 Jan 1:1352458517751049. doi: 10.1177/1352458517751049.
PubMed Abstract available

LAVERY AM, Collins BN, Waldman AT, Hart CN, et al
The contribution of secondhand tobacco smoke exposure to pediatric multiple sclerosis risk.
Mult Scler. 2018 Jan 1:1352458518757089. doi: 10.1177/1352458518757089.
PubMed Abstract available

December 2017

KROTH J, Ciolac D, Fleischer V, Koirala N, et al
Increased cerebrospinal fluid albumin and immunoglobulin A fractions forecast cortical atrophy and longitudinal functional deterioration in relapsing-remitting multiple sclerosis.
Mult Scler. 2017 Dec 1:1352458517748474. doi: 10.1177/1352458517748474.
PubMed Abstract available

HUGOS CL, Chen Z, Chen Y, Turner AP, et al
A multicenter randomized controlled trial of two group education programs for fatigue in multiple sclerosis: Short- and medium-term benefits.
Mult Scler. 2017 Dec 1:1352458517745723. doi: 10.1177/1352458517745723.
PubMed Abstract available

CALLESEN J, Richter C, Kristensen C, Sunesen I, et al
Test-retest agreement and reliability of the Six Spot Step Test in persons with multiple sclerosis.
Mult Scler. 2017 Dec 1:1352458517745725. doi: 10.1177/1352458517745725.
PubMed Abstract available

PEETERS LM
Fair data for next-generation management of multiple sclerosis.
Mult Scler. 2017 Dec 1:1352458517748475. doi: 10.1177/1352458517748475.
PubMed Abstract available

November 2017

GRAN-RUAZ S, Mani A, O'Quinn S
An overview of biosimilars and non-biologic complex drugs in Europe, the United States, and Canada and their relevance to multiple sclerosis.
Mult Scler. 2017 Nov 1:1352458517739976. doi: 10.1177/1352458517739976.
PubMed Abstract available

MANCARDI G, Sormani MP, Muraro PA, Boffa G, et al
Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis.
Mult Scler. 2017 Nov 1:1352458517742532. doi: 10.1177/1352458517742532.
PubMed Abstract available

PIETROBONI AM, Dell'Arti L, Caprioli M, Scarioni M, et al
The loss of macular ganglion cells begins from the early stages of disease and correlates with brain atrophy in multiple sclerosis patients.
Mult Scler. 2017 Nov 1:1352458517740214. doi: 10.1177/1352458517740214.
PubMed Abstract available

MALHOTRA S, Sorosina M, Rio J, Peroni S, et al
NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients.
Mult Scler. 2017 Nov 1:1352458517739137. doi: 10.1177/1352458517739137.
PubMed Abstract available

MALINOVA TS, Dijkstra CD, de Vries HE
Serotonin: A mediator of the gut-brain axis in multiple sclerosis.
Mult Scler. 2017 Nov 1:1352458517739975. doi: 10.1177/1352458517739975.
PubMed Abstract available

ABBOUD H, Hill E, Siddiqui J, Serra A, et al
Neuromodulation in multiple sclerosis.
Mult Scler. 2017;23:1663-1676.
PubMed Abstract available

FEYS P, Moumdjian L, Van Halewyck F, Wens I, et al
Effects of an individual 12-week community-located "start-to-run" program on physical capacity, walking, fatigue, cognitive function, brain volumes, and structures in persons with multiple sclerosis.
Mult Scler. 2017 Nov 1:1352458517740211. doi: 10.1177/1352458517740211.
PubMed Abstract available

LOREFICE L, Fenu G, Sardu C, Frau J, et al
Multiple sclerosis and HLA genotypes: A possible influence on brain atrophy.
Mult Scler. 2017 Nov 1:1352458517739989. doi: 10.1177/1352458517739989.
PubMed Abstract available

WINGES KM, Murchison CF, Bourdette DN, Spain RI, et al
Longitudinal optical coherence tomography study of optic atrophy in secondary progressive multiple sclerosis: Results from a clinical trial cohort.
Mult Scler. 2017 Nov 1:1352458517739136. doi: 10.1177/1352458517739136.
PubMed Abstract available

UHER T, Vaneckova M, Krasensky J, Sobisek L, et al
Pathological cut-offs of global and regional brain volume loss in multiple sclerosis.
Mult Scler. 2017 Nov 1:1352458517742739. doi: 10.1177/1352458517742739.
PubMed Abstract available

KAVALIUNAS A, Danylaite Karrenbauer V, Gyllensten H, Manouchehrinia A, et al
Cognitive function is a major determinant of income among multiple sclerosis patients in Sweden acting independently from physical disability.
Mult Scler. 2017 Nov 1:1352458517740212. doi: 10.1177/1352458517740212.
PubMed Abstract available

AGIUS MA, Klodowska-Duda G, Maciejowski M, Potemkowski A, et al
Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study.
Mult Scler. 2017 Nov 1:1352458517740641. doi: 10.1177/1352458517740641.
PubMed Abstract available

SPITERI S, Hassa T, Claros-Salinas D, Dettmers C, et al
Neural correlates of effort-dependent and effort-independent cognitive fatigue components in patients with multiple sclerosis.
Mult Scler. 2017 Nov 1:1352458517743090. doi: 10.1177/1352458517743090.
PubMed Abstract available

RICCITELLI GC, Pagani E, Rodegher M, Colombo B, et al
Imaging patterns of gray and white matter abnormalities associated with PASAT and SDMT performance in relapsing-remitting multiple sclerosis.
Mult Scler. 2017 Nov 1:1352458517743091. doi: 10.1177/1352458517743091.
PubMed Abstract available

October 2017

MOSS-MORRIS R, Norton S
Aerobic exercise, cognitive behavioural therapy and energy conservation management for multiple sclerosis (MS) fatigue: Are three trials better than one?
Mult Scler. 2017;23:1436-1440.
PubMed

ZETTERBERG H, Teunissen C
Fluid biomarkers for disease activity in multiple sclerosis.
Mult Scler. 2017 Oct 1:1352458517736151. doi: 10.1177/1352458517736151.
PubMed

BOESEN F, Norgaard M, Trenel P, Rasmussen PV, et al
Longer term effectiveness of inpatient multidisciplinary rehabilitation on health-related quality of life in MS patients: a pragmatic randomized controlled trial - The Danish MS Hospitals Rehabilitation Study.
Mult Scler. 2017 Oct 1:1352458517735188. doi: 10.1177/1352458517735188.
PubMed Abstract available

GIANFRANCESCO MA, Stridh P, Shao X, Rhead B, et al
Genetic risk factors for pediatric-onset multiple sclerosis.
Mult Scler. 2017 Oct 1:1352458517733551. doi: 10.1177/1352458517733551.
PubMed Abstract available

VAN KEMPEN ZL, Rispens T, Killestein J
Response to "Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing".
Mult Scler. 2017 Oct 1:1352458517734073. doi: 10.1177/1352458517734073.
PubMed

FOX RJ, Chataway J
Advancing trial design in progressive multiple sclerosis.
Mult Scler. 2017;23:1573-1578.
PubMed Abstract available

MILLER DH, Thompson AJ
Advancing trial design in progressive multiple sclerosis.
Mult Scler. 2017;23:1571-1572.
PubMed

MOCCIA M, de Stefano N, Barkhof F
Imaging outcome measures for progressive multiple sclerosis trials.
Mult Scler. 2017;23:1614-1626.
PubMed Abstract available

PICHLER A, Khalil M, Langkammer C, Pinter D, et al
The impact of vascular risk factors on brain volume and lesion load in patients with early multiple sclerosis.
Mult Scler. 2017 Oct 1:1352458517736149. doi: 10.1177/1352458517736149.
PubMed Abstract available

GLAZER CH, Tottenborg SS, Giwercman A, Brauner EV, et al
Male factor infertility and risk of multiple sclerosis: A register-based cohort study.
Mult Scler. 2017 Oct 1:1352458517734069. doi: 10.1177/1352458517734069.
PubMed Abstract available

TINELLI M, Kanavos P, Efthymiadou O, Visintin E, et al
Using IMPrESS to guide policy change in multiple sclerosis.
Mult Scler. 2017 Oct 1:1352458517737388. doi: 10.1177/1352458517737388.
PubMed Abstract available

DONADIEU M, Le Fur Y, Maarouf A, Gherib S, et al
Metabolic counterparts of sodium accumulation in multiple sclerosis: A whole brain 23Na-MRI and fast 1H-MRSI study.
Mult Scler. 2017 Oct 1:1352458517736146. doi: 10.1177/1352458517736146.
PubMed Abstract available

FLEMING J, Hernandez G, Hartman L, Maksimovic J, et al
Safety and efficacy of helminth treatment in relapsing-remitting multiple sclerosis: Results of the HINT 2 clinical trial.
Mult Scler. 2017 Oct 1:1352458517736377. doi: 10.1177/1352458517736377.
PubMed Abstract available

BSTEH G, Hegen H, Teuchner B, Amprosi M, et al
Peripapillary retinal nerve fibre layer as measured by optical coherence tomography is a prognostic biomarker not only for physical but also for cognitive disability progression in multiple sclerosis.
Mult Scler. 2017 Oct 1:1352458517740216. doi: 10.1177/1352458517740216.
PubMed Abstract available

LEAVITT VM, Blanchard AR, Guo CY, Gelernt E, et al
Aspirin is an effective pretreatment for exercise in multiple sclerosis: A double-blind randomized controlled pilot trial.
Mult Scler. 2017 Oct 1:1352458517739138. doi: 10.1177/1352458517739138.
PubMed Abstract available

DEKKER I, Sombekke MH, Witte BI, Geurts JJ, et al
Asymptomatic spinal cord lesions do not predict the time to disability in patients with early multiple sclerosis.
Mult Scler. 2017 Oct 1:1352458517736147. doi: 10.1177/1352458517736147.
PubMed Abstract available

September 2017

TOBYNE SM, Ochoa WB, Bireley JD, Smith VM, et al
Cognitive impairment and the regional distribution of cerebellar lesions in multiple sclerosis.
Mult Scler. 2017 Sep 1:1352458517730132. doi: 10.1177/1352458517730132.
PubMed Abstract available

FAZIA T, Pastorino R, Foco L, Han L, et al
Investigating multiple sclerosis genetic susceptibility on the founder population of east-central Sardinia via association and linkage analysis of immune-related loci.
Mult Scler. 2017 Sep 1:1352458517732841. doi: 10.1177/1352458517732841.
PubMed Abstract available

HUPPKE P, Huppke B, Ellenberger D, Rostasy K, et al
Therapy of highly active pediatric multiple sclerosis.
Mult Scler. 2017 Sep 1:1352458517732843. doi: 10.1177/1352458517732843.
PubMed Abstract available

LANZILLO R, Cennamo G, Criscuolo C, Carotenuto A, et al
Optical coherence tomography angiography retinal vascular network assessment in multiple sclerosis.
Mult Scler. 2017 Sep 1:1352458517729463. doi: 10.1177/1352458517729463.
PubMed Abstract available

COMBER L, Quinn G, McGuigan C, Galvin R, et al
Medication usage and falls in people with multiple sclerosis.
Mult Scler. 2017 Sep 1:1352458517731912. doi: 10.1177/1352458517731912.
PubMed Abstract available

MEINL I, Havla J, Hohlfeld R, Kumpfel T, et al
Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis.
Mult Scler. 2017 Sep 1:1352458517731913. doi: 10.1177/1352458517731913.
PubMed Abstract available

GIOVANNONI G, Wiendl H, Turner B, Umans K, et al
Circulating lymphocyte levels and relationship with infection status in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta.
Mult Scler. 2017 Sep 1:1352458517729464. doi: 10.1177/1352458517729464.
PubMed Abstract available

KAPPOS L, Arnold DL, Bar-Or A, Camm AJ, et al
Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis.
Mult Scler. 2017 Sep 1:1352458517728343. doi: 10.1177/1352458517728343.
PubMed Abstract available

BISECCO A, Nardo FD, Docimo R, Caiazzo G, et al
Fatigue in multiple sclerosis: The contribution of resting-state functional connectivity reorganization.
Mult Scler. 2017 Sep 1:1352458517730932. doi: 10.1177/1352458517730932.
PubMed Abstract available

CHARVET LE, Dobbs B, Shaw MT, Bikson M, et al
Remotely supervised transcranial direct current stimulation for the treatment of fatigue in multiple sclerosis: Results from a randomized, sham-controlled trial.
Mult Scler. 2017 Sep 1:1352458517732842. doi: 10.1177/1352458517732842.
PubMed Abstract available

August 2017

BRUNDIN L, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for Sweden.
Mult Scler. 2017;23.
PubMed Abstract available

BATTAGLIA M, Kobelt G, Ponzio M, Berg J, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for Italy.
Mult Scler. 2017;23.
PubMed Abstract available

BERGER T, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for Austria.
Mult Scler. 2017;23.
PubMed Abstract available

DUBOIS B, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for Belgium.
Mult Scler. 2017;23.
PubMed Abstract available

OREJA-GUEVARA C, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for Spain.
Mult Scler. 2017;23.
PubMed Abstract available

CALABRESE P, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for Switzerland.
Mult Scler. 2017;23.
PubMed Abstract available

UITDEHAAG B, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for the Netherlands.
Mult Scler. 2017;23.
PubMed Abstract available

FLACHENECKER P, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for Germany.
Mult Scler. 2017;23.
PubMed Abstract available

KOBELT G, Eriksson J, Phillips G, Berg J, et al
The burden of multiple sclerosis 2015: Methods of data collection, assessment and analysis of costs, quality of life and symptoms.
Mult Scler. 2017;23.
PubMed Abstract available

PENTEK M, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for Hungary.
Mult Scler. 2017;23.
PubMed Abstract available

BOYKO A, Kobelt G, Berg J, Boyko O, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for Russia.
Mult Scler. 2017;23.
PubMed Abstract available

RASMUSSEN PV, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for Denmark.
Mult Scler. 2017;23.
PubMed Abstract available

LEBRUN-FRENAY C, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for France.
Mult Scler. 2017;23.
PubMed Abstract available

THOMPSON A, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for the United Kingdom.
Mult Scler. 2017;23.
PubMed Abstract available

SELMAJ K, Kobelt G, Berg J, Orlewska E, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for Poland.
Mult Scler. 2017;23.
PubMed Abstract available

SA MJ, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results for Portugal.
Mult Scler. 2017;23.
PubMed Abstract available

HAVRDOVA E, Kobelt G, Berg J, Capsa D, et al
New insights into the burden and costs of multiple sclerosis in Europe: Results of the Czech Republic.
Mult Scler. 2017;23.
PubMed Abstract available

VERMOHLEN V, Schiller P, Schickendantz S, Drache M, et al
Hippotherapy for patients with multiple sclerosis: A multicenter randomized controlled trial (MS-HIPPO).
Mult Scler. 2017 Aug 1:1352458517721354. doi: 10.1177/1352458517721354.
PubMed Abstract available

RUHRMANN S, Ewing E, Piket E, Kular L, et al
Hypermethylation of MIR21 in CD4+ T cells from patients with relapsing-remitting multiple sclerosis associates with lower miRNA-21 levels and concomitant up-regulation of its target genes.
Mult Scler. 2017 Aug 1:1352458517721356. doi: 10.1177/1352458517721356.
PubMed Abstract available

LAROCCA NG, Hudson LD, Rudick R, Amtmann D, et al
The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.
Mult Scler. 2017 Aug 1:1352458517723718. doi: 10.1177/1352458517723718.
PubMed Abstract available

VAVASOUR IM, Huijskens SC, Li DK, Traboulsee AL, et al
Global loss of myelin water over 5 years in multiple sclerosis normal-appearing white matter.
Mult Scler. 2017 Aug 1:1352458517723717. doi: 10.1177/1352458517723717.
PubMed Abstract available

BERGAMASCHI R, Cortese A, Pichiecchio A, Berzolari FG, et al
Air pollution is associated to the multiple sclerosis inflammatory activity as measured by brain MRI.
Mult Scler. 2017 Aug 1:1352458517726866. doi: 10.1177/1352458517726866.
PubMed Abstract available

SEHR T, Proschmann U, Thomas K, Ziemssen T, et al
Letter to the editor on the paper: "The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing".
Mult Scler. 2017 Aug 1:1352458517726384. doi: 10.1177/1352458517726384.
PubMed

LOUAPRE C, Govindarajan ST, Gianni C, Madigan N, et al
Heterogeneous pathological processes account for thalamic degeneration in multiple sclerosis: Insights from 7 T imaging.
Mult Scler. 2017 Aug 1:1352458517726382. doi: 10.1177/1352458517726382.
PubMed Abstract available

SELLEBJERG F, Bornsen L, Ammitzboll C, Nielsen JE, et al
Defining active progressive multiple sclerosis.
Mult Scler. 2017 Aug 1:1352458517726592. doi: 10.1177/1352458517726592.
PubMed Abstract available

ZIMMER P, Bloch W, Schenk A, Oberste M, et al
High-intensity interval exercise improves cognitive performance and reduces matrix metalloproteinases-2 serum levels in persons with multiple sclerosis: A randomized controlled trial.
Mult Scler. 2017 Aug 1:1352458517728342. doi: 10.1177/1352458517728342.
PubMed Abstract available

LEURS CE, van Kempen ZL, Dekker I, Balk LJ, et al
Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients.
Mult Scler. 2017 Aug 1:1352458517726381. doi: 10.1177/1352458517726381.
PubMed Abstract available

SOLOMON AJ, Watts R, Ontaneda D, Absinta M, et al
Diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.
Mult Scler. 2017 Aug 1:1352458517726383. doi: 10.1177/1352458517726383.
PubMed Abstract available

AFOLABI D, Albor C, Zalewski L, Altmann DR, et al
Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis.
Mult Scler. 2017 Aug 1:1352458517726380. doi: 10.1177/1352458517726380.
PubMed Abstract available

FAISSNER S, Mahjoub Y, Mishra M, Haupeltshofer S, et al
Unexpected additive effects of minocycline and hydroxychloroquine in models of multiple sclerosis: Prospective combination treatment for progressive disease?
Mult Scler. 2017 Aug 1:1352458517728811. doi: 10.1177/1352458517728811.
PubMed Abstract available

KALINCIK T, Jokubaitis V, Spelman T, Horakova D, et al
Cladribine versus fingolimod, natalizumab and interferon beta for multiple sclerosis.
Mult Scler. 2017 Aug 1:1352458517728812. doi: 10.1177/1352458517728812.
PubMed Abstract available

BOVE R, Chitnis T, Cree BA, Tintore M, et al
SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts.
Mult Scler. 2017 Aug 1:1352458517726657. doi: 10.1177/1352458517726657.
PubMed Abstract available

GIOVANNONI G, Soelberg Sorensen P, Cook S, Rammohan K, et al
Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
Mult Scler. 2017 Aug 1:1352458517727603. doi: 10.1177/1352458517727603.
PubMed Abstract available

July 2017

MIGLIORE S, Curcio G, Couyoumdjian A, Ghazaryan A, et al
Executive functioning in relapsing-remitting multiple sclerosis patients without cognitive impairment: A task-switching protocol.
Mult Scler. 2017 Jul 1:1352458517719149. doi: 10.1177/1352458517719149.
PubMed Abstract available

KJOLHEDE T, Siemonsen S, Wenzel D, Stellmann JP, et al
Can resistance training impact MRI outcomes in relapsing-remitting multiple sclerosis?
Mult Scler. 2017 Jul 1:1352458517722645. doi: 10.1177/1352458517722645.
PubMed Abstract available

TANAKA M, Kinoshita M, Tanaka K
Intermittent drug holidays in fingolimod therapy for multiple sclerosis.
Mult Scler. 2017 Jul 1:1352458517722647. doi: 10.1177/1352458517722647.
PubMed

RODRIGUEZ-LEAL FA, Haase R, Thomas K, Eisele JC, et al
Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria?
Mult Scler. 2017 Jul 1:1352458517720043. doi: 10.1177/1352458517720043.
PubMed Abstract available

STAMPANONI BASSI M, Leocani L, Comi G, Iezzi E, et al
Can pharmacological manipulation of LTP favor the effects of motor rehabilitation in multiple sclerosis?
Mult Scler. 2017 Jul 1:1352458517721358. doi: 10.1177/1352458517721358.
PubMed Abstract available

ROLF L, Muris AH, Mathias A, Du Pasquier R, et al
Exploring the effect of vitamin D3 supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosis.
Mult Scler. 2017 Jul 1:1352458517722646. doi: 10.1177/1352458517722646.
PubMed Abstract available

BALDASSARI LE, Salter AR, Longbrake EE, Cross AH, et al
Streamlined EDSS for use in multiple sclerosis clinical practice: Development and cross-sectional comparison to EDSS.
Mult Scler. 2017 Jul 1:1352458517721357. doi: 10.1177/1352458517721357.
PubMed Abstract available

DUNN N, Juto A, Ryner M, Manouchehrinia A, et al
Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies.
Mult Scler. 2017 Jul 1:1352458517720044. doi: 10.1177/1352458517720044.
PubMed Abstract available

CANCELLI A, Cottone C, Giordani A, Migliore S, et al
Personalized, bilateral whole-body somatosensory cortex stimulation to relieve fatigue in multiple sclerosis.
Mult Scler. 2017 Jul 1:1352458517720528. doi: 10.1177/1352458517720528.
PubMed Abstract available

June 2017

CHOI IY, Lee P, Adany P, Hughes AJ, et al
In vivo evidence of oxidative stress in brains of patients with progressive multiple sclerosis.
Mult Scler. 2017 Jun 1:1352458517711568. doi: 10.1177/1352458517711568.
PubMed Abstract available

SATTARNEZHAD N, Farrow S, Kimbrough D, Glanz B, et al
Agreement analysis comparing iPad LCVA and Sloan testing in multiple sclerosis patients.
Mult Scler. 2017 Jun 1:1352458517713667. doi: 10.1177/1352458517713667.
PubMed Abstract available

LEE H, Nakamura K, Narayanan S, Brown R, et al
Impact of immunoablation and autologous hematopoietic stem cell transplantation on gray and white matter atrophy in multiple sclerosis.
Mult Scler. 2017 Jun 1:1352458517715811. doi: 10.1177/1352458517715811.
PubMed Abstract available

BOESEN MS, Magyari M, Koch-Henriksen N, Thygesen LC, et al
Pediatric-onset multiple sclerosis and other acquired demyelinating syndromes of the central nervous system in Denmark during 1977-2015: A nationwide population-based incidence study.
Mult Scler. 2017 Jun 1:1352458517713669. doi: 10.1177/1352458517713669.
PubMed Abstract available

PAKPOOR J, Seminatore B, Graves JS, Schreiner T, et al
Dietary factors and pediatric multiple sclerosis: A case-control study.
Mult Scler. 2017 Jun 1:1352458517713343. doi: 10.1177/1352458517713343.
PubMed Abstract available

SALMEN A
Clinical commentary on "Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab".
Mult Scler. 2017 Jun 1:1352458517717810. doi: 10.1177/1352458517717810.
PubMed

MULERO P, Auger C, Parolin L, Fonseca E, et al
Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab.
Mult Scler. 2017 Jun 1:1352458517711569. doi: 10.1177/1352458517711569.
PubMed Abstract available

FOLEY RW, Tagg NT, Schindler MK, Fenton KM, et al
Recurrent natalizumab-related aseptic meningitis in a patient with multiple sclerosis.
Mult Scler. 2017 Jun 1:1352458517702533. doi: 10.1177/1352458517702533.
PubMed Abstract available

DOBRYAKOVA E, Hulst HE, Spirou A, Chiaravalloti ND, et al
Fronto-striatal network activation leads to less fatigue in multiple sclerosis.
Mult Scler. 2017 Jun 1:1352458517717087. doi: 10.1177/1352458517717087.
PubMed Abstract available

RANGANATHAN U, Kaunzner U, Foster S, Vartanian T, et al
Thrombocytopenia at the time of alemtuzumab infusion in relapsing-remitting multiple sclerosis.
Mult Scler. 2017 Jun 1:1352458517719152. doi: 10.1177/1352458517719152.
PubMed

YAP SM, McNicholas N, Hutchinson M, McGuigan C, et al
Immediate thrombocytopenia at time of alemtuzumab infusion for multiple sclerosis - Not always self-limiting, fully reversible or predictable.
Mult Scler. 2017 Jun 1:1352458517719151. doi: 10.1177/1352458517719151.
PubMed

WEYGANDT M, Wakonig K, Behrens J, Meyer-Arndt L, et al
Brain activity, regional gray matter loss, and decision-making in multiple sclerosis.
Mult Scler. 2017 Jun 1:1352458517717089. doi: 10.1177/1352458517717089.
PubMed Abstract available

HIDALGO DE LA CRUZ M, d'Ambrosio A, Valsasina P, Pagani E, et al
Abnormal functional connectivity of thalamic sub-regions contributes to fatigue in multiple sclerosis.
Mult Scler. 2017 Jun 1:1352458517717807. doi: 10.1177/1352458517717807.
PubMed Abstract available

RUANO L, Branco M, Portaccio E, Goretti B, et al
Patients with paediatric-onset multiple sclerosis are at higher risk of cognitive impairment in adulthood: An Italian collaborative study.
Mult Scler. 2017 Jun 1:1352458517717341. doi: 10.1177/1352458517717341.
PubMed Abstract available

BOZ C, Terzi M, Zengin Karahan S, Sen S, et al
Safety of IV pulse methylprednisolone therapy during breastfeeding in patients with multiple sclerosis.
Mult Scler. 2017 Jun 1:1352458517717806. doi: 10.1177/1352458517717806.
PubMed Abstract available

May 2017

VAN KEMPEN ZL, Leurs CE, Witte BI, de Vries A, et al
The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing.
Mult Scler. 2017 May 1:1352458517708464. doi: 10.1177/1352458517708464.
PubMed Abstract available

GOVEROVER Y, Chiaravalloti N, Genova H, DeLuca J, et al
A randomized controlled trial to treat impaired learning and memory in multiple sclerosis: The self-GEN trial.
Mult Scler. 2017 May 1:1352458517709955. doi: 10.1177/1352458517709955.
PubMed Abstract available

BENEDICT RH, Cohan S, Lynch SG, Riester K, et al
Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study.
Mult Scler. 2017 May 1:1352458517707345. doi: 10.1177/1352458517707345.
PubMed Abstract available

FREILICH J, Manouchehrinia A, Trusheim M, Baird LG, et al
Characterization of annual disease progression of multiple sclerosis patients: A population-based study.
Mult Scler. 2017 May 1:1352458517706252. doi: 10.1177/1352458517706252.
PubMed Abstract available

ZEYDAN B, Lowe VJ, Schwarz CG, Przybelski SA, et al
Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis.
Mult Scler. 2017 May 1:1352458517707346. doi: 10.1177/1352458517707346.
PubMed Abstract available

SHINODA K, Matsushita T, Nakamura Y, Masaki K, et al
HLA-DRB1*04:05 allele is associated with intracortical lesions on three-dimensional double inversion recovery images in Japanese patients with multiple sclerosis.
Mult Scler. 2017 May 1:1352458517707067. doi: 10.1177/1352458517707067.
PubMed Abstract available

SALTER A, Thomas NP, Tyry T, Cutter GR, et al
A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS Registry.
Mult Scler. 2017 May 1:1352458517711274. doi: 10.1177/1352458517711274.
PubMed Abstract available

SUMOWSKI JF, Leavitt VM, Rocca MA, Inglese M, et al
Mesial temporal lobe and subcortical grey matter volumes differentially predict memory across stages of multiple sclerosis.
Mult Scler. 2017 May 1:1352458517708873. doi: 10.1177/1352458517708873.
PubMed Abstract available

CAWLEY N, Tur C, Prados F, Plantone D, et al
Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis.
Mult Scler. 2017 May 1:1352458517709954. doi: 10.1177/1352458517709954.
PubMed Abstract available

BALK LJ, Coric D, Nij Bijvank JA, Killestein J, et al
Retinal atrophy in relation to visual functioning and vision-related quality of life in patients with multiple sclerosis.
Mult Scler. 2017 May 1:1352458517708463. doi: 10.1177/1352458517708463.
PubMed Abstract available

PRINEAS JW, Parratt JDE
Multiple sclerosis: Serum anti-CNS autoantibodies.
Mult Scler. 2017 May 1:1352458517706037. doi: 10.1177/1352458517706037.
PubMed Abstract available

PALOTAI M, Mike A, Cavallari M, Strammer E, et al
Changes to the septo-fornical area might play a role in the pathogenesis of anxiety in multiple sclerosis.
Mult Scler. 2017 May 1:1352458517711273. doi: 10.1177/1352458517711273.
PubMed Abstract available

MARINO M, Frisullo G, Di Sante G, Samengo DM, et al
Low reliability of anti-KIR4.183-120 peptide auto-antibodies in multiple sclerosis patients.
Mult Scler. 2017 May 1:1352458517711275. doi: 10.1177/1352458517711275.
PubMed Abstract available

REDONDO J, Sarkar P, Kemp K, Virgo PF, et al
Reduced cellularity of bone marrow in multiple sclerosis with decreased MSC expansion potential and premature ageing in vitro.
Mult Scler. 2017 May 1:1352458517711276. doi: 10.1177/1352458517711276.
PubMed Abstract available

BIBERACHER V, Schmidt P, Selter RC, Pernpeinter V, et al
Fatigue in multiple sclerosis: Associations with clinical, MRI and CSF parameters.
Mult Scler. 2017 May 1:1352458517712078. doi: 10.1177/1352458517712078.
PubMed Abstract available

SMOOT K, Spinelli KJ, Stuchiner T, Lucas L, et al
Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center.
Mult Scler. 2017 May 1:1352458517709956. doi: 10.1177/1352458517709956.
PubMed Abstract available

TORTORELLA C, Direnzo V, Ruggieri M, Zoccolella S, et al
Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis.
Mult Scler. 2017 May 1:1352458517711774. doi: 10.1177/1352458517711774.
PubMed Abstract available

VAN DER VUURST DE VRIES RM, van den Dorpel JJ, Mescheriakova JY, Runia TF, et al
Fatigue after a first attack of suspected multiple sclerosis.
Mult Scler. 2017 May 1:1352458517709348. doi: 10.1177/1352458517709348.
PubMed Abstract available

VAN DEN AKKER LE, Beckerman H, Collette EH, Twisk JW, et al
Cognitive behavioral therapy positively affects fatigue in patients with multiple sclerosis: Results of a randomized controlled trial.
Mult Scler. 2017 May 1:1352458517709361. doi: 10.1177/1352458517709361.
PubMed Abstract available

HEINE M, Verschuren O, Hoogervorst EL, van Munster E, et al
Does aerobic training alleviate fatigue and improve societal participation in patients with multiple sclerosis? A randomized controlled trial.
Mult Scler. 2017 May 1:1352458517696596. doi: 10.1177/1352458517696596.
PubMed Abstract available

BLIKMAN LJ, van Meeteren J, Twisk JW, de Laat FA, et al
Effectiveness of energy conservation management on fatigue and participation in multiple sclerosis: A randomized controlled trial.
Mult Scler. 2017 May 1:1352458517702751. doi: 10.1177/1352458517702751.
PubMed Abstract available

KAPPOS L, Butzkueven H, Wiendl H, Spelman T, et al
Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study.
Mult Scler. 2017 May 1:1352458517709619. doi: 10.1177/1352458517709619.
PubMed Abstract available

SORMANI MP
Why non-inferiority is more challenging than superiority?
Mult Scler. 2017;23:790-791.
PubMed Abstract available

HOEPNER R, Kolb EM, Dahlhaus S, Hellwig K, et al
Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy.
Mult Scler. 2017;23:830-835.
PubMed Abstract available

NETRAVATHI M, Saini J, Mahadevan A, Hari-Krishna B, et al
Is pruritus an indicator of aquaporin-positive neuromyelitis optica?
Mult Scler. 2017;23:810-817.
PubMed Abstract available

PITTERI M, Romualdi C, Magliozzi R, Monaco S, et al
Cognitive impairment predicts disability progression and cortical thinning in MS: An 8-year study.
Mult Scler. 2017;23:848-854.
PubMed Abstract available

April 2017

AL-LOUZI O, Button J, Newsome SD, Calabresi PA, et al
Retrograde trans-synaptic visual pathway degeneration in multiple sclerosis: A case series.
Mult Scler. 2017 Apr 1:1352458516679035. doi: 10.1177/1352458516679035.
PubMed Abstract available

SIGNORI A, Izquierdo G, Lugaresi A, Hupperts R, et al
Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.
Mult Scler. 2017 Apr 1:1352458517703800. doi: 10.1177/1352458517703800.
PubMed Abstract available

SOLARI A, Giordano A, Patti F, Grasso MG, et al
Randomized controlled trial of a home-based palliative approach for people with severe multiple sclerosis.
Mult Scler. 2017 Apr 1:1352458517704078. doi: 10.1177/1352458517704078.
PubMed Abstract available

COHEN JA, Imrey PB, Planchon SM, Bermel RA, et al
Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.
Mult Scler. 2017 Apr 1:1352458517703802. doi: 10.1177/1352458517703802.
PubMed Abstract available

GIOVANNONI G, Tomic D, Bright JR, Havrdova E, et al
"No evident disease activity": The use of combined assessments in the management of patients with multiple sclerosis.
Mult Scler. 2017 Apr 1:1352458517703193. doi: 10.1177/1352458517703193.
PubMed Abstract available

MORANDI E, Tarlinton RE, Tanasescu R, Gran B, et al
Human endogenous retroviruses and multiple sclerosis: Causation, association, or after-effect?
Mult Scler. 2017 Apr 1:1352458517704711. doi: 10.1177/1352458517704711.
PubMed Abstract available

KLAUSER AM, Wiebenga OT, Eijlers AJ, Schoonheim MM, et al
Metabolites predict lesion formation and severity in relapsing-remitting multiple sclerosis.
Mult Scler. 2017 Apr 1:1352458517702534. doi: 10.1177/1352458517702534.
PubMed Abstract available

AMATO MP
The diagnostic dilemma of multiple sclerosis presenting with isolated cognitive and behavioral disorders.
Mult Scler. 2017 Apr 1:1352458517705002. doi: 10.1177/1352458517705002.
PubMed Abstract available

ZAMBON AA, Cecchetti G, Caso F, Santangelo R, et al
Primary progressive multiple sclerosis presenting with severe predominant cognitive impairment and psychiatric symptoms: A challenging case.
Mult Scler. 2017 Apr 1:1352458517702550. doi: 10.1177/1352458517702550.
PubMed Abstract available

CIAMPI E, Uribe-San-Martin R, Godoy-Santin J, Cruz JP, et al
Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical-radiological features and treatment. Case report of seven patients.
Mult Scler. 2017 Apr 1:1352458517702968. doi: 10.1177/1352458517702968.
PubMed Abstract available

POP R, Kipfer S
Paroxysmal kinesigenic dyskinesia-like phenotype in multiple sclerosis.
Mult Scler. 2017 Apr 1:1352458517702535. doi: 10.1177/1352458517702535.
PubMed Abstract available

PAREES I
Clinical commentary on "Paroxysmal kinesigenic dyskinesia-like phenotype in multiple sclerosis" and "Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical-radiological features and treatment. Case report of seven patients".
Mult Scler. 2017 Apr 1:1352458517702555. doi: 10.1177/1352458517702555.
PubMed Abstract available

BODINI B, Branzoli F, Poirion E, Garcia-Lorenzo D, et al
Dysregulation of energy metabolism in multiple sclerosis measured in vivo with diffusion-weighted spectroscopy.
Mult Scler. 2017 Apr 1:1352458517698249. doi: 10.1177/1352458517698249.
PubMed Abstract available

KOLBER P, Droby A, Roebroeck A, Goebel R, et al
A "kissing lesion": In-vivo 7T evidence of meningeal inflammation in early multiple sclerosis.
Mult Scler. 2017 Apr 1:1352458516683267. doi: 10.1177/1352458516683267.
PubMed Abstract available

KILSDONK ID, Schoonheim M, Wattjes MP
In-vivo imaging of meningeal inflammation in multiple sclerosis: Presence of evidence or evidence of presence?
Mult Scler. 2017 Apr 1:1352458517704924. doi: 10.1177/1352458517704924.
PubMed

TOUSSAINT-DUYSTER LC, Wong YYM, Van der Cammen-van Zijp MH, Van Pelt-Gravesteijn D, et al
Fatigue and physical functioning in children with multiple sclerosis and acute disseminated encephalomyelitis.
Mult Scler. 2017 Apr 1:1352458517706038. doi: 10.1177/1352458517706038.
PubMed Abstract available

HAGENS MH, Killestein J, Yaqub MM, van Dongen GA, et al
Cerebral rituximab uptake in multiple sclerosis: A 89Zr-immunoPET pilot study.
Mult Scler. 2017 Apr 1:1352458517704507. doi: 10.1177/1352458517704507.
PubMed Abstract available

SORMANI MP
Indirect comparisons of treatment effects: Network meta-analyses.
Mult Scler. 2017;23:510-512.
PubMed Abstract available

BOUDOT DE LA MOTTE M, Louapre C, Bertrand A, Reach P, et al
Extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse?
Mult Scler. 2017;23:614-616.
PubMed Abstract available

AIRAS L, Rissanen E, Rinne J
Imaging of microglial activation in MS using PET: Research use and potential future clinical application.
Mult Scler. 2017;23:496-504.
PubMed Abstract available

HUM S, Lapierre Y, Scott SC, Duquette P, et al
Trajectory of MS disease course for men and women over three eras.
Mult Scler. 2017;23:534-545.
PubMed Abstract available

D'SOUZA M, Yaldizli O, John R, Vogt DR, et al
Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study.
Mult Scler. 2017;23:597-603.
PubMed Abstract available

VERMERSCH P, Hobart J, Dive-Pouletty C, Bozzi S, et al
Measuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose?
Mult Scler. 2017;23:604-613.
PubMed Abstract available

CIAMPI E, Pareto D, Sastre-Garriga J, Vidal-Jordana A, et al
Grey matter atrophy is associated with disability increase in natalizumab-treated patients.
Mult Scler. 2017;23:556-566.
PubMed Abstract available

BROWNLEE WJ, Altmann DR, Alves Da Mota P, Swanton JK, et al
Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome.
Mult Scler. 2017;23:665-674.
PubMed Abstract available

SORMANI MP, Kappos L, Radue EW, Cohen J, et al
Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS.
Mult Scler. 2017;23:656-664.
PubMed Abstract available

COETZEE T, Thompson A
When are we going to take modifiable risk factors more seriously in multiple sclerosis?
Mult Scler. 2017;23:494-495.
PubMed

March 2017

FEINSTEIN A, Pavisian B
Multiple sclerosis and suicide.
Mult Scler. 2017 Mar 1:1352458517702553. doi: 10.1177/1352458517702553.
PubMed Abstract available

ASGARI N, Jarius S, Laustrup H, Skejoe HP, et al
Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: A predominantly population-based study.
Mult Scler. 2017 Mar 1:1352458517699791. doi: 10.1177/1352458517699791.
PubMed Abstract available

CHARVET LE, Shaw M, Frontario A, Langdon D, et al
Cognitive impairment in pediatric-onset multiple sclerosis is detected by the Brief International Cognitive Assessment for Multiple Sclerosis and computerized cognitive testing.
Mult Scler. 2017 Mar 1:1352458517701588. doi: 10.1177/1352458517701588.
PubMed Abstract available

HOUTCHENS MK, Zapata LB, Curtis KM, Whiteman MK, et al
Contraception for women with multiple sclerosis: Guidance for healthcare providers.
Mult Scler. 2017 Mar 1:1352458517701314. doi: 10.1177/1352458517701314.
PubMed Abstract available

RUGGIERI S, Fanelli F, Castelli L, Petsas N, et al
Lesion symptom map of cognitive-postural interference in multiple sclerosis.
Mult Scler. 2017 Mar 1:1352458517701313. doi: 10.1177/1352458517701313.
PubMed Abstract available

TOURBAH A, Sedel F
Reply to the letter: Biotinidase deficiency masquerading as multiple sclerosis?
Mult Scler. 2017 Mar 1:1352458517702554. doi: 10.1177/1352458517702554.
PubMed

WOLF B
Biotinidase deficiency masquerading as multiple sclerosis?
Mult Scler. 2017 Mar 1:1352458517702551. doi: 10.1177/1352458517702551.
PubMed

GYLLENSTEN H, Wiberg M, Alexanderson K, Friberg E, et al
Comparing costs of illness of multiple sclerosis in three different years: A population-based study.
Mult Scler. 2017 Mar 1:1352458517702549. doi: 10.1177/1352458517702549.
PubMed Abstract available

INEICHEN BV, Schneider MP, Hlavica M, Hagenbuch N, et al
High EDSS can predict risk for upper urinary tract damage in patients with multiple sclerosis.
Mult Scler. 2017 Mar 1:1352458517703801. doi: 10.1177/1352458517703801.
PubMed Abstract available

SORMANI MP
Prognostic factors versus markers of response to treatment versus surrogate endpoints: Three different concepts.
Mult Scler. 2017;23:378-381.
PubMed Abstract available

HUH SY, Kim SH, Hyun JW, Jeong IH, et al
Short segment myelitis as a first manifestation of neuromyelitis optica spectrum disorders.
Mult Scler. 2017;23:413-419.
PubMed Abstract available

GRAVES JS, Chohan H, Cedars B, Arnow S, et al
Sex differences and subclinical retinal injury in pediatric-onset MS.
Mult Scler. 2017;23:447-455.
PubMed Abstract available

ARRAMBIDE G
Commentary on "Successful pregnancy after natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis".
Mult Scler. 2017;23:486-487.
PubMed

RIO J, Rovira A, Tintore M, Otero-Romero S, et al
Disability progression markers over 6-12 years in interferon-beta-treated multiple sclerosis patients.
Mult Scler. 2017 Mar 1:1352458517698052. doi: 10.1177/1352458517698052.
PubMed Abstract available

CORTESE M, Riise T, Bjornevik K, Myhr KM, et al
Body size and physical exercise, and the risk of multiple sclerosis.
Mult Scler. 2017 Mar 1:1352458517699289. doi: 10.1177/1352458517699289.
PubMed Abstract available

BOGIE JF, Boelen E, Louagie E, Delputte P, et al
CD169 is a marker for highly pathogenic phagocytes in multiple sclerosis.
Mult Scler. 2017 Mar 1:1352458517698759. doi: 10.1177/1352458517698759.
PubMed Abstract available

LEURS CE, Podlesniy P, Trullas R, Balk L, et al
Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment.
Mult Scler. 2017 Mar 1:1352458517699874. doi: 10.1177/1352458517699874.
PubMed Abstract available

ROCCA MA, Valsasina P, Leavitt VM, Rodegher M, et al
Functional network connectivity abnormalities in multiple sclerosis: Correlations with disability and cognitive impairment.
Mult Scler. 2017 Mar 1:1352458517699875. doi: 10.1177/1352458517699875.
PubMed Abstract available

RANGANATHAN U, Kaunzner U, Foster S, Vartanian T, et al
Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis.
Mult Scler. 2017 Mar 1:1352458517699876. doi: 10.1177/1352458517699876.
PubMed Abstract available

February 2017

BACCHETTA F, Mathias A, Schluep M, Du Pasquier R, et al
Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence.
Mult Scler. 2017;23:300-303.
PubMed Abstract available

HAMID SH, Elsone L, Mutch K, Solomon T, et al
The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates.
Mult Scler. 2017;23:228-233.
PubMed Abstract available

SORMANI MP, Bruzzi P
Estimating a treatment effect: Choosing between relative and absolute measures.
Mult Scler. 2017;23:197-200.
PubMed Abstract available

SORMANI MP, Muraro PA, Saccardi R, Mancardi G, et al
NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs.
Mult Scler. 2017;23:201-204.
PubMed Abstract available

HULST HE, Thompson AJ, Geurts JJ
The measure tells the tale: Clinical outcome measures in multiple sclerosis.
Mult Scler. 2017 Feb 1:1352458517690825. doi: 10.1177/1352458517690825.
PubMed

ROVIRA A
Peripheral nervous system involvement in multiple sclerosis.
Mult Scler. 2017 Feb 1:1352458517693469. doi: 10.1177/1352458517693469.
PubMed

CAMERON MH, McMillan G
Methylphenidate is likely less effective than placebo for improving imbalance, walking, and fatigue in people with multiple sclerosis.
Mult Scler. 2017 Feb 1:1352458517692421. doi: 10.1177/1352458517692421.
PubMed

CORIC D, Balk LJ, Verrijp M, Eijlers A, et al
Cognitive impairment in patients with multiple sclerosis is associated with atrophy of the inner retinal layers.
Mult Scler. 2017 Feb 1:1352458517694090. doi: 10.1177/1352458517694090.
PubMed Abstract available

GIACOMINI E, Rizzo F, Etna MP, Cruciani M, et al
Thymosin-alpha1 expands deficient IL-10-producing regulatory B cell subsets in relapsing-remitting multiple sclerosis patients.
Mult Scler. 2017 Feb 1:1352458517695892. doi: 10.1177/1352458517695892.
PubMed Abstract available

MAILLEUX J, Vanmierlo T, Bogie JF, Wouters E, et al
Active liver X receptor signaling in phagocytes in multiple sclerosis lesions.
Mult Scler. 2017 Feb 1:1352458517696595. doi: 10.1177/1352458517696595.
PubMed Abstract available

ROY S, Drake AS, Eizaguirre MB, Zivadinov R, et al
Trait neuroticism, extraversion, and conscientiousness in multiple sclerosis: Link to cognitive impairment?
Mult Scler. 2017 Feb 1:1352458517695467. doi: 10.1177/1352458517695467.
PubMed Abstract available

SCHWARTZ CE, Grover SA, Powell VE, Noguera A, et al
Risk factors for non-adherence to disease-modifying therapy in pediatric multiple sclerosis.
Mult Scler. 2017 Feb 1:1352458517695469. doi: 10.1177/1352458517695469.
PubMed Abstract available

CACAO G, Santos E, Martins Silva A
Concurrent autoimmune hepatitis in multiple sclerosis.
Mult Scler. 2017 Feb 1:1352458517692885. doi: 10.1177/1352458517692885.
PubMed Abstract available

ZECCA C, Merlini A, Disanto G, Rodegher M, et al
Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study.
Mult Scler. 2017 Feb 1:1352458517694089. doi: 10.1177/1352458517694089.
PubMed Abstract available

WESNES K, Myhr KM, Riise T, Cortese M, et al
Physical activity is associated with a decreased multiple sclerosis risk: The EnvIMS study.
Mult Scler. 2017 Feb 1:1352458517694088. doi: 10.1177/1352458517694088.
PubMed Abstract available

PATEL VP, Walker LA, Feinstein A
Revisiting cognitive reserve and cognition in multiple sclerosis: A closer look at depression.
Mult Scler. 2017 Feb 1:1352458517692887. doi: 10.1177/1352458517692887.
PubMed Abstract available

SONNENBERG A, Ajdacic-Gross V
Similar birth-cohort patterns in Crohn's disease and multiple sclerosis.
Mult Scler. 2017 Feb 1:1352458517691620. doi: 10.1177/1352458517691620.
PubMed Abstract available

GALAZKA G, Mycko MP, Selmaj I, Raine CS, et al
Multiple sclerosis: Serum-derived exosomes express myelin proteins.
Mult Scler. 2017 Feb 1:1352458517696597. doi: 10.1177/1352458517696597.
PubMed Abstract available

January 2017

AMATO MP, Derfuss T, Hemmer B, Liblau R, et al
Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop.
Mult Scler. 2017 Jan 6:1352458516686847. doi: 10.1177/1352458516686847.
PubMed Abstract available

DECARD BF, Thone J, Haghikia A, Bornke C, et al
Listeria rhombencephalitis mimicking a demyelinating event in an immunocompetent young patient.
Mult Scler. 2017;23:123-125.
PubMed Abstract available

GIRARD B, Bonnemains C, Schmitt E, Raffo E, et al
Biotinidase deficiency mimicking neuromyelitis optica beginning at the age of 4: A treatable disease.
Mult Scler. 2017;23:119-122.
PubMed Abstract available

LAROCHELLE C, Metz I, Lecuyer MA, Terouz S, et al
Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal.
Mult Scler. 2017;23:72-81.
PubMed Abstract available

BURTON JM, Eliasziw M, Trufyn J, Tung C, et al
A prospective cohort study of vitamin D in optic neuritis recovery.
Mult Scler. 2017;23:82-93.
PubMed Abstract available

HAAS J, Schneider K, Schwarz A, Korporal-Kuhnke M, et al
Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?
Mult Scler. 2017;23:114-118.
PubMed Abstract available

KALINCIK T, Sormani MP
Reporting treatment outcomes in observational data: A fine balance.
Mult Scler. 2017;23:21-22.
PubMed Abstract available

SORMANI MP
Subgroup analysis in MS trials.
Mult Scler. 2017;23:34-35.
PubMed Abstract available

DE STEFANO N, Giorgio A, Battaglini M, De Leucio A, et al
Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets.
Mult Scler. 2017 Jan 1:1352458517690269. doi: 10.1177/1352458517690269.
PubMed Abstract available

MOTL RW, Mowry EM, Ehde DM, LaRocca NG, et al
Wellness and multiple sclerosis: The National MS Society establishes a Wellness Research Working Group and research priorities.
Mult Scler. 2017 Jan 1:1352458516687404. doi: 10.1177/1352458516687404.
PubMed Abstract available

December 2016

GHEZZI A
Randomized clinical trials (RCTs) in pediatric multiple sclerosis: Are they really necessary?
Mult Scler. 2016 Dec 1:1352458516684025. doi: 10.1177/1352458516684025.
PubMed

September 2016

HENGSTMAN GJ
Controversies in MS: All relapsing multiple sclerosis patients should be managed at a specialist clinic - Combine the best of two worlds!
Mult Scler. 2016 Sep 21. pii: 1352458516670737.
PubMed

October 2015

WILLIS MD, Harding KE, Pickersgill TP, Wardle M, et al
Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort.
Mult Scler. 2015 Oct 29. pii: 1352458515614092.
PubMed Abstract available

UDDIN MN, Lebel RM, Seres P, Blevins G, et al
Spin echo transverse relaxation and atrophy in multiple sclerosis deep gray matter: A two-year longitudinal study.
Mult Scler. 2015 Oct 26. pii: 1352458515614091.
PubMed Abstract available

AHLBRECHT J, Martino F, Pul R, Skripuletz T, et al
Deregulation of microRNA-181c in cerebrospinal fluid of patients with clinically isolated syndrome is associated with early conversion to relapsing-remitting multiple sclerosis.
Mult Scler. 2015 Oct 22. pii: 1352458515613641.
PubMed Abstract available

ROCCA MA, Meani A, Riccitelli GC, Colombo B, et al
Abnormal adaptation over time of motor network recruitment in multiple sclerosis patients with fatigue.
Mult Scler. 2015 Oct 22. pii: 1352458515614407.
PubMed Abstract available

HEITMANN H, Biberacher V, Tiemann L, Buck D, et al
Prevalence of neuropathic pain in early multiple sclerosis.
Mult Scler. 2015 Oct 19. pii: 1352458515613643.
PubMed Abstract available

LANZILLO R, Quarantelli M, Pozzilli C, Trojano M, et al
No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon beta1a therapy in relapsing-remitting multiple sclerosis (the ARIANNA study).
Mult Scler. 2015 Oct 14. pii: 1352458515611222.
PubMed Abstract available

KARAKY M, Alcina A, Fedetz M, Barrionuevo C, et al
The multiple sclerosis-associated regulatory variant rs10877013 affects expression of CYP27B1 and VDR under inflammatory or vitamin D stimuli.
Mult Scler. 2015 Oct 14. pii: 1352458515610208.
PubMed Abstract available

SANDBERG L, Bistrom M, Salzer J, Vagberg M, et al
Vitamin D and axonal injury in multiple sclerosis.
Mult Scler. 2015 Oct 13. pii: 1352458515606986.
PubMed Abstract available

ZECCA C, Disanto G, Sormani MP, Riccitelli GC, et al
Relevance of asymptomatic spinal MRI lesions in patients with multiple sclerosis.
Mult Scler. 2015 Oct 12. pii: 1352458515599246.
PubMed Abstract available

HEDSTROM AK, Olsson T, Alfredsson L
Smoking is a major preventable risk factor for multiple sclerosis.
Mult Scler. 2015 Oct 12. pii: 1352458515609794.
PubMed Abstract available

LONGBRAKE EE, Ramsbottom MJ, Cantoni C, Ghezzi L, et al
Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
Mult Scler. 2015 Oct 12. pii: 1352458515608961.
PubMed Abstract available

AKHTAR S, Alroughani R, Ahmed SF, Al-Hashel JY, et al
Prognostic indicators of secondary progression in a paediatric-onset multiple sclerosis cohort in Kuwait.
Mult Scler. 2015 Oct 9. pii: 1352458515608960.
PubMed Abstract available

SIGNORIELLO E, Lanzillo R, Brescia Morra V, Di Iorio G, et al
Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis.
Mult Scler. 2015 Oct 9. pii: 1352458515604381.
PubMed Abstract available

EISELE P, Konstandin S, Griebe M, Szabo K, et al
Heterogeneity of acute multiple sclerosis lesions on sodium (23Na) MRI.
Mult Scler. 2015 Oct 9. pii: 1352458515609430.
PubMed Abstract available

RICCELLI R, Passamonti L, Cerasa A, Nigro S, et al
Individual differences in depression are associated with abnormal function of the limbic system in multiple sclerosis patients.
Mult Scler. 2015 Oct 9. pii: 1352458515606987.
PubMed Abstract available

DEGN M, Modvig S, Dyring-Andersen B, Bonefeld CM, et al
Increased prevalence of lymphoid tissue inducer cells in the cerebrospinal fluid of patients with early multiple sclerosis.
Mult Scler. 2015 Oct 9. pii: 1352458515609795.
PubMed Abstract available

MACDONELL R, Nagels G, Laplaud DA, Pozzilli C, et al
Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine.
Mult Scler. 2015 Oct 7. pii: 1352458515606809.
PubMed Abstract available

BOVE R, Healy BC, Musallam A, Glanz BI, et al
Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort.
Mult Scler. 2015 Oct 7. pii: 1352458515606211.
PubMed Abstract available

VERCELLINO M, Fenoglio C, Galimberti D, Mattioda A, et al
Progranulin genetic polymorphisms influence progression of disability and relapse recovery in multiple sclerosis.
Mult Scler. 2015 Oct 7. pii: 1352458515610646.
PubMed Abstract available

TILLEMA JM, Hulst HE, Rocca MA, Vrenken H, et al
Regional cortical thinning in multiple sclerosis and its relation with cognitive impairment: A multicenter study.
Mult Scler. 2015 Oct 2. pii: 1352458515607650.
PubMed Abstract available

RATZER R, Iversen P, Bornsen L, Dyrby TB, et al
Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis.
Mult Scler. 2015 Oct 2. pii: 1352458515605908.
PubMed Abstract available

KEARNEY H, Miszkiel KA, Yiannakas MC, Altmann DR, et al
Grey matter involvement by focal cervical spinal cord lesions is associated with progressive multiple sclerosis.
Mult Scler. 2015 Oct 2. pii: 1352458515604905.
PubMed Abstract available

September 2015

GUTTMANN CR, Rousset M, Roch JA, Hannoun S, et al
Multiple sclerosis lesion formation and early evolution revisited: A weekly high-resolution magnetic resonance imaging study.
Mult Scler. 2015 Sep 11. pii: 1352458515600247.
PubMed Abstract available

MARTINEZ-RODRIGUEZ JE, Cobo-Calvo A, Villar LM, Munteis E, et al
Adaptive natural killer cell response to cytomegalovirus and disability progression in multiple sclerosis.
Mult Scler. 2015 Sep 11. pii: 1352458515601215.
PubMed Abstract available

UHER T, Horakova D, Tyblova M, Zeman D, et al
Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later.
Mult Scler. 2015 Sep 11. pii: 1352458515601903.
PubMed Abstract available

BINZER S, Stenager E, Binzer M, Kyvik KO, et al
Genetic analysis of the isolated Faroe Islands reveals SORCS3 as a potential multiple sclerosis risk gene.
Mult Scler. 2015 Sep 11. pii: 1352458515602338.
PubMed Abstract available

SIMULA S, Laitinen T, Laitinen TM, Tarkiainen T, et al
Effect of fingolimod on cardiac autonomic regulation in patients with multiple sclerosis.
Mult Scler. 2015 Sep 11. pii: 1352458515604384.
PubMed Abstract available

August 2015

GONSETTE R, Debouverie M, Sindic C, Ferre JC, et al
Pixantrone: a B-cell-depleting immunosuppressant for multiple sclerosis patients with active disease.
Mult Scler. 2015 Aug 18. pii: 1352458515601902.
PubMed Abstract available

BHARGAVA P, Steele SU, Waubant E, Revirajan NR, et al
Multiple sclerosis patients have a diminished serologic response to vitamin D supplementation compared to healthy controls.
Mult Scler. 2015 Aug 18. pii: 1352458515600248.
PubMed Abstract available

TACCONI P, Peltz MT, Lorefice L, Marrosu MG, et al
Facial synkinesis as a first symptom of multiple sclerosis.
Mult Scler. 2015 Aug 5. pii: 1352458515584415.
PubMed Abstract available

MILLER DM, Bethoux F, Victorson D, Nowinski CJ, et al
Validating Neuro-QoL short forms and targeted scales with people who have multiple sclerosis.
Mult Scler. 2015 Aug 3. pii: 1352458515599450.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: